



US010004558B2

(12) **United States Patent**
Long et al.

(10) **Patent No.:** **US 10,004,558 B2**
(45) **Date of Patent:** **Jun. 26, 2018**

(54) **ELECTRICAL ABLATION DEVICES**

(71) Applicant: **Ethicon Endo-Surgery, Inc.**,
Cincinnati, OH (US)

(72) Inventors: **Gary L. Long**, Cincinnati, OH (US);
Ragae M. Ghabrial, Pittsburgh, PA
(US); **David N. Plescia**, Mentor, OH
(US); **Omar J. Vakharia**, Cincinnati,
OH (US)

(73) Assignee: **Ethicon Endo-Surgery, Inc.**,
Cincinnati, OH (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 524 days.

(21) Appl. No.: **14/673,111**

(22) Filed: **Mar. 30, 2015**

(65) **Prior Publication Data**

US 2015/0265342 A1 Sep. 24, 2015

Related U.S. Application Data

(60) Continuation of application No. 13/602,742, filed on
Sep. 4, 2012, now Pat. No. 9,011,431, which is a
(Continued)

(51) **Int. Cl.**

A61B 18/14 (2006.01)

A61B 18/12 (2006.01)

A61B 18/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61B 18/1492** (2013.01); **A61B 18/1206**
(2013.01); **A61B 18/1477** (2013.01);
(Continued)

(58) **Field of Classification Search**

CPC A61M 25/10; A61M 25/1043; A61M
25/1084

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

645,576 A 3/1900 Tesla

649,621 A 5/1900 Tesla

(Continued)

FOREIGN PATENT DOCUMENTS

AU 666310 B2 2/1996

DE 3008120 A1 9/1980

(Continued)

OTHER PUBLICATIONS

"Ethicon Endo-Surgery Novel Investigational Notes and SSL
Devices Featured in 15 Presentations at Sages," Apr. 22, 2009 Press
Release; URL http://www.jnj.com/connect/news/all/20090422_152000; accessed Aug. 28, 2009 (3 pages).


(Continued)

Primary Examiner — Laura Bouchelle

(57) **ABSTRACT**

An electrical ablation apparatus comprises first and second electrodes. Each electrode comprises a first end configured to couple an energy source and a second end configured to couple to a tissue treatment region. An energy source is coupled to the first and second electrodes. The energy source is configured to deliver a first series of electrical pulses sufficient to induce cell necrosis by irreversible electroporation and a second series of electrical pulses sufficient to induce cell necrosis by thermal heating, through at least one of the first and second electrodes. The first series of electrical pulses is characterized by a first amplitude, a first pulse length, and a first frequency. The second series of electrical pulses is characterized by a second amplitude, a second pulse length, and a second frequency.

13 Claims, 16 Drawing Sheets



Related U.S. Application Data

division of application No. 12/352,375, filed on Jan. 12, 2009, now Pat. No. 8,361,066.

(52) U.S. Cl.

CPC *A61B 2018/00214* (2013.01); *A61B 2018/00482* (2013.01); *A61B 2018/00547* (2013.01); *A61B 2018/00577* (2013.01); *A61B 2018/00613* (2013.01); *A61B 2018/00898* (2013.01); *A61B 2018/124* (2013.01); *A61B 2018/1425* (2013.01)

(56)**References Cited**

U.S. PATENT DOCUMENTS

| | | | | | |
|-------------|---------|--------------------|-------------|---------|--------------------|
| 787,412 A | 4/1905 | Tesla | 4,461,281 A | 7/1984 | Carson |
| 1,039,354 A | 9/1912 | Bonadio | 4,491,132 A | 1/1985 | Aikins |
| 1,127,948 A | 2/1915 | Wappler | 4,492,232 A | 1/1985 | Green |
| 1,482,653 A | 2/1924 | Lilly | 4,527,331 A | 7/1985 | Lasner et al. |
| 1,581,706 A | 4/1926 | White | 4,527,564 A | 7/1985 | Eguchi et al. |
| 1,581,707 A | 4/1926 | White | 4,538,594 A | 9/1985 | Boebel et al. |
| 1,581,708 A | 4/1926 | White | D281,104 S | 10/1985 | Davison |
| 1,581,709 A | 4/1926 | White | 4,569,347 A | 2/1986 | Frisbie |
| 1,581,710 A | 4/1926 | White | 4,580,551 A | 4/1986 | Siegmund et al. |
| 1,625,602 A | 4/1927 | Gould | 4,646,722 A | 3/1987 | Silverstein et al. |
| 1,916,722 A | 7/1933 | Ende | 4,649,904 A | 3/1987 | Krauter et al. |
| 2,028,635 A | 1/1936 | Wappler | 4,653,476 A | 3/1987 | Bonnet |
| 2,031,682 A | 2/1936 | Wappler | 4,655,219 A | 4/1987 | Petruzzi |
| 2,113,246 A | 4/1938 | Wappler | 4,657,016 A | 4/1987 | Garito et al. |
| 2,137,710 A | 11/1938 | Anderson | 4,657,018 A | 4/1987 | Hakky |
| 2,155,365 A | 4/1939 | Rankin | 4,669,470 A | 6/1987 | Brandfield |
| 2,191,858 A | 2/1940 | Moore | 4,671,477 A | 6/1987 | Cullen |
| 2,196,620 A | 4/1940 | Attarian | 4,677,982 A | 7/1987 | Llinas et al. |
| 2,388,137 A | 10/1945 | Graumlich | 4,685,447 A | 8/1987 | Iversen et al. |
| 2,451,077 A | 10/1948 | Emsig | 4,711,240 A | 12/1987 | Goldwasser et al. |
| 2,493,108 A | 1/1950 | Casey | 4,712,545 A | 12/1987 | Honkanen |
| 2,504,152 A | 4/1950 | Riker | 4,721,116 A | 1/1988 | Schintgen et al. |
| 2,938,382 A | 5/1960 | De Graaf | 4,727,600 A | 2/1988 | Avakian |
| 2,952,206 A | 9/1960 | Becksted | 4,733,662 A | 3/1988 | DeSatnick et al. |
| 3,044,461 A | 7/1962 | Murdock | D295,894 S | 5/1988 | Sharkany et al. |
| 3,069,195 A | 12/1962 | Buck | 4,742,817 A | 5/1988 | Kawashima et al. |
| 3,070,088 A | 12/1962 | Brahos | 4,753,223 A | 6/1988 | Bremer |
| 3,170,471 A | 2/1965 | Schnitzer | 4,763,669 A | 8/1988 | Jaeger |
| 3,435,824 A | 4/1969 | Gamponia | 4,770,188 A | 9/1988 | Chikama |
| 3,470,876 A | 10/1969 | Barchilon | 4,790,624 A | 12/1988 | Van Hoyer et al. |
| 3,481,325 A | 12/1969 | Glassman | 4,791,707 A | 12/1988 | Tucker |
| 3,595,239 A | 7/1971 | Petersen | 4,796,627 A | 1/1989 | Tucker |
| 3,669,487 A | 6/1972 | Roberts et al. | 4,807,593 A | 2/1989 | Ito |
| 3,746,881 A | 7/1973 | Fitch et al. | 4,815,450 A | 3/1989 | Patel |
| 3,799,672 A | 3/1974 | Vurek | 4,819,620 A | 4/1989 | Okutsu |
| 3,946,740 A | 3/1976 | Bassett | 4,823,794 A | 4/1989 | Pierce |
| 3,948,251 A | 4/1976 | Hosono | 4,829,999 A | 5/1989 | Auth |
| 3,961,632 A | 6/1976 | Moossun | 4,836,188 A | 6/1989 | Berry |
| 3,965,890 A | 6/1976 | Gauthier | 4,846,573 A | 7/1989 | Taylor et al. |
| 3,994,301 A | 11/1976 | Agris | 4,867,140 A | 9/1989 | Hovis et al. |
| 4,011,872 A | 3/1977 | Komiya | 4,869,238 A | 9/1989 | Opie et al. |
| 4,012,812 A | 3/1977 | Black | 4,869,459 A | 9/1989 | Bourne |
| 4,085,743 A | 4/1978 | Yoon | 4,873,979 A | 10/1989 | Hanna |
| 4,164,225 A | 8/1979 | Johnson et al. | 4,880,015 A | 11/1989 | Nierman |
| 4,170,997 A | 10/1979 | Pinnow et al. | 4,904,048 A | 2/1990 | Sogawa et al. |
| 4,174,715 A | 11/1979 | Hasson | 4,911,148 A | 3/1990 | Sosnowski et al. |
| 4,178,920 A | 12/1979 | Cawood, Jr. et al. | 4,926,860 A | 5/1990 | Stice et al. |
| 4,207,873 A | 6/1980 | Kruy | 4,934,364 A | 6/1990 | Green |
| 4,235,238 A | 11/1980 | Ogiu et al. | 4,938,214 A | 7/1990 | Specht et al. |
| 4,258,716 A | 3/1981 | Sutherland | 4,950,273 A | 8/1990 | Briggs |
| 4,269,174 A | 5/1981 | Adair | 4,950,285 A | 8/1990 | Wilk |
| 4,278,077 A | 7/1981 | Mizumoto | 4,953,539 A | 9/1990 | Nakamura et al. |
| 4,281,646 A | 8/1981 | Kinoshita | 4,960,133 A | 10/1990 | Hewson |
| 4,285,344 A | 8/1981 | Marshall | 4,977,887 A | 12/1990 | Gouda |
| 4,311,143 A | 1/1982 | Komiya | 4,979,496 A | 12/1990 | Komi |
| 4,329,980 A | 5/1982 | Terada | 4,979,950 A | 12/1990 | Transue et al. |
| 4,393,872 A | 7/1983 | Reznik et al. | 4,984,581 A | 1/1991 | Stice |
| 4,396,021 A | 8/1983 | Baumgartner | 4,990,152 A | 2/1991 | Yoon |
| 4,406,656 A | 9/1983 | Hattler et al. | 4,991,565 A | 2/1991 | Takahashi et al. |
| 4,452,246 A | 6/1984 | Bader et al. | 4,994,079 A | 2/1991 | Genese et al. |
| | | | 5,007,917 A | 4/1991 | Evans |
| | | | 5,010,876 A | 4/1991 | Henley et al. |
| | | | 5,020,514 A | 6/1991 | Heckele |
| | | | 5,020,535 A | 6/1991 | Parker et al. |
| | | | 5,025,778 A | 6/1991 | Silverstein et al. |
| | | | 5,026,379 A | 6/1991 | Yoon |
| | | | 5,033,169 A | 7/1991 | Bindon |
| | | | 5,037,433 A | 8/1991 | Wilk et al. |
| | | | 5,041,129 A | 8/1991 | Hayhurst et al. |
| | | | 5,046,513 A | 9/1991 | Gattuma et al. |
| | | | 5,050,585 A | 9/1991 | Takahashi |
| | | | 5,052,372 A | 10/1991 | Shapiro |
| | | | 5,065,516 A | 11/1991 | Dulebohn |
| | | | 5,066,295 A | 11/1991 | Kozak et al. |
| | | | 5,098,378 A | 3/1992 | Piontek et al. |
| | | | 5,108,421 A | 4/1992 | Fowler |
| | | | 5,123,913 A | 6/1992 | Wilk et al. |
| | | | 5,123,914 A | 6/1992 | Cope |
| | | | 5,133,727 A | 7/1992 | Bales et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|-------------|---------|--------------------|-------------|---------|-------------------|
| 5,147,374 A | 9/1992 | Fernandez | 5,364,408 A | 11/1994 | Gordon |
| 5,174,300 A | 12/1992 | Bales et al. | 5,364,410 A | 11/1994 | Failla et al. |
| 5,176,126 A | 1/1993 | Chikama | 5,366,466 A | 11/1994 | Christian et al. |
| 5,190,050 A | 3/1993 | Nitzsche | 5,366,467 A | 11/1994 | Lynch et al. |
| 5,190,555 A | 3/1993 | Wetter et al. | 5,368,605 A | 11/1994 | Miller, Jr. |
| 5,192,284 A | 3/1993 | Pleatman | 5,370,647 A | 12/1994 | Graber et al. |
| 5,192,300 A | 3/1993 | Fowler | 5,370,679 A | 12/1994 | Atlee, III |
| 5,197,963 A | 3/1993 | Parins | 5,374,273 A | 12/1994 | Nakao et al. |
| 5,201,752 A | 4/1993 | Brown et al. | 5,374,275 A | 12/1994 | Bradley et al. |
| 5,201,908 A | 4/1993 | Jones | 5,374,277 A | 12/1994 | Hassler |
| 5,203,785 A | 4/1993 | Slater | 5,374,953 A | 12/1994 | Sasaki et al. |
| 5,203,787 A | 4/1993 | Noblitt et al. | 5,376,077 A | 12/1994 | Gomringer |
| 5,209,747 A | 5/1993 | Knoepfler | 5,377,695 A | 1/1995 | An Haack |
| 5,217,003 A | 6/1993 | Wilk | 5,383,877 A | 1/1995 | Clarke |
| 5,217,453 A | 6/1993 | Wilk | 5,383,888 A | 1/1995 | Zvenyatsky et al. |
| 5,219,357 A | 6/1993 | Honkanen et al. | 5,386,817 A | 2/1995 | Jones |
| 5,219,358 A | 6/1993 | Bendel et al. | 5,387,259 A | 2/1995 | Davidson |
| 5,222,362 A | 6/1993 | Maus et al. | 5,391,174 A | 2/1995 | Weston |
| 5,222,965 A | 6/1993 | Houghton | 5,392,789 A | 2/1995 | Slater et al. |
| 5,234,437 A | 8/1993 | Sepetka | 5,395,386 A | 3/1995 | Slater |
| 5,234,453 A | 8/1993 | Smith et al. | 5,397,332 A | 3/1995 | Kammerer et al. |
| 5,235,964 A | 8/1993 | Abenaim | 5,401,248 A | 3/1995 | Bencini |
| 5,242,456 A | 9/1993 | Nash et al. | 5,403,311 A | 4/1995 | Abele et al. |
| 5,245,460 A | 9/1993 | Allen et al. | 5,403,328 A | 4/1995 | Shallman |
| 5,246,424 A | 9/1993 | Wilk | 5,403,342 A | 4/1995 | Tovey et al. |
| 5,257,999 A | 11/1993 | Slanetz, Jr. | 5,403,348 A | 4/1995 | Bonutti |
| 5,259,366 A | 11/1993 | Reydel et al. | 5,405,073 A | 4/1995 | Porter |
| 5,263,958 A | 11/1993 | deGuillebon et al. | 5,405,359 A | 4/1995 | Pierce |
| 5,273,524 A | 12/1993 | Fox et al. | 5,409,478 A | 4/1995 | Gerry et al. |
| 5,275,607 A | 1/1994 | Lo et al. | 5,417,699 A | 5/1995 | Klein et al. |
| 5,275,614 A | 1/1994 | Haber et al. | 5,423,821 A | 6/1995 | Pasque |
| 5,275,616 A | 1/1994 | Fowler | 5,431,635 A | 7/1995 | Yoon |
| 5,284,128 A | 2/1994 | Hart | 5,433,721 A | 7/1995 | Hoooven et al. |
| 5,284,162 A | 2/1994 | Wilk | 5,433,735 A | 7/1995 | Zanakis et al. |
| 5,287,845 A | 2/1994 | Faul et al. | 5,439,471 A | 8/1995 | Kerr |
| 5,287,852 A | 2/1994 | Arkinstall | 5,439,478 A | 8/1995 | Palmer |
| 5,290,299 A | 3/1994 | Fain et al. | 5,441,059 A | 8/1995 | Dannan |
| 5,290,302 A | 3/1994 | Pericic | 5,441,494 A | 8/1995 | Ortiz |
| 5,295,977 A | 3/1994 | Cohen et al. | 5,441,498 A | 8/1995 | Perkins |
| 5,297,536 A | 3/1994 | Wilk | 5,441,499 A | 8/1995 | Fritzsch |
| 5,297,687 A | 3/1994 | Freed | 5,443,463 A | 8/1995 | Stern et al. |
| 5,301,061 A | 4/1994 | Nakada et al. | 5,445,638 A | 8/1995 | Rydell et al. |
| 5,312,023 A | 5/1994 | Green et al. | 5,445,648 A | 8/1995 | Cook |
| 5,312,333 A | 5/1994 | Churinetz et al. | 5,449,021 A | 9/1995 | Chikama |
| 5,312,351 A | 5/1994 | Gerrone | 5,454,827 A | 10/1995 | Aust et al. |
| 5,312,416 A | 5/1994 | Spaeth et al. | 5,456,667 A | 10/1995 | Ham et al. |
| 5,312,423 A | 5/1994 | Rosenbluth et al. | 5,456,684 A | 10/1995 | Schmidt et al. |
| 5,318,589 A | 6/1994 | Lichtman | 5,458,131 A | 10/1995 | Wilk |
| 5,320,636 A | 6/1994 | Slater | 5,458,583 A | 10/1995 | McNeely et al. |
| 5,324,261 A | 6/1994 | Amundson et al. | 5,460,168 A | 10/1995 | Masubuchi et al. |
| 5,325,845 A | 7/1994 | Adair | 5,460,629 A | 10/1995 | Shlain et al. |
| 5,330,471 A | 7/1994 | Eggers | 5,462,561 A | 10/1995 | Voda |
| 5,330,486 A | 7/1994 | Wilk | 5,465,731 A | 11/1995 | Bell et al. |
| 5,330,488 A | 7/1994 | Goldrath | 5,467,763 A | 11/1995 | McMahon et al. |
| 5,330,496 A | 7/1994 | Alferness | 5,468,250 A | 11/1995 | Paraschac et al. |
| 5,330,502 A | 7/1994 | Hassler et al. | 5,470,308 A | 11/1995 | Edwards et al. |
| 5,331,971 A | 7/1994 | Bales et al. | 5,470,320 A | 11/1995 | Tiefenbrun et al. |
| 5,334,168 A | 8/1994 | Hemmer | 5,472,441 A | 12/1995 | Edwards et al. |
| 5,334,198 A | 8/1994 | Hart et al. | 5,478,347 A | 12/1995 | Aranyi |
| 5,336,192 A | 8/1994 | Palestrant | 5,478,352 A | 12/1995 | Fowler |
| 5,336,222 A | 8/1994 | Durgin, Jr. et al. | 5,480,404 A | 1/1996 | Kammerer et al. |
| 5,339,805 A | 8/1994 | Parker | 5,482,029 A | 1/1996 | Sekiguchi et al. |
| 5,341,815 A | 8/1994 | Cofone et al. | 5,482,054 A | 1/1996 | Slater et al. |
| 5,342,396 A | 8/1994 | Cook | 5,484,451 A | 1/1996 | Akopov et al. |
| 5,344,428 A | 9/1994 | Griffiths | 5,489,256 A | 2/1996 | Adair |
| 5,345,927 A | 9/1994 | Bonutti | 5,496,347 A | 3/1996 | Hashiguchi et al. |
| 5,348,259 A | 9/1994 | Blanco et al. | 5,499,990 A | 3/1996 | Schulken et al. |
| 5,350,391 A | 9/1994 | Iacovelli | 5,499,992 A | 3/1996 | Meade et al. |
| 5,352,184 A | 10/1994 | Goldberg et al. | 5,499,997 A | 3/1996 | Sharpe et al. |
| 5,352,222 A | 10/1994 | Rydell | 5,500,012 A | 3/1996 | Brucker et al. |
| 5,354,302 A | 10/1994 | Ko | 5,501,692 A | 3/1996 | Riza |
| 5,354,311 A | 10/1994 | Kambin et al. | 5,503,616 A | 4/1996 | Jones |
| 5,356,381 A | 10/1994 | Ensminger et al. | 5,505,686 A | 4/1996 | Willis et al. |
| 5,356,408 A | 10/1994 | Rydell | 5,507,755 A | 4/1996 | Gresl et al. |
| 5,360,428 A | 11/1994 | Hutchinson, Jr. | 5,511,564 A | 4/1996 | Wilk |
| | | | 5,514,157 A | 5/1996 | Nicholas et al. |
| | | | 5,518,501 A | 5/1996 | Oneda et al. |
| | | | 5,522,829 A | 6/1996 | Michalos |
| | | | 5,522,830 A | 6/1996 | Aranyi |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|-------------|---------|---------------------|-------------|---------|---------------------|
| 5,527,321 A | 6/1996 | Hinchliffe | 5,700,275 A | 12/1997 | Bell et al. |
| 5,533,418 A | 7/1996 | Wu et al. | 5,702,438 A | 12/1997 | Avitall |
| 5,536,234 A | 7/1996 | Newman | 5,704,892 A | 1/1998 | Adair |
| 5,536,248 A | 7/1996 | Weaver et al. | 5,709,708 A | 1/1998 | Thal |
| 5,538,509 A | 7/1996 | Dunlap et al. | 5,711,921 A | 1/1998 | Langford |
| 5,540,648 A | 7/1996 | Yoon | 5,716,326 A | 2/1998 | Dannan |
| 5,549,637 A | 8/1996 | Crainich | 5,716,375 A | 2/1998 | Fowler |
| 5,554,151 A | 9/1996 | Hinchliffe | 5,725,542 A | 3/1998 | Yoon |
| 5,555,883 A | 9/1996 | Avitall | 5,728,094 A | 3/1998 | Edwards |
| 5,558,133 A | 9/1996 | Bortoli et al. | 5,730,740 A | 3/1998 | Wales et al. |
| 5,562,693 A | 10/1996 | Devlin et al. | 5,735,849 A | 4/1998 | Baden et al. |
| 5,569,243 A | 10/1996 | Kortenbach et al. | 5,741,234 A | 4/1998 | Aboul-Hosn |
| 5,569,298 A | 10/1996 | Schnell | 5,741,278 A | 4/1998 | Stevens |
| 5,571,090 A | 11/1996 | Sherts | 5,741,285 A | 4/1998 | McBrayer et al. |
| 5,573,540 A | 11/1996 | Yoon | 5,741,429 A | 4/1998 | Donadio, III et al. |
| 5,578,030 A | 11/1996 | Levin | 5,743,456 A | 4/1998 | Jones et al. |
| 5,582,611 A | 12/1996 | Tsuruta et al. | 5,746,759 A | 5/1998 | Meade et al. |
| 5,582,617 A | 12/1996 | Klieman et al. | 5,749,826 A | 5/1998 | Faulkner |
| 5,584,845 A | 12/1996 | Hart | 5,749,881 A | 5/1998 | Sackier et al. |
| 5,590,660 A | 1/1997 | MacAulay et al. | 5,749,889 A | 5/1998 | Bacich et al. |
| 5,591,179 A | 1/1997 | Edelstein | 5,752,951 A | 5/1998 | Yanik |
| 5,591,205 A | 1/1997 | Fowler | 5,755,731 A | 5/1998 | Grinberg |
| 5,593,420 A | 1/1997 | Eubanks, Jr. et al. | 5,759,150 A | 6/1998 | Konou et al. |
| 5,595,562 A | 1/1997 | Grier | 5,759,151 A | 6/1998 | Sturges |
| 5,597,378 A | 1/1997 | Jervis | 5,762,604 A | 6/1998 | Kieturakis |
| 5,601,573 A | 2/1997 | Fogelberg et al. | 5,766,167 A | 6/1998 | Eggers et al. |
| 5,601,574 A | 2/1997 | Stefanchik et al. | 5,766,170 A | 6/1998 | Eggers |
| 5,601,588 A | 2/1997 | Tonomura et al. | 5,766,205 A | 6/1998 | Zvenyatsky et al. |
| 5,601,602 A | 2/1997 | Fowler | 5,769,849 A | 6/1998 | Eggers |
| 5,604,531 A | 2/1997 | Iddan et al. | 5,776,188 A | 7/1998 | Shepherd et al. |
| 5,607,386 A | 3/1997 | Flam | 5,779,701 A | 7/1998 | McBrayer et al. |
| 5,607,389 A | 3/1997 | Edwards et al. | 5,779,716 A | 7/1998 | Cano et al. |
| 5,607,406 A | 3/1997 | Hernandez et al. | 5,779,720 A | 7/1998 | Walder-Utz et al. |
| 5,607,450 A | 3/1997 | Zvenyatsky et al. | 5,779,727 A | 7/1998 | Orejola |
| 5,609,601 A | 3/1997 | Kolesa et al. | 5,782,859 A | 7/1998 | Nicholas et al. |
| 5,613,975 A | 3/1997 | Christy | 5,782,861 A | 7/1998 | Cragg et al. |
| 5,613,977 A | 3/1997 | Weber et al. | 5,782,866 A | 7/1998 | Wenstrom, Jr. |
| 5,614,943 A | 3/1997 | Nakamura et al. | 5,791,022 A | 8/1998 | Bohman |
| 5,616,117 A | 4/1997 | Dinkler et al. | 5,792,113 A | 8/1998 | Kramer et al. |
| 5,618,303 A | 4/1997 | Marlow et al. | 5,792,153 A | 8/1998 | Swain et al. |
| 5,620,415 A | 4/1997 | Lucey et al. | 5,792,165 A | 8/1998 | Klieman et al. |
| 5,624,399 A | 4/1997 | Ackerman | 5,797,835 A | 8/1998 | Green |
| 5,624,431 A | 4/1997 | Gerry et al. | 5,797,928 A | 8/1998 | Kogasaka |
| 5,626,578 A | 5/1997 | Tihon | 5,797,939 A | 8/1998 | Yoon |
| 5,626,587 A | 5/1997 | Bishop et al. | 5,797,941 A | 8/1998 | Schulze et al. |
| 5,628,732 A | 5/1997 | Antoon, Jr. et al. | 5,797,959 A | 8/1998 | Castro et al. |
| 5,630,782 A | 5/1997 | Adair | 5,797,960 A | 8/1998 | Stevens et al. |
| 5,630,795 A | 5/1997 | Kuramoto et al. | 5,800,449 A | 9/1998 | Wales |
| 5,643,283 A | 7/1997 | Younker | 5,800,451 A | 9/1998 | Buess et al. |
| 5,643,292 A | 7/1997 | Hart | 5,803,903 A | 9/1998 | Athas et al. |
| 5,643,294 A | 7/1997 | Tovey et al. | 5,807,395 A | 9/1998 | Mulier et al. |
| 5,644,798 A | 7/1997 | Shah | 5,808,665 A | 9/1998 | Green |
| 5,645,083 A | 7/1997 | Essig et al. | 5,810,805 A | 9/1998 | Sutcu et al. |
| 5,645,519 A | 7/1997 | Lee et al. | 5,810,806 A | 9/1998 | Ritchart et al. |
| 5,645,565 A | 7/1997 | Rudd et al. | 5,810,849 A | 9/1998 | Kontos |
| 5,649,372 A | 7/1997 | Souza | 5,810,865 A | 9/1998 | Koscher et al. |
| 5,653,677 A | 8/1997 | Okada et al. | 5,810,876 A | 9/1998 | Kelleher |
| 5,653,690 A | 8/1997 | Booth et al. | 5,810,877 A | 9/1998 | Roth et al. |
| 5,653,722 A | 8/1997 | Kieturakis | 5,813,976 A | 9/1998 | Filipi et al. |
| 5,657,755 A | 8/1997 | Desai | 5,814,026 A | 9/1998 | Yoon |
| 5,662,621 A | 9/1997 | Lafontaine | 5,814,058 A | 9/1998 | Carlson et al. |
| 5,662,663 A | 9/1997 | Shallman | 5,817,061 A | 10/1998 | Goodwin et al. |
| 5,667,527 A | 9/1997 | Cook | 5,817,107 A | 10/1998 | Schaller |
| 5,669,875 A | 9/1997 | van Eerdenburg | 5,817,119 A | 10/1998 | Klieman et al. |
| 5,681,276 A | 10/1997 | Lundquist | 5,818,527 A | 10/1998 | Yamaguchi et al. |
| 5,681,279 A | 10/1997 | Roper et al. | 5,819,736 A | 10/1998 | Avny et al. |
| 5,681,324 A | 10/1997 | Kammerer et al. | 5,823,947 A | 10/1998 | Yoon et al. |
| 5,681,330 A | 10/1997 | Hughett et al. | 5,824,071 A | 10/1998 | Nelson et al. |
| 5,685,820 A | 11/1997 | Riek et al. | 5,827,190 A | 10/1998 | Palcic et al. |
| 5,690,606 A | 11/1997 | Slotman | 5,827,276 A | 10/1998 | LeVeen et al. |
| 5,690,656 A | 11/1997 | Cope et al. | 5,827,281 A | 10/1998 | Levin |
| 5,690,660 A | 11/1997 | Kauker et al. | 5,827,299 A | 10/1998 | Thomason et al. |
| 5,695,448 A | 12/1997 | Kimura et al. | 5,827,323 A | 10/1998 | Klieman et al. |
| 5,695,505 A | 12/1997 | Yoon | 5,830,221 A | 11/1998 | Stein et al. |
| 5,695,511 A | 12/1997 | Cano et al. | 5,830,231 A | 11/1998 | Geiges, Jr. |
| | | | 5,833,603 A | 11/1998 | Kovacs et al. |
| | | | 5,833,700 A | 11/1998 | Fogelberg et al. |
| | | | 5,833,703 A | 11/1998 | Manushakian |
| | | | 5,833,715 A | 11/1998 | Vachon et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | | | |
|-----------|---|---------|---------------------|-----------|-----|---------|---------------------------------|
| 5,836,960 | A | 11/1998 | Kolesa et al. | 6,027,522 | A | 2/2000 | Palmer |
| 5,843,017 | A | 12/1998 | Yoon | 6,030,365 | A | 2/2000 | Laufer |
| 5,843,121 | A | 12/1998 | Yoon | 6,030,384 | A | 2/2000 | Nezhat |
| 5,849,022 | A | 12/1998 | Sakashita et al. | 6,030,634 | A | 2/2000 | Wu et al. |
| 5,853,374 | A | 12/1998 | Hart et al. | 6,033,399 | A | 3/2000 | Gines |
| 5,855,569 | A | 1/1999 | Komi | 6,033,401 | A | 3/2000 | Edwards et al. |
| 5,855,585 | A | 1/1999 | Kontos | 6,036,640 | A | 3/2000 | Corace et al. |
| 5,860,913 | A | 1/1999 | Yamaya et al. | 6,036,685 | A | 3/2000 | Mueller |
| 5,860,995 | A | 1/1999 | Berkelaar | 6,050,992 | A | 4/2000 | Nichols |
| 5,868,762 | A | 2/1999 | Cragg et al. | 6,053,927 | A | 4/2000 | Hamas |
| 5,873,849 | A | 2/1999 | Bernard | 6,053,937 | A | 4/2000 | Edwards et al. |
| 5,876,411 | A | 3/1999 | Kontos | 6,059,719 | A | 5/2000 | Yamamoto et al. |
| 5,882,331 | A | 3/1999 | Sasaki | 6,066,160 | A | 5/2000 | Colvin et al. |
| 5,882,344 | A | 3/1999 | Stouder, Jr. | 6,068,603 | A | 5/2000 | Suzuki |
| 5,893,846 | A | 4/1999 | Bales et al. | 6,068,629 | A | 5/2000 | Haissaguerre et al. |
| 5,893,874 | A | 4/1999 | Bourque et al. | 6,071,233 | A | 6/2000 | Ishikawa et al. |
| 5,893,875 | A | 4/1999 | O'Connor et al. | 6,074,408 | A | 6/2000 | Freeman |
| 5,897,487 | A | 4/1999 | Ouchi | 6,086,530 | A | 7/2000 | Mack |
| 5,899,919 | A | 5/1999 | Eubanks, Jr. et al. | 6,090,105 | A | 7/2000 | Lepeda et al. |
| 5,902,238 | A | 5/1999 | Golden et al. | 6,090,108 | A | 7/2000 | McBrayer et al. |
| 5,902,254 | A | 5/1999 | Magram | 6,090,129 | A | 7/2000 | Ouchi |
| 5,904,702 | A | 5/1999 | Ek et al. | 6,096,046 | A | 8/2000 | Weiss |
| 5,906,625 | A | 5/1999 | Bito et al. | 6,102,909 | A | 8/2000 | Chen et al. |
| 5,908,420 | A | 6/1999 | Parins et al. | 6,102,926 | A | 8/2000 | Tartaglia et al. |
| 5,908,429 | A | 6/1999 | Yoon | 6,106,473 | A | 8/2000 | Violante et al. |
| 5,911,737 | A | 6/1999 | Lee et al. | 6,106,521 | A | 8/2000 | Blewett et al. |
| 5,916,146 | A | 6/1999 | Allotta et al. | 6,109,852 | A | 8/2000 | Shahinpoor et al. |
| 5,916,147 | A | 6/1999 | Boury | 6,110,154 | A | 8/2000 | Shimomura et al. |
| 5,921,892 | A | 7/1999 | Easton | 6,110,183 | A | 8/2000 | Cope |
| 5,921,993 | A | 7/1999 | Yoon | 6,113,593 | A | 9/2000 | Tu et al. |
| 5,921,997 | A | 7/1999 | Fogelberg et al. | 6,117,144 | A | 9/2000 | Nobles et al. |
| 5,922,008 | A | 7/1999 | Gimpelson | 6,117,158 | A | 9/2000 | Measamer et al. |
| 5,925,052 | A | 7/1999 | Simmons | 6,123,718 | A * | 9/2000 | Tu A61B 18/1492 606/41 |
| 5,928,255 | A | 7/1999 | Meade et al. | 6,131,790 | A | 10/2000 | Piraka |
| 5,928,266 | A | 7/1999 | Kontos | 6,139,555 | A | 10/2000 | Hart et al. |
| 5,936,536 | A | 8/1999 | Morris | 6,141,037 | A | 10/2000 | Upton et al. |
| 5,938,661 | A | 8/1999 | Hahnen | 6,146,391 | A | 11/2000 | Cigaina |
| 5,941,815 | A | 8/1999 | Chang | 6,148,222 | A | 11/2000 | Ramsey, III |
| 5,944,718 | A | 8/1999 | Austin et al. | 6,149,653 | A | 11/2000 | Deslauriers |
| 5,951,547 | A | 9/1999 | Gough et al. | 6,149,662 | A | 11/2000 | Pugliesi et al. |
| 5,951,549 | A | 9/1999 | Richardson et al. | 6,152,871 | A | 11/2000 | Foley et al. |
| 5,954,720 | A | 9/1999 | Wilson et al. | 6,152,920 | A | 11/2000 | Thompson et al. |
| 5,954,731 | A | 9/1999 | Yoon | 6,156,006 | A | 12/2000 | Brosens et al. |
| 5,957,936 | A | 9/1999 | Yoon et al. | 6,159,200 | A | 12/2000 | Verdura et al. |
| 5,957,943 | A | 9/1999 | Vaitekunas | 6,165,175 | A | 12/2000 | Wampler et al. |
| 5,957,953 | A | 9/1999 | DiPoto et al. | 6,165,184 | A | 12/2000 | Verdura et al. |
| 5,964,782 | A | 10/1999 | Lafontaine et al. | 6,168,570 | B1 | 1/2001 | Ferrera |
| 5,970,581 | A | 10/1999 | Chadwick et al. | 6,168,605 | B1 | 1/2001 | Measamer et al. |
| 5,971,995 | A | 10/1999 | Rousseau | 6,169,269 | B1 | 1/2001 | Maynard |
| 5,972,002 | A | 10/1999 | Bark et al. | 6,170,130 | B1 | 1/2001 | Hamilton et al. |
| 5,976,074 | A | 11/1999 | Moriyama | 6,173,872 | B1 | 1/2001 | Cohen |
| 5,976,075 | A | 11/1999 | Beane et al. | 6,179,776 | B1 | 1/2001 | Adams et al. |
| 5,976,130 | A | 11/1999 | McBrayer et al. | 6,179,832 | B1 | 1/2001 | Jones et al. |
| 5,976,131 | A | 11/1999 | Guglielmi et al. | 6,179,837 | B1 | 1/2001 | Hoooven |
| 5,980,539 | A | 11/1999 | Kontos | 6,183,420 | B1 | 2/2001 | Douk et al. |
| 5,980,556 | A | 11/1999 | Giordano et al. | 6,190,353 | B1 | 2/2001 | Makower et al. |
| 5,984,938 | A | 11/1999 | Yoon | 6,190,383 | B1 | 2/2001 | Schmaltz et al. |
| 5,984,939 | A | 11/1999 | Yoon | 6,190,384 | B1 | 2/2001 | Ouchi |
| 5,984,950 | A | 11/1999 | Cragg et al. | 6,190,399 | B1 | 2/2001 | Palmer et al. |
| 5,989,182 | A | 11/1999 | Hori et al. | 6,203,533 | B1 | 3/2001 | Ouchi |
| 5,993,447 | A | 11/1999 | Blewett et al. | 6,206,872 | B1 | 3/2001 | Lafond et al. |
| 5,993,474 | A | 11/1999 | Ouchi | 6,206,877 | B1 | 3/2001 | Kese et al. |
| 5,995,875 | A | 11/1999 | Blewett et al. | 6,206,904 | B1 | 3/2001 | Ouchi |
| 5,997,555 | A | 12/1999 | Kontos | 6,210,409 | B1 | 4/2001 | Ellman et al. |
| 6,001,120 | A | 12/1999 | Levin | 6,214,007 | B1 | 4/2001 | Anderson |
| 6,004,269 | A | 12/1999 | Crowley et al. | 6,214,028 | B1 | 4/2001 | Yoon et al. |
| 6,004,330 | A | 12/1999 | Middleman et al. | 6,216,043 | B1 | 4/2001 | Swanson et al. |
| 6,007,566 | A | 12/1999 | Wenstrom, Jr. | 6,228,096 | B1 | 5/2001 | Marchand |
| 6,010,515 | A | 1/2000 | Swain et al. | 6,231,506 | B1 | 5/2001 | Hu et al. |
| 6,012,494 | A | 1/2000 | Balazs | 6,234,958 | B1 | 5/2001 | Snoke et al. |
| 6,016,452 | A | 1/2000 | Kasevich | 6,240,312 | B1 | 5/2001 | Alfano et al. |
| 6,017,356 | A | 1/2000 | Frederick et al. | 6,245,079 | B1 | 6/2001 | Nobles et al. |
| 6,019,770 | A | 2/2000 | Christoudias | 6,246,914 | B1 | 6/2001 | de la Rama et al. |
| 6,024,708 | A | 2/2000 | Bales et al. | 6,258,064 | B1 | 7/2001 | Smith et al. |
| 6,024,747 | A | 2/2000 | Kontos | 6,261,242 | B1 | 7/2001 | Roberts et al. |
| | | | | 6,264,664 | B1 | 7/2001 | Avellanet |
| | | | | 6,270,497 | B1 | 8/2001 | Sekino et al. |
| | | | | 6,270,505 | B1 | 8/2001 | Yoshida et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | | | |
|-----------|----|---------|-------------------|-----------|----|---------|---------------------|
| 6,277,136 | B1 | 8/2001 | Bonutti | 6,554,823 | B2 | 4/2003 | Palmer et al. |
| 6,283,963 | B1 | 9/2001 | Regula | 6,554,829 | B2 | 4/2003 | Schulze et al. |
| 6,287,304 | B1 | 9/2001 | Eggers et al. | 6,558,384 | B2 | 5/2003 | Mayenberger |
| 6,293,909 | B1 | 9/2001 | Chu et al. | 6,562,034 | B2 | 5/2003 | Edwards et al. |
| 6,293,952 | B1 | 9/2001 | Brosens et al. | 6,562,035 | B1 | 5/2003 | Levin |
| 6,296,630 | B1 | 10/2001 | Altman et al. | 6,562,052 | B2 | 5/2003 | Nobles et al. |
| 6,314,963 | B1 | 11/2001 | Vaska et al. | 6,569,085 | B2 | 5/2003 | Kortenbach et al. |
| 6,322,578 | B1 | 11/2001 | Houle et al. | 6,569,091 | B2 | 5/2003 | Diokno et al. |
| 6,325,534 | B1 | 12/2001 | Hawley et al. | 6,569,120 | B1 | 5/2003 | Green et al. |
| 6,326,177 | B1 | 12/2001 | Schoenbach et al. | 6,569,159 | B1 | 5/2003 | Edwards et al. |
| 6,328,730 | B1 | 12/2001 | Harkrider, Jr. | 6,572,629 | B2 | 6/2003 | Kalloo et al. |
| 6,350,267 | B1 | 2/2002 | Stefanchik | 6,572,635 | B1 | 6/2003 | Bonutti |
| 6,350,278 | B1 | 2/2002 | Lenker et al. | 6,575,988 | B2 | 6/2003 | Rousseau |
| 6,352,503 | B1 | 3/2002 | Matsui et al. | 6,579,311 | B1 | 6/2003 | Makower |
| 6,352,541 | B1 | 3/2002 | Kienzle et al. | 6,581,889 | B2 | 6/2003 | Carpenter et al. |
| 6,352,543 | B1 | 3/2002 | Cole | 6,585,642 | B2 | 7/2003 | Christopher |
| 6,355,013 | B1 | 3/2002 | van Muiden | 6,585,717 | B1 | 7/2003 | Wittenberger et al. |
| 6,355,035 | B1 | 3/2002 | Manushakian | 6,587,750 | B2 | 7/2003 | Gerbi et al. |
| 6,361,534 | B1 | 3/2002 | Chen et al. | 6,592,559 | B1 | 7/2003 | Pakter et al. |
| 6,364,879 | B1 | 4/2002 | Chen et al. | 6,592,603 | B2 | 7/2003 | Lasner |
| 6,368,340 | B2 | 4/2002 | Malecki et al. | 6,594,971 | B1 | 7/2003 | Addy et al. |
| 6,371,956 | B1 | 4/2002 | Wilson et al. | 6,602,262 | B2 | 8/2003 | Griego et al. |
| 6,379,366 | B1 | 4/2002 | Fleischman et al. | 6,605,105 | B1 | 8/2003 | Cuschieri et al. |
| 6,383,195 | B1 | 5/2002 | Richard | 6,610,072 | B1 | 8/2003 | Christy et al. |
| 6,383,197 | B1 | 5/2002 | Conlon et al. | 6,610,074 | B2 | 8/2003 | Santilli |
| 6,387,671 | B1 | 5/2002 | Rubinsky et al. | 6,613,038 | B2 | 9/2003 | Bonutti et al. |
| 6,391,029 | B1 | 5/2002 | Hooven et al. | 6,613,068 | B2 | 9/2003 | Ouchi |
| 6,398,708 | B1 | 6/2002 | Hastings et al. | 6,616,632 | B2 | 9/2003 | Sharp et al. |
| 6,402,735 | B1 | 6/2002 | Langevin | 6,620,193 | B1 | 9/2003 | Lau et al. |
| 6,402,746 | B1 | 6/2002 | Wayne et al. | 6,623,448 | B2 | 9/2003 | Slater |
| 6,406,440 | B1 | 6/2002 | Stefanchik | 6,626,919 | B1 | 9/2003 | Swanstrom |
| 6,409,727 | B1 | 6/2002 | Bales et al. | 6,632,171 | B2 | 10/2003 | Iddan et al. |
| 6,409,733 | B1 | 6/2002 | Conlon et al. | 6,632,229 | B1 | 10/2003 | Yamanouchi |
| 6,419,639 | B2 | 7/2002 | Walther et al. | 6,632,234 | B2 | 10/2003 | Kieturakis et al. |
| 6,419,641 | B1 | 7/2002 | Mark et al. | 6,638,275 | B1 | 10/2003 | McGaffigan et al. |
| 6,427,089 | B1 | 7/2002 | Knowlton | 6,638,286 | B1 | 10/2003 | Burbank et al. |
| 6,431,500 | B1 | 8/2002 | Jacobs et al. | 6,645,225 | B1 | 11/2003 | Atkinson |
| 6,436,107 | B1 | 8/2002 | Wang et al. | 6,652,518 | B2 | 11/2003 | Wellman et al. |
| 6,443,970 | B1 | 9/2002 | Schulze et al. | 6,652,521 | B2 | 11/2003 | Schulze |
| 6,443,988 | B2 | 9/2002 | Felt et al. | 6,652,545 | B2 | 11/2003 | Shipp et al. |
| 6,447,444 | B1 | 9/2002 | Avni et al. | 6,652,551 | B1 | 11/2003 | Heiss |
| 6,447,511 | B1 | 9/2002 | Slater | 6,656,194 | B1 | 12/2003 | Gannoe et al. |
| 6,447,523 | B1 | 9/2002 | Middleman et al. | 6,663,641 | B1 | 12/2003 | Kovac et al. |
| 6,454,783 | B1 | 9/2002 | Piskun | 6,663,655 | B2 | 12/2003 | Ginn et al. |
| 6,454,785 | B2 | 9/2002 | De Hoyos Garza | 6,666,854 | B1 | 12/2003 | Lange |
| 6,458,074 | B1 | 10/2002 | Matsui et al. | 6,672,338 | B1 | 1/2004 | Esashi et al. |
| 6,458,076 | B1 | 10/2002 | Pruitt | 6,673,058 | B2 | 1/2004 | Snow |
| 6,464,701 | B1 | 10/2002 | Hooven et al. | 6,673,070 | B2 | 1/2004 | Edwards et al. |
| 6,464,702 | B2 | 10/2002 | Schulze et al. | 6,673,087 | B1 | 1/2004 | Chang et al. |
| 6,470,218 | B1 | 10/2002 | Behl | 6,673,092 | B1 | 1/2004 | Bacher |
| 6,475,104 | B1 | 11/2002 | Lutz et al. | 6,676,685 | B2 | 1/2004 | Pedros et al. |
| 6,485,411 | B1 | 11/2002 | Konstorum et al. | 6,679,882 | B1 | 1/2004 | Kornerup |
| 6,489,745 | B1 | 12/2002 | Koreis | 6,685,628 | B2 | 2/2004 | Vu |
| 6,491,626 | B1 | 12/2002 | Stone et al. | 6,685,724 | B1 | 2/2004 | Haluck |
| 6,491,627 | B1 | 12/2002 | Komi | 6,692,445 | B2 | 2/2004 | Roberts et al. |
| 6,491,691 | B1 | 12/2002 | Morley et al. | 6,692,462 | B2 | 2/2004 | Mackenzie et al. |
| 6,493,590 | B1 | 12/2002 | Wessman et al. | 6,692,493 | B2 | 2/2004 | McGovern et al. |
| 6,494,893 | B2 | 12/2002 | Dubrul et al. | 6,699,180 | B2 | 3/2004 | Kobayashi |
| 6,500,176 | B1 | 12/2002 | Truckai et al. | 6,699,256 | B1 | 3/2004 | Logan et al. |
| 6,503,192 | B1 | 1/2003 | Ouchi | 6,699,263 | B2 | 3/2004 | Cope |
| 6,506,190 | B1 | 1/2003 | Walshe | 6,706,018 | B2 | 3/2004 | Westlund et al. |
| 6,508,827 | B1 | 1/2003 | Manhes | 6,708,066 | B2 | 3/2004 | Herbst et al. |
| 6,514,239 | B2 | 2/2003 | Shimmura et al. | 6,709,188 | B2 | 3/2004 | Ushimaru |
| 6,517,534 | B1 | 2/2003 | McGovern et al. | 6,709,445 | B2 | 3/2004 | Boebel et al. |
| 6,520,954 | B2 | 2/2003 | Ouchi | 6,716,226 | B2 | 4/2004 | Sixto, Jr. et al. |
| 6,526,320 | B2 | 2/2003 | Mitchell | 6,731,875 | B1 | 5/2004 | Kartalopoulos |
| 6,527,782 | B2 | 3/2003 | Hogg et al. | 6,736,822 | B2 | 5/2004 | McClellan et al. |
| 6,530,880 | B2 | 3/2003 | Pagliuca | 6,740,030 | B2 | 5/2004 | Martone et al. |
| 6,530,922 | B2 | 3/2003 | Cosman et al. | 6,740,082 | B2 | 5/2004 | Shaddock |
| 6,535,764 | B2 | 3/2003 | Imran et al. | 6,743,166 | B2 | 6/2004 | Berci et al. |
| 6,537,200 | B2 | 3/2003 | Laysieffer et al. | 6,743,226 | B2 | 6/2004 | Cosman et al. |
| 6,543,456 | B1 | 4/2003 | Freeman | 6,743,239 | B1 | 6/2004 | Kuehn et al. |
| 6,551,270 | B1 | 4/2003 | Bimbo et al. | 6,743,240 | B2 | 6/2004 | Smith et al. |
| 6,551,356 | B2 | 4/2003 | Rousseau | 6,749,560 | B1 | 6/2004 | Konstorum et al. |
| 6,554,766 | B2 | 4/2003 | Maeda et al. | 6,749,609 | B1 | 6/2004 | Lunsford et al. |
| | | | | 6,752,768 | B2 | 6/2004 | Burdorff et al. |
| | | | | 6,752,811 | B2 | 6/2004 | Chu et al. |
| | | | | 6,752,822 | B2 | 6/2004 | Jespersen |
| | | | | 6,758,857 | B2 | 7/2004 | Cioanta et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | | | |
|-----------|----|---------|-------------------|-----------|----|---------|--------------------|
| 6,761,685 | B2 | 7/2004 | Adams et al. | 6,960,163 | B2 | 11/2005 | Ewers et al. |
| 6,761,718 | B2 | 7/2004 | Madsen | 6,960,183 | B2 | 11/2005 | Nicolette |
| 6,761,722 | B2 | 7/2004 | Cole et al. | 6,962,587 | B2 | 11/2005 | Johnson et al. |
| 6,767,356 | B2 | 7/2004 | Kanner et al. | 6,964,662 | B2 | 11/2005 | Kidooka |
| 6,773,434 | B2 | 8/2004 | Ciarrocca | 6,966,909 | B2 | 11/2005 | Marshall et al. |
| 6,776,165 | B2 | 8/2004 | Jin | 6,966,919 | B2 | 11/2005 | Sixto, Jr. et al. |
| 6,776,787 | B2 | 8/2004 | Phung et al. | 6,967,462 | B1 | 11/2005 | Landis |
| 6,780,151 | B2 | 8/2004 | Grabover et al. | 6,971,988 | B2 | 12/2005 | Orban, III |
| 6,780,352 | B2 | 8/2004 | Jacobson | 6,972,017 | B2 | 12/2005 | Smith et al. |
| 6,783,491 | B2 | 8/2004 | Saadat et al. | 6,974,411 | B2 | 12/2005 | Belson |
| 6,786,382 | B1 | 9/2004 | Hoffman | 6,976,992 | B2 | 12/2005 | Sachatello et al. |
| 6,786,864 | B2 | 9/2004 | Matsuura et al. | 6,980,858 | B2 | 12/2005 | Fuimaono et al. |
| 6,786,905 | B2 | 9/2004 | Swanson et al. | 6,984,203 | B2 | 1/2006 | Tartaglia et al. |
| 6,788,977 | B2 | 9/2004 | Fenn et al. | 6,984,205 | B2 | 1/2006 | Gazdzinski |
| 6,790,173 | B2 | 9/2004 | Saadat et al. | 6,986,738 | B2 | 1/2006 | Glukhovskiy et al. |
| 6,790,217 | B2 | 9/2004 | Schulze et al. | 6,986,774 | B2 | 1/2006 | Middleman et al. |
| 6,795,728 | B2 | 9/2004 | Chornenky et al. | 6,988,987 | B2 | 1/2006 | Ishikawa et al. |
| 6,800,056 | B2 | 10/2004 | Tartaglia et al. | 6,989,028 | B2 | 1/2006 | Lashinski et al. |
| 6,808,491 | B2 | 10/2004 | Kortenbach et al. | 6,991,602 | B2 | 1/2006 | Nakazawa et al. |
| 6,814,697 | B2 | 11/2004 | Ouchi | 6,991,627 | B2 | 1/2006 | Madhani et al. |
| 6,817,974 | B2 | 11/2004 | Cooper et al. | 6,991,631 | B2 | 1/2006 | Woloszko et al. |
| 6,818,007 | B1 | 11/2004 | Dampney et al. | 6,994,706 | B2 | 2/2006 | Chornenky et al. |
| 6,824,548 | B2 | 11/2004 | Smith et al. | 6,994,708 | B2 | 2/2006 | Manzo |
| 6,830,545 | B2 | 12/2004 | Bendall | 6,997,870 | B2 | 2/2006 | Couvillon, Jr. |
| 6,836,688 | B2 | 12/2004 | Ingle et al. | 6,997,931 | B2 | 2/2006 | Sauer et al. |
| 6,837,847 | B2 | 1/2005 | Ewers et al. | 7,000,818 | B2 | 2/2006 | Shelton, IV et al. |
| 6,840,246 | B2 | 1/2005 | Downing | 7,001,329 | B2 | 2/2006 | Kobayashi et al. |
| 6,840,938 | B1 | 1/2005 | Morley et al. | 7,001,341 | B2 | 2/2006 | Gellman et al. |
| 6,843,794 | B2 | 1/2005 | Sixto, Jr. et al. | 7,008,375 | B2 | 3/2006 | Weisel |
| 6,852,078 | B2 | 2/2005 | Ouchi | 7,008,419 | B2 | 3/2006 | Shaddock |
| 6,861,250 | B1 | 3/2005 | Cole et al. | 7,009,634 | B2 | 3/2006 | Iddan et al. |
| 6,866,627 | B2 | 3/2005 | Nozue | 7,010,340 | B2 | 3/2006 | Scarantino et al. |
| 6,866,628 | B2 | 3/2005 | Goodman et al. | 7,011,669 | B2 | 3/2006 | Kimblad |
| 6,869,394 | B2 | 3/2005 | Ishibiki | 7,018,373 | B2 | 3/2006 | Suzuki |
| 6,869,395 | B2 | 3/2005 | Page et al. | 7,020,531 | B1 | 3/2006 | Colliou et al. |
| 6,869,398 | B2 | 3/2005 | Obenchain et al. | 7,025,580 | B2 | 4/2006 | Heagy et al. |
| 6,878,106 | B1 | 4/2005 | Herrmann | 7,025,721 | B2 | 4/2006 | Cohen et al. |
| 6,878,110 | B2 | 4/2005 | Yang et al. | 7,029,435 | B2 | 4/2006 | Nakao |
| 6,881,213 | B2 | 4/2005 | Ryan et al. | 7,029,438 | B2 | 4/2006 | Morin et al. |
| 6,881,216 | B2 | 4/2005 | Di Caprio et al. | 7,029,450 | B2 | 4/2006 | Gellman |
| 6,884,213 | B2 | 4/2005 | Raz et al. | 7,032,600 | B2 | 4/2006 | Fukuda et al. |
| 6,887,255 | B2 | 5/2005 | Shimm | 7,035,680 | B2 | 4/2006 | Partridge et al. |
| 6,889,089 | B2 | 5/2005 | Behl et al. | 7,037,290 | B2 | 5/2006 | Gardeski et al. |
| 6,890,295 | B2 | 5/2005 | Michels et al. | 7,041,052 | B2 | 5/2006 | Saadat et al. |
| 6,896,683 | B1 | 5/2005 | Gadberry et al. | 7,052,454 | B2 | 5/2006 | Taylor |
| 6,896,692 | B2 | 5/2005 | Ginn et al. | 7,052,489 | B2 | 5/2006 | Griego et al. |
| 6,899,710 | B2 | 5/2005 | Hoooven | 7,056,330 | B2 | 6/2006 | Gayton |
| 6,908,427 | B2 | 6/2005 | Fleener et al. | 7,060,024 | B2 | 6/2006 | Long et al. |
| 6,908,476 | B2 | 6/2005 | Jud et al. | 7,060,025 | B2 | 6/2006 | Long et al. |
| 6,911,019 | B2 | 6/2005 | Mulier et al. | 7,063,697 | B2 | 6/2006 | Slater |
| 6,913,613 | B2 | 7/2005 | Schwarz et al. | 7,063,715 | B2 | 6/2006 | Onuki et al. |
| 6,916,284 | B2 | 7/2005 | Moriyama | 7,066,879 | B2 | 6/2006 | Fowler et al. |
| 6,918,871 | B2 | 7/2005 | Schulze | 7,066,936 | B2 | 6/2006 | Ryan |
| 6,918,906 | B2 | 7/2005 | Long | 7,070,559 | B2 | 7/2006 | Adams et al. |
| 6,918,908 | B2 | 7/2005 | Bonner et al. | 7,070,602 | B2 | 7/2006 | Smith et al. |
| 6,926,723 | B1 | 8/2005 | Mulhauser et al. | 7,076,305 | B2 | 7/2006 | Imran et al. |
| 6,926,725 | B2 | 8/2005 | Cooke et al. | 7,083,618 | B2 | 8/2006 | Couture et al. |
| 6,932,810 | B2 | 8/2005 | Ryan | 7,083,620 | B2 | 8/2006 | Jahns et al. |
| 6,932,824 | B1 | 8/2005 | Roop et al. | 7,083,629 | B2 | 8/2006 | Weller et al. |
| 6,932,827 | B2 | 8/2005 | Cole | 7,083,635 | B2 | 8/2006 | Ginn |
| 6,932,834 | B2 | 8/2005 | Lizardi et al. | 7,087,010 | B2 | 8/2006 | Ootawara et al. |
| 6,936,003 | B2 | 8/2005 | Iddan | 7,087,071 | B2 | 8/2006 | Nicholas et al. |
| 6,939,290 | B2 | 9/2005 | Iddan | 7,088,923 | B2 | 8/2006 | Haruyama |
| 6,939,292 | B2 | 9/2005 | Mizuno | 7,090,673 | B2 | 8/2006 | Dycus et al. |
| 6,939,327 | B2 | 9/2005 | Hall et al. | 7,090,683 | B2 | 8/2006 | Brock et al. |
| 6,939,347 | B2 | 9/2005 | Thompson | 7,090,685 | B2 | 8/2006 | Kortenbach et al. |
| 6,942,613 | B2 | 9/2005 | Ewers et al. | 7,093,518 | B2 | 8/2006 | Gmeilbauer |
| 6,944,490 | B1 | 9/2005 | Chow | 7,101,371 | B2 | 9/2006 | Dycus et al. |
| 6,945,472 | B2 | 9/2005 | Wuttke et al. | 7,101,372 | B2 | 9/2006 | Dycus et al. |
| 6,945,979 | B2 | 9/2005 | Kortenbach et al. | 7,101,373 | B2 | 9/2006 | Dycus et al. |
| 6,949,096 | B2 | 9/2005 | Davison et al. | 7,105,000 | B2 | 9/2006 | McBrayer |
| 6,955,641 | B2 | 10/2005 | Lubock | 7,105,005 | B2 | 9/2006 | Blake |
| 6,955,683 | B2 | 10/2005 | Bonutti | 7,108,696 | B2 | 9/2006 | Daniel et al. |
| 6,958,035 | B2 | 10/2005 | Friedman et al. | 7,108,703 | B2 | 9/2006 | Danitz et al. |
| 6,960,162 | B2 | 11/2005 | Saadat et al. | 7,112,208 | B2 | 9/2006 | Morris et al. |
| | | | | 7,115,092 | B2 | 10/2006 | Park et al. |
| | | | | 7,115,124 | B1 | 10/2006 | Xiao |
| | | | | 7,117,703 | B2 | 10/2006 | Kato et al. |
| | | | | 7,118,531 | B2 | 10/2006 | Krill |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | | | |
|-----------|----|---------|---------------------|-----------|----|---------|---------------------|
| 7,118,578 | B2 | 10/2006 | West, Jr. et al. | 7,381,216 | B2 | 6/2008 | Buzzard et al. |
| 7,118,587 | B2 | 10/2006 | Dycus et al. | 7,390,324 | B2 | 6/2008 | Whalen et al. |
| 7,128,708 | B2 | 10/2006 | Saadat et al. | 7,393,322 | B2 | 7/2008 | Wenchell |
| 7,130,697 | B2 | 10/2006 | Chornenky et al. | 7,402,162 | B2 | 7/2008 | Ouchi |
| RE39,415 | E | 11/2006 | Bales et al. | 7,404,791 | B2 | 7/2008 | Linares et al. |
| 7,131,978 | B2 | 11/2006 | Sancoff et al. | 7,410,483 | B2 | 8/2008 | Danitz et al. |
| 7,131,979 | B2 | 11/2006 | DiCarlo et al. | 7,413,563 | B2 | 8/2008 | Corcoran et al. |
| 7,131,980 | B1 | 11/2006 | Field et al. | 7,416,554 | B2 | 8/2008 | Lam et al. |
| 7,137,980 | B2 | 11/2006 | Buyse et al. | 7,422,590 | B2 | 9/2008 | Kupferschmid et al. |
| 7,137,981 | B2 | 11/2006 | Long | 7,431,694 | B2 | 10/2008 | Stefanchik et al. |
| 7,146,984 | B2 | 12/2006 | Stack et al. | 7,435,229 | B2 | 10/2008 | Wolf |
| 7,147,650 | B2 | 12/2006 | Lee | 7,435,257 | B2 | 10/2008 | Lashinski et al. |
| 7,150,097 | B2 | 12/2006 | Sremcich et al. | 7,441,507 | B2 | 10/2008 | Teraura et al. |
| 7,150,655 | B2 | 12/2006 | Mastrototaro et al. | 7,442,166 | B2 | 10/2008 | Huang et al. |
| 7,150,750 | B2 | 12/2006 | Damarati | 7,452,327 | B2 | 11/2008 | Durgin et al. |
| 7,152,488 | B2 | 12/2006 | Hedrich et al. | 7,455,208 | B2 | 11/2008 | Wales et al. |
| 7,153,321 | B2 | 12/2006 | Andrews | 7,455,675 | B2 | 11/2008 | Schur et al. |
| 7,156,845 | B2 | 1/2007 | Mulier et al. | 7,468,066 | B2 | 12/2008 | Vargas et al. |
| 7,160,296 | B2 | 1/2007 | Pearson et al. | 7,476,237 | B2 | 1/2009 | Taniguchi et al. |
| 7,163,525 | B2 | 1/2007 | Franer | 7,479,104 | B2 | 1/2009 | Lau et al. |
| 7,169,104 | B2 | 1/2007 | Ueda et al. | 7,485,093 | B2 | 2/2009 | Glukhovsky |
| 7,169,115 | B2 | 1/2007 | Nobis et al. | 7,488,295 | B2 | 2/2009 | Burbank et al. |
| 7,172,714 | B2 | 2/2007 | Jacobson | 7,494,499 | B2 | 2/2009 | Nagase et al. |
| 7,175,591 | B2 | 2/2007 | Kaladelfos | 7,497,867 | B2 | 3/2009 | Lasner et al. |
| 7,179,254 | B2 | 2/2007 | Pendekanti et al. | 7,498,950 | B1 | 3/2009 | Ertas et al. |
| 7,186,265 | B2 | 3/2007 | Sharkawy et al. | 7,507,200 | B2 | 3/2009 | Okada |
| 7,188,627 | B2 | 3/2007 | Nelson et al. | 7,507,239 | B2 | 3/2009 | Shaddock |
| 7,189,231 | B2 | 3/2007 | Clague et al. | 7,510,107 | B2 | 3/2009 | Timm et al. |
| 7,195,612 | B2 | 3/2007 | van Sloten et al. | 7,511,733 | B2 | 3/2009 | Takizawa et al. |
| 7,195,631 | B2 | 3/2007 | Dumbauld | 7,515,953 | B2 | 4/2009 | Madar et al. |
| 7,204,804 | B2 | 4/2007 | Zirps et al. | 7,520,876 | B2 | 4/2009 | Ressemann et al. |
| 7,204,820 | B2 | 4/2007 | Akahoshi | 7,520,950 | B2 | 4/2009 | Saadat et al. |
| 7,207,997 | B2 | 4/2007 | Shipp et al. | 7,524,281 | B2 | 4/2009 | Chu et al. |
| 7,208,005 | B2 | 4/2007 | Frecker et al. | 7,524,302 | B2 | 4/2009 | Tower |
| 7,211,089 | B2 | 5/2007 | Kear et al. | 7,534,228 | B2 | 5/2009 | Williams |
| 7,211,092 | B2 | 5/2007 | Hughett | 7,536,217 | B2 | 5/2009 | Minai et al. |
| 7,220,227 | B2 | 5/2007 | Sasaki et al. | 7,540,872 | B2 | 6/2009 | Schechter et al. |
| 7,223,271 | B2 | 5/2007 | Muramatsu et al. | 7,542,807 | B2 | 6/2009 | Bertolero et al. |
| 7,223,272 | B2 | 5/2007 | Francesse et al. | 7,544,195 | B2 | 6/2009 | Lunsford et al. |
| 7,229,438 | B2 | 6/2007 | Young | 7,544,203 | B2 | 6/2009 | Chin et al. |
| 7,232,414 | B2 | 6/2007 | Gonzalez | 7,547,310 | B2 | 6/2009 | Whitfield |
| 7,232,445 | B2 | 6/2007 | Kortenbach et al. | 7,548,040 | B2 | 6/2009 | Lee et al. |
| 7,235,089 | B1 | 6/2007 | McGuckin, Jr. | 7,549,564 | B2 | 6/2009 | Boudreaux |
| 7,241,290 | B2 | 7/2007 | Doyle et al. | 7,549,990 | B2 | 6/2009 | Canady |
| 7,241,295 | B2 | 7/2007 | Maguire et al. | 7,549,991 | B2 | 6/2009 | Lu et al. |
| 7,244,228 | B2 | 7/2007 | Lubowski | 7,549,998 | B2 | 6/2009 | Braun |
| 7,250,027 | B2 | 7/2007 | Barry | 7,553,278 | B2 | 6/2009 | Kucklick |
| 7,252,660 | B2 | 8/2007 | Kunz | 7,553,298 | B2 | 6/2009 | Hunt et al. |
| 7,255,675 | B2 | 8/2007 | Gertner et al. | 7,559,452 | B2 | 7/2009 | Wales et al. |
| 7,261,725 | B2 | 8/2007 | Binmoeller | 7,559,887 | B2 | 7/2009 | Dannan |
| 7,261,728 | B2 | 8/2007 | Long et al. | 7,559,916 | B2 | 7/2009 | Smith et al. |
| 7,270,663 | B2 | 9/2007 | Nakao | 7,560,006 | B2 | 7/2009 | Rakos et al. |
| 7,288,075 | B2 | 10/2007 | Parihar et al. | 7,561,907 | B2 | 7/2009 | Fuimaono et al. |
| 7,291,127 | B2 | 11/2007 | Eidenschink | 7,561,916 | B2 | 7/2009 | Hunt et al. |
| 7,294,139 | B1 | 11/2007 | Gengler | 7,565,201 | B2 | 7/2009 | Blackmore et al. |
| 7,301,250 | B2 | 11/2007 | Cassel | 7,566,300 | B2 | 7/2009 | Devierre et al. |
| 7,306,597 | B2 | 12/2007 | Manzo | 7,566,334 | B2 | 7/2009 | Christian et al. |
| 7,308,828 | B2 | 12/2007 | Hashimoto | 7,575,144 | B2 | 8/2009 | Ortiz et al. |
| 7,311,107 | B2 | 12/2007 | Harel et al. | 7,575,548 | B2 | 8/2009 | Takemoto et al. |
| 7,318,802 | B2 | 1/2008 | Suzuki et al. | 7,578,832 | B2 | 8/2009 | Johnson et al. |
| 7,320,695 | B2 | 1/2008 | Carroll | 7,579,550 | B2 | 8/2009 | Dayton et al. |
| 7,322,934 | B2 | 1/2008 | Miyake et al. | 7,582,096 | B2 | 9/2009 | Gellman et al. |
| 7,323,006 | B2 | 1/2008 | Andreas et al. | 7,588,177 | B2 | 9/2009 | Racenet |
| 7,329,256 | B2 | 2/2008 | Johnson et al. | 7,588,557 | B2 | 9/2009 | Nakao |
| 7,329,257 | B2 | 2/2008 | Kanehira et al. | 7,591,781 | B2 | 9/2009 | Hirata |
| 7,329,383 | B2 | 2/2008 | Stinson | 7,591,783 | B2 | 9/2009 | Boulais et al. |
| 7,331,968 | B2 | 2/2008 | Arp et al. | 7,597,229 | B2 | 10/2009 | Boudreaux et al. |
| 7,335,220 | B2 | 2/2008 | Khosravi et al. | 7,604,150 | B2 | 10/2009 | Boudreaux |
| 7,341,554 | B2 | 3/2008 | Sekine et al. | 7,608,083 | B2 | 10/2009 | Lee et al. |
| 7,344,536 | B1 | 3/2008 | Lunsford et al. | 7,611,479 | B2 | 11/2009 | Cragg et al. |
| 7,352,387 | B2 | 4/2008 | Yamamoto | 7,615,002 | B2 | 11/2009 | Rothweiler et al. |
| 7,357,806 | B2 | 4/2008 | Rivera et al. | 7,615,003 | B2 | 11/2009 | Stefanchik et al. |
| 7,364,582 | B2 | 4/2008 | Lee | 7,615,005 | B2 | 11/2009 | Stefanchik et al. |
| 7,367,939 | B2 | 5/2008 | Smith et al. | 7,615,058 | B2 | 11/2009 | Sixto, Jr. et al. |
| 7,371,215 | B2 | 5/2008 | Colliou et al. | 7,615,067 | B2 | 11/2009 | Lee et al. |
| | | | | 7,618,398 | B2 | 11/2009 | Holman et al. |
| | | | | 7,618,437 | B2 | 11/2009 | Nakao |
| | | | | 7,621,927 | B2 | 11/2009 | Messerly et al. |
| | | | | 7,621,936 | B2 | 11/2009 | Cragg et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|--------------|---------|---------------------|--------------|---------|--------------------|
| 7,628,792 B2 | 12/2009 | Guerra | 7,798,960 B2 | 9/2010 | Jaeger |
| 7,628,797 B2 | 12/2009 | Tieu et al. | 7,813,590 B2 | 10/2010 | Horn et al. |
| 7,632,250 B2 | 12/2009 | Smith et al. | 7,813,789 B2 | 10/2010 | Glukhovsky |
| 7,635,373 B2 | 12/2009 | Ortiz | 7,815,565 B2 | 10/2010 | Stefanchik et al. |
| 7,637,903 B2 | 12/2009 | Lentz et al. | 7,815,566 B2 | 10/2010 | Stefanchik et al. |
| 7,637,905 B2 | 12/2009 | Saadat et al. | 7,815,659 B2 | 10/2010 | Conlon et al. |
| 7,645,288 B2 | 1/2010 | McKenna et al. | 7,815,662 B2 | 10/2010 | Spivey et al. |
| 7,648,457 B2 | 1/2010 | Stefanchik et al. | 7,819,836 B2 | 10/2010 | Levine et al. |
| 7,648,519 B2 | 1/2010 | Lee et al. | 7,828,186 B2 | 11/2010 | Wales |
| 7,650,742 B2 | 1/2010 | Ushijima | 7,828,808 B2 | 11/2010 | Hinman et al. |
| 7,651,483 B2 | 1/2010 | Byrum et al. | 7,833,156 B2 | 11/2010 | Williams et al. |
| 7,651,509 B2 | 1/2010 | Bojarski et al. | 7,833,238 B2 | 11/2010 | Nakao |
| 7,653,438 B2 | 1/2010 | Deem et al. | 7,837,615 B2 | 11/2010 | Le et al. |
| 7,654,431 B2 | 2/2010 | Hueil et al. | 7,842,028 B2 | 11/2010 | Lee |
| 7,655,004 B2 | 2/2010 | Long | 7,842,050 B2 | 11/2010 | Diduch et al. |
| 7,658,738 B2 | 2/2010 | Nobis et al. | 7,842,068 B2 | 11/2010 | Ginn |
| 7,662,089 B2 | 2/2010 | Okada et al. | 7,846,087 B2 | 12/2010 | Stefanchik et al. |
| 7,666,180 B2 | 2/2010 | Holsten et al. | 7,846,107 B2 | 12/2010 | Hoffman et al. |
| 7,666,203 B2 | 2/2010 | Chanduszko et al. | 7,846,171 B2 | 12/2010 | Kullas et al. |
| 7,670,282 B2 | 3/2010 | Mathis | 7,850,660 B2 | 12/2010 | Uth et al. |
| 7,670,336 B2 | 3/2010 | Young et al. | 7,850,686 B2 | 12/2010 | Nobis et al. |
| 7,670,346 B2 | 3/2010 | Whitfield | 7,850,712 B2 | 12/2010 | Conlon et al. |
| 7,674,259 B2 | 3/2010 | Shadduck | 7,857,183 B2 | 12/2010 | Shelton, IV |
| 7,674,275 B2 | 3/2010 | Martin et al. | 7,862,546 B2 | 1/2011 | Conlon et al. |
| 7,678,043 B2 | 3/2010 | Gilad | 7,862,553 B2 | 1/2011 | Ewaschuk |
| 7,680,543 B2 | 3/2010 | Azure | 7,862,572 B2 | 1/2011 | Meade et al. |
| 7,684,599 B2 | 3/2010 | Horn et al. | 7,862,582 B2 | 1/2011 | Ortiz et al. |
| 7,684,851 B2 | 3/2010 | Miyake et al. | 7,867,216 B2 | 1/2011 | Wahr et al. |
| 7,686,826 B2 | 3/2010 | Lee et al. | 7,871,371 B2 | 1/2011 | Komiya et al. |
| 7,691,103 B2 | 4/2010 | Fernandez et al. | 7,875,042 B2 | 1/2011 | Martin et al. |
| 7,697,970 B2 | 4/2010 | Uchiyama et al. | 7,879,004 B2 | 2/2011 | Seibel et al. |
| 7,699,835 B2 | 4/2010 | Lee et al. | 7,883,458 B2 | 2/2011 | Hamel |
| 7,699,864 B2 | 4/2010 | Kick et al. | 7,887,530 B2 | 2/2011 | Zemlok et al. |
| 7,708,756 B2 | 5/2010 | Nobis et al. | 7,887,558 B2 | 2/2011 | Lin et al. |
| 7,713,189 B2 | 5/2010 | Hanke | 7,892,220 B2 | 2/2011 | Faller et al. |
| 7,713,270 B2 | 5/2010 | Suzuki | 7,896,804 B2 | 3/2011 | Uchimura et al. |
| 7,721,742 B2 | 5/2010 | Kaloo et al. | 7,896,887 B2 | 3/2011 | Rimbaugh et al. |
| 7,727,242 B2 | 6/2010 | Sepetka et al. | 7,905,828 B2 | 3/2011 | Brock et al. |
| 7,727,246 B2 | 6/2010 | Sixto, Jr. et al. | 7,905,830 B2 | 3/2011 | Stefanchik et al. |
| 7,727,248 B2 | 6/2010 | Smith et al. | 7,909,809 B2 | 3/2011 | Scopton et al. |
| 7,727,249 B2 | 6/2010 | Rahmani | 7,914,513 B2 | 3/2011 | Voorhees, Jr. |
| 7,731,725 B2 | 6/2010 | Gadberry et al. | 7,918,783 B2 | 4/2011 | Maseda et al. |
| 7,736,374 B2 | 6/2010 | Vaughan et al. | 7,918,785 B2 | 4/2011 | Okada et al. |
| 7,744,591 B2 | 6/2010 | Rioux et al. | 7,918,844 B2 | 4/2011 | Byrum et al. |
| 7,744,615 B2 | 6/2010 | Couture | 7,918,845 B2 | 4/2011 | Saadat et al. |
| 7,749,161 B2 | 7/2010 | Beckman et al. | 7,918,848 B2 | 4/2011 | Lau et al. |
| 7,749,163 B2 | 7/2010 | Mulac et al. | 7,918,869 B2 | 4/2011 | Saadat et al. |
| 7,751,866 B2 | 7/2010 | Aoki et al. | 7,922,650 B2 | 4/2011 | McWeeney et al. |
| 7,751,869 B2 | 7/2010 | Rioux et al. | 7,922,717 B2 | 4/2011 | Sugita |
| 7,753,901 B2 | 7/2010 | Piskun et al. | 7,922,739 B2 | 4/2011 | Downey |
| 7,753,933 B2 | 7/2010 | Ginn et al. | 7,922,743 B2 | 4/2011 | Heinrich et al. |
| 7,758,577 B2 | 7/2010 | Nobis et al. | 7,927,271 B2 | 4/2011 | Dimitriou et al. |
| 7,758,598 B2 | 7/2010 | Conlon et al. | 7,931,624 B2 | 4/2011 | Smith et al. |
| 7,762,949 B2 | 7/2010 | Nakao | 7,931,661 B2 | 4/2011 | Saadat et al. |
| 7,762,959 B2 | 7/2010 | Bilsbury | 7,935,130 B2 | 5/2011 | Williams |
| 7,762,960 B2 | 7/2010 | Timberlake et al. | 7,937,143 B2 | 5/2011 | Demarais et al. |
| 7,762,998 B2 | 7/2010 | Birk et al. | 7,945,332 B2 | 5/2011 | Schechter |
| 7,763,012 B2 | 7/2010 | Petrack et al. | 7,947,000 B2 | 5/2011 | Vargas et al. |
| 7,765,010 B2 | 7/2010 | Chornenky et al. | 7,951,073 B2 | 5/2011 | Freed |
| 7,766,896 B2 | 8/2010 | Komkven Volk et al. | 7,953,326 B2 | 5/2011 | Farr et al. |
| 7,770,584 B2 | 8/2010 | Danek et al. | 7,955,298 B2 | 6/2011 | Carroll et al. |
| 7,771,416 B2 | 8/2010 | Spivey et al. | 7,955,340 B2 | 6/2011 | Michlitsch et al. |
| 7,771,437 B2 | 8/2010 | Hogg et al. | 7,955,355 B2 | 6/2011 | Chin |
| 7,776,035 B2 | 8/2010 | Rick et al. | 7,959,627 B2 | 6/2011 | Utley et al. |
| 7,780,639 B2 | 8/2010 | Van Lue | 7,959,629 B2 | 6/2011 | Young et al. |
| 7,780,683 B2 | 8/2010 | Roue et al. | 7,959,642 B2 | 6/2011 | Nobis et al. |
| 7,780,691 B2 | 8/2010 | Stefanchik | 7,963,192 B2 | 6/2011 | Mayenberger et al. |
| 7,784,663 B2 | 8/2010 | Shelton, IV | 7,963,912 B2 | 6/2011 | Zwolinski et al. |
| 7,785,348 B2 | 8/2010 | Kuhns et al. | 7,963,975 B2 | 6/2011 | Criscuolo |
| 7,789,825 B2 | 9/2010 | Nobis et al. | 7,965,180 B2 | 6/2011 | Koyama |
| 7,794,409 B2 | 9/2010 | Damarati | 7,967,808 B2 | 6/2011 | Fitzgerald et al. |
| 7,794,447 B2 | 9/2010 | Dann et al. | 7,967,842 B2 | 6/2011 | Bakos |
| 7,794,458 B2 | 9/2010 | McIntyre et al. | 7,969,473 B2 | 6/2011 | Kotoda |
| 7,794,475 B2 | 9/2010 | Hess et al. | 7,972,330 B2 | 7/2011 | Alejandro et al. |
| 7,798,386 B2 | 9/2010 | Schall et al. | 7,972,333 B2 | 7/2011 | Nishimura |
| | | | 7,976,458 B2 | 7/2011 | Stefanchik et al. |
| | | | 7,976,552 B2 | 7/2011 | Suzuki |
| | | | 7,985,239 B2 | 7/2011 | Suzuki |
| | | | 7,988,618 B2 | 8/2011 | Mikkaichi et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|--------------|---------|----------------------|--------------|---------|----------------------|
| 7,988,685 B2 | 8/2011 | Ziaie et al. | 8,251,068 B2 | 8/2012 | Schnell |
| 7,988,690 B2 | 8/2011 | Chanduszko et al. | 8,252,057 B2 | 8/2012 | Fox |
| 7,998,132 B2 | 8/2011 | Gregorich et al. | 8,262,563 B2 | 9/2012 | Bakos et al. |
| 8,007,474 B2 | 8/2011 | Uth et al. | 8,262,655 B2 | 9/2012 | Ghabrial et al. |
| 8,021,358 B2 | 9/2011 | Doyle et al. | 8,262,680 B2 | 9/2012 | Swain et al. |
| 8,021,362 B2 | 9/2011 | Deem et al. | 8,267,854 B2 | 9/2012 | Asada et al. |
| 8,021,378 B2 | 9/2011 | Sixto, Jr. et al. | 8,277,373 B2 | 10/2012 | Maahs et al. |
| 8,029,504 B2 | 10/2011 | Long | 8,282,665 B2 | 10/2012 | Kieturakis et al. |
| 8,034,046 B2 | 10/2011 | Eidenschink | 8,298,161 B2 | 10/2012 | Vargas |
| 8,037,591 B2 | 10/2011 | Spivey et al. | 8,303,581 B2 | 11/2012 | Arts et al. |
| 8,038,596 B2 | 10/2011 | Miyake et al. | 8,308,682 B2 | 11/2012 | Kramer et al. |
| 8,038,612 B2 | 10/2011 | Paz | 8,308,738 B2 | 11/2012 | Nobis et al. |
| 8,043,289 B2 | 10/2011 | Behl et al. | 8,308,743 B2 | 11/2012 | Matsuno et al. |
| 8,048,060 B2 | 11/2011 | Griffin et al. | 8,313,496 B2 | 11/2012 | Sauer et al. |
| 8,048,067 B2 | 11/2011 | Davalos et al. | 8,317,806 B2 | 11/2012 | Coe et al. |
| 8,048,108 B2 | 11/2011 | Sibbitt, Jr. et al. | 8,317,814 B2 | 11/2012 | Karasawa et al. |
| 8,052,597 B2 | 11/2011 | Boulais | 8,328,836 B2 | 12/2012 | Conlon et al. |
| 8,052,699 B1 | 11/2011 | Sherwinter | 8,333,691 B2 | 12/2012 | Schaaf |
| 8,057,462 B2 | 11/2011 | Weitzner et al. | 8,333,777 B2 | 12/2012 | Schaller et al. |
| 8,057,510 B2 | 11/2011 | Ginn et al. | 8,337,394 B2 | 12/2012 | Vakharia |
| 8,062,306 B2 | 11/2011 | Nobis et al. | 8,337,492 B2 | 12/2012 | Kunis et al. |
| 8,062,311 B2 | 11/2011 | Litscher et al. | 8,337,510 B2 | 12/2012 | Rieber et al. |
| 8,066,632 B2 | 11/2011 | Dario et al. | 8,343,041 B2 | 1/2013 | Byers et al. |
| 8,066,702 B2 | 11/2011 | Rittman, III et al. | 8,348,827 B2 | 1/2013 | Zwolinski |
| 8,070,743 B2 | 12/2011 | Kagan et al. | 8,353,487 B2 | 1/2013 | Trusty et al. |
| 8,070,759 B2 | 12/2011 | Stefanchik et al. | 8,357,170 B2 | 1/2013 | Stefanchik |
| 8,070,804 B2 | 12/2011 | Hyde et al. | 8,359,093 B2 | 1/2013 | Warior |
| 8,075,478 B2 | 12/2011 | Campos | 8,361,066 B2 | 1/2013 | Long et al. |
| 8,075,567 B2 | 12/2011 | Taylor et al. | 8,361,112 B2 | 1/2013 | Carroll, II et al. |
| 8,075,572 B2 | 12/2011 | Stefanchik et al. | 8,366,606 B2 | 2/2013 | Watanabe et al. |
| 8,075,573 B2 | 12/2011 | Gambale et al. | 8,377,044 B2 | 2/2013 | Coe et al. |
| 8,075,587 B2 | 12/2011 | Ginn | 8,377,057 B2 | 2/2013 | Rick et al. |
| 8,088,062 B2 | 1/2012 | Zwolinski | 8,382,790 B2 | 2/2013 | Uenohara et al. |
| 8,092,374 B2 | 1/2012 | Smith et al. | 8,388,653 B2 | 3/2013 | Nobis et al. |
| 8,092,549 B2 | 1/2012 | Hillis et al. | 8,394,090 B2 | 3/2013 | Ootsubo |
| 8,096,459 B2 | 1/2012 | Ortiz et al. | 8,403,926 B2 | 3/2013 | Nobis et al. |
| 8,096,941 B2 | 1/2012 | Fowler et al. | 8,409,076 B2 | 4/2013 | Pang et al. |
| 8,096,998 B2 | 1/2012 | Cresina | 8,409,197 B2 | 4/2013 | Slater |
| 8,097,001 B2 | 1/2012 | Nakao | 8,409,200 B2 | 4/2013 | Holcomb et al. |
| 8,100,922 B2 | 1/2012 | Griffith | 8,425,505 B2 | 4/2013 | Long |
| 8,109,872 B2 | 2/2012 | Kennedy, II et al. | 8,430,811 B2 | 4/2013 | Hess et al. |
| 8,109,919 B2 | 2/2012 | Kraft et al. | 8,449,452 B2 | 5/2013 | Iddan et al. |
| 8,109,926 B2 | 2/2012 | Azure | 8,449,538 B2 | 5/2013 | Long |
| 8,114,072 B2 | 2/2012 | Long et al. | 8,454,594 B2 | 6/2013 | Demarais et al. |
| 8,114,113 B2 | 2/2012 | Becker | 8,460,275 B2 | 6/2013 | Taylor et al. |
| 8,114,119 B2 | 2/2012 | Spivey et al. | 8,465,419 B2 | 6/2013 | Moriyama |
| 8,118,738 B2 | 2/2012 | Larkin | 8,465,484 B2 | 6/2013 | Davalos et al. |
| 8,118,821 B2 | 2/2012 | Mouw | 8,469,993 B2 | 6/2013 | Rothberg et al. |
| 8,118,834 B1 | 2/2012 | Goralchouk et al. | 8,475,359 B2 | 7/2013 | Asada et al. |
| 8,118,835 B2 | 2/2012 | Weisel et al. | 8,475,361 B2 | 7/2013 | Barlow et al. |
| 8,123,677 B2 | 2/2012 | Fujimori | 8,475,452 B2 | 7/2013 | Van Wyk et al. |
| 8,131,371 B2 | 3/2012 | Demarals et al. | 8,480,657 B2 | 7/2013 | Bakos |
| 8,147,424 B2 | 4/2012 | Kassab et al. | 8,480,689 B2 | 7/2013 | Spivey et al. |
| 8,157,813 B2 | 4/2012 | Ko et al. | 8,485,968 B2 | 7/2013 | Weimer et al. |
| 8,157,817 B2 | 4/2012 | Bonadio et al. | 8,496,574 B2 | 7/2013 | Trusty et al. |
| 8,157,834 B2 | 4/2012 | Conlon | 8,500,697 B2 | 8/2013 | Kurth et al. |
| 8,159,549 B2 | 4/2012 | Glukhovskiy et al. | 8,506,564 B2 | 8/2013 | Long et al. |
| 8,167,894 B2 | 5/2012 | Miles et al. | 8,512,335 B2 | 8/2013 | Cheng et al. |
| 8,172,772 B2 | 5/2012 | Zwolinski et al. | 8,517,921 B2 | 8/2013 | Tremaglio et al. |
| 8,182,414 B2 | 5/2012 | Handa et al. | 8,518,024 B2 | 8/2013 | Williams et al. |
| 8,187,166 B2 | 5/2012 | Kuth et al. | 8,518,052 B2 | 8/2013 | Burgermeister et al. |
| 8,200,334 B1 | 6/2012 | Min et al. | 8,518,062 B2 | 8/2013 | Cole et al. |
| 8,202,265 B2 | 6/2012 | Boulais | 8,523,939 B1 | 9/2013 | Hausen |
| 8,202,295 B2 | 6/2012 | Kaplan | 8,529,563 B2 | 9/2013 | Long et al. |
| 8,206,295 B2 | 6/2012 | Kaul | 8,540,744 B2 | 9/2013 | Spivey et al. |
| 8,211,119 B2 | 7/2012 | Palmer et al. | 8,545,396 B2 | 10/2013 | Cover et al. |
| 8,211,125 B2 | 7/2012 | Spivey | 8,545,450 B2 | 10/2013 | Voegelé et al. |
| 8,216,224 B2 | 7/2012 | Morris et al. | 8,551,058 B2 | 10/2013 | Measamer et al. |
| 8,216,252 B2 | 7/2012 | Vaughan et al. | 8,562,513 B2 | 10/2013 | Yamatani |
| 8,216,255 B2 | 7/2012 | Smith et al. | 8,562,602 B2 | 10/2013 | Azure |
| 8,221,310 B2 | 7/2012 | Saadat et al. | 8,568,410 B2 | 10/2013 | Vakharia et al. |
| 8,221,411 B2 | 7/2012 | Francischelli et al. | 8,579,176 B2 | 11/2013 | Smith et al. |
| 8,241,204 B2 | 8/2012 | Spivey | 8,579,897 B2 | 11/2013 | Vakharia et al. |
| 8,241,309 B2 | 8/2012 | Miles et al. | 8,602,970 B2 | 12/2013 | Muyari et al. |
| 8,246,633 B2 | 8/2012 | Omori | 8,603,138 B2 | 12/2013 | Faller et al. |
| | | | 8,608,652 B2 | 12/2013 | Voegelé et al. |
| | | | 8,617,156 B2 | 12/2013 | Werneth et al. |
| | | | 8,623,011 B2 | 1/2014 | Spivey |
| | | | 8,632,534 B2 | 1/2014 | Pearson et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|--------------|---------|------------------------|-----------------|---------|-------------------|
| 8,632,563 B2 | 1/2014 | Nagase et al. | 9,427,255 B2 | 8/2016 | Griffith et al. |
| 8,636,648 B2 | 1/2014 | Gazdzinski | 9,486,241 B2 | 11/2016 | Leiner et al. |
| 8,636,650 B2 | 1/2014 | Lee | 9,492,148 B2 | 11/2016 | Ginn et al. |
| 8,636,730 B2 | 1/2014 | Keppel | 9,545,290 B2 | 1/2017 | Tellio et al. |
| 8,640,940 B2 | 2/2014 | Ohdaira | 9,549,719 B2 | 1/2017 | Shohat et al. |
| 8,641,728 B2 | 2/2014 | Stokes et al. | 9,566,126 B2 | 2/2017 | Weitzner et al. |
| 8,652,150 B2 | 2/2014 | Swain et al. | 9,572,623 B2 | 2/2017 | Long |
| 8,657,174 B2 | 2/2014 | Yates et al. | 9,598,691 B2 | 3/2017 | Davalos |
| 8,663,236 B2 | 3/2014 | Chen et al. | 9,627,120 B2 | 4/2017 | Scott et al. |
| 8,668,686 B2 | 3/2014 | Govari et al. | 2001/0023333 A1 | 9/2001 | Wise et al. |
| 8,679,003 B2 | 3/2014 | Spivey | 2002/0022857 A1 | 2/2002 | Goldsteen et al. |
| 8,684,967 B2 | 4/2014 | Engel et al. | 2002/0023353 A1 | 2/2002 | Ting-Kung |
| 8,704,923 B2 | 4/2014 | Ogasawara et al. | 2002/0029055 A1 | 3/2002 | Bonutti |
| 8,715,281 B2 | 5/2014 | Barlow et al. | 2002/0042562 A1 | 4/2002 | Meron et al. |
| 8,721,658 B2 | 5/2014 | Kahle et al. | 2002/0068945 A1 | 6/2002 | Sixto et al. |
| 8,723,936 B2 | 5/2014 | Amling et al. | 2002/0082551 A1 | 6/2002 | Yachia et al. |
| 8,727,967 B2 | 5/2014 | Weitzner | 2002/0095164 A1 | 7/2002 | Andreas et al. |
| 8,747,401 B2 | 6/2014 | Gonzalez et al. | 2002/0133115 A1 | 9/2002 | Gordon et al. |
| 8,753,262 B2 | 6/2014 | Sugiyama et al. | 2002/0138086 A1 | 9/2002 | Sixto et al. |
| 8,753,335 B2 | 6/2014 | Moshe et al. | 2002/0165592 A1 | 11/2002 | Glukhovsky et al. |
| 8,764,735 B2 | 7/2014 | Coe et al. | 2003/0014090 A1 | 1/2003 | Abrahamson |
| 8,771,173 B2 | 7/2014 | Fonger et al. | 2003/0018373 A1 | 1/2003 | Eckhardt et al. |
| 8,771,260 B2 | 7/2014 | Conlon et al. | 2003/0069602 A1 | 4/2003 | Jacobs et al. |
| 8,774,913 B2 | 7/2014 | Demarais et al. | 2003/0078471 A1 | 4/2003 | Foley et al. |
| 8,784,436 B2 | 7/2014 | Ho et al. | 2003/0083681 A1 | 5/2003 | Moutafis et al. |
| 8,795,161 B2 | 8/2014 | Carter | 2003/0114731 A1 | 6/2003 | Cadeddu et al. |
| 8,821,520 B2 | 9/2014 | Schwemberger et al. | 2003/0114732 A1 | 6/2003 | Webler et al. |
| 8,821,532 B2 | 9/2014 | Schaeffer | 2003/0120257 A1 | 6/2003 | Houston et al. |
| 8,828,031 B2 | 9/2014 | Fox et al. | 2003/0124009 A1 | 7/2003 | Ravi et al. |
| 8,834,461 B2 | 9/2014 | Werneth et al. | 2003/0130656 A1 | 7/2003 | Levin |
| 8,858,590 B2 | 10/2014 | Shelton, IV et al. | 2003/0139646 A1 | 7/2003 | Sharrow et al. |
| 8,876,701 B2 | 11/2014 | Surti et al. | 2003/0158521 A1 | 8/2003 | Ameri |
| 8,876,772 B2 | 11/2014 | Weber et al. | 2003/0167062 A1 | 9/2003 | Gambale et al. |
| 8,880,185 B2 | 11/2014 | Hastings et al. | 2003/0187351 A1 | 10/2003 | Franck et al. |
| 8,888,792 B2 | 11/2014 | Harris et al. | 2003/0225312 A1 | 12/2003 | Suzuki et al. |
| 8,906,035 B2 | 12/2014 | Zwolinski et al. | 2003/0225332 A1 | 12/2003 | Okada et al. |
| 8,911,452 B2 | 12/2014 | Skakoon et al. | 2003/0229269 A1 | 12/2003 | Humphrey |
| 8,920,442 B2 | 12/2014 | Sibbitt, Jr. et al. | 2003/0229371 A1 | 12/2003 | Whitworth |
| 8,926,606 B2 | 1/2015 | Davalos et al. | 2004/0002683 A1 | 1/2004 | Nicholson et al. |
| 8,932,208 B2 | 1/2015 | Kendale et al. | 2004/0024414 A1 | 2/2004 | Downing |
| 8,939,897 B2 | 1/2015 | Nobis | 2004/0098007 A1 | 5/2004 | Heiss |
| 8,986,199 B2 | 3/2015 | Weisenburgh, II et al. | 2004/0101456 A1 | 5/2004 | Kuroshima et al. |
| 8,992,517 B2 | 3/2015 | Davalos et al. | 2004/0104999 A1 | 6/2004 | Okada |
| 9,005,198 B2 | 4/2015 | Long et al. | 2004/0133089 A1 | 7/2004 | Kilcoyne et al. |
| 9,011,431 B2 | 4/2015 | Long et al. | 2004/0136779 A1 | 7/2004 | Bhaskar |
| 9,028,483 B2 | 5/2015 | Long et al. | 2004/0138529 A1 | 7/2004 | Wiltshire et al. |
| 9,049,987 B2 | 6/2015 | Conlon et al. | 2004/0138587 A1 | 7/2004 | Lyons |
| 9,060,782 B2 | 6/2015 | Daniel et al. | 2004/0161451 A1 | 8/2004 | Pierce et al. |
| 9,066,655 B2 | 6/2015 | Stefanchik et al. | 2004/0167545 A1 | 8/2004 | Sadler et al. |
| 9,078,662 B2 | 7/2015 | Bakos et al. | 2004/0176699 A1 | 9/2004 | Walker et al. |
| 9,084,621 B2 | 7/2015 | Weitzner et al. | 2004/0186350 A1 | 9/2004 | Brenneman et al. |
| 9,089,323 B2 | 7/2015 | Bonutti et al. | 2004/0193009 A1 | 9/2004 | Jaffe et al. |
| 9,125,557 B2 | 9/2015 | Lien et al. | 2004/0193186 A1 | 9/2004 | Kortenbach et al. |
| 9,125,631 B2 | 9/2015 | Smith et al. | 2004/0193188 A1 | 9/2004 | Francese |
| 9,125,639 B2 | 9/2015 | Mathis et al. | 2004/0193189 A1 | 9/2004 | Kortenbach et al. |
| 9,149,172 B2 | 10/2015 | Iddan et al. | 2004/0193200 A1 | 9/2004 | Dworschak et al. |
| 9,155,587 B2 | 10/2015 | Willis et al. | 2004/0199052 A1 | 10/2004 | Banik et al. |
| 9,186,203 B2 | 11/2015 | Spivey et al. | 2004/0199159 A1 | 10/2004 | Lee et al. |
| 9,198,733 B2 | 12/2015 | Neal, II et al. | 2004/0206859 A1 | 10/2004 | Chong et al. |
| 9,220,526 B2 | 12/2015 | Conlon | 2004/0210245 A1 | 10/2004 | Erickson et al. |
| 9,226,772 B2 | 1/2016 | Fox | 2004/0225186 A1 | 11/2004 | Horne et al. |
| 9,233,241 B2 | 1/2016 | Long | 2004/0243108 A1 | 12/2004 | Suzuki |
| 9,248,278 B2 | 2/2016 | Crosby et al. | 2004/0249367 A1 | 12/2004 | Saadat et al. |
| 9,254,169 B2 | 2/2016 | Long et al. | 2004/0249394 A1 | 12/2004 | Morris et al. |
| 9,265,407 B2 | 2/2016 | Goldfarb et al. | 2004/0249443 A1 | 12/2004 | Shanley et al. |
| 9,271,796 B2 | 3/2016 | Buyse et al. | 2004/0254572 A1 | 12/2004 | McIntyre et al. |
| 9,277,957 B2 | 3/2016 | Long et al. | 2004/0260315 A1 | 12/2004 | Dell et al. |
| 9,295,485 B2 | 3/2016 | Conlon et al. | 2004/0260337 A1 | 12/2004 | Freed |
| 9,308,049 B2 | 4/2016 | Dejima | 2005/0004515 A1 | 1/2005 | Hart et al. |
| 9,314,620 B2 | 4/2016 | Long et al. | 2005/0043690 A1 | 2/2005 | Todd |
| 9,339,328 B2 | 5/2016 | Ortiz et al. | 2005/0059963 A1 | 3/2005 | Phan et al. |
| 9,345,462 B2 | 5/2016 | Weitzner et al. | 2005/0059964 A1 | 3/2005 | Fitz |
| 9,352,152 B2 | 5/2016 | Lindenthaler et al. | 2005/0065509 A1 | 3/2005 | Coldwell et al. |
| 9,370,341 B2 | 6/2016 | Ceniccola et al. | 2005/0070947 A1 | 3/2005 | Franer et al. |
| 9,375,268 B2 | 6/2016 | Long | 2005/0080435 A1 | 4/2005 | Smith et al. |
| | | | 2005/0085693 A1 | 4/2005 | Belson et al. |
| | | | 2005/0085832 A1 | 4/2005 | Sancoff et al. |
| | | | 2005/0090837 A1 | 4/2005 | Sixto et al. |
| | | | 2005/0096502 A1 | 5/2005 | Khalili |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | | | |
|--------------|-----|---------|-------------------|--------------|----|---------|-------------------|
| 2005/0101837 | A1 | 5/2005 | Kaloo et al. | 2006/0200121 | A1 | 9/2006 | Mowery |
| 2005/0101838 | A1 | 5/2005 | Camillocci et al. | 2006/0200169 | A1 | 9/2006 | Sniffin |
| 2005/0107663 | A1 | 5/2005 | Saadat et al. | 2006/0200170 | A1 | 9/2006 | Aranyi |
| 2005/0107664 | A1 | 5/2005 | Kaloo et al. | 2006/0217665 | A1 | 9/2006 | Prosek |
| 2005/0119613 | A1 | 6/2005 | Moenning et al. | 2006/0217742 | A1 | 9/2006 | Messerly et al. |
| 2005/0124855 | A1 | 6/2005 | Jaffe et al. | 2006/0237023 | A1 | 10/2006 | Cox et al. |
| 2005/0125010 | A1 | 6/2005 | Smith et al. | 2006/0241570 | A1 | 10/2006 | Wilk |
| 2005/0131457 | A1 | 6/2005 | Douglas et al. | 2006/0247500 | A1 | 11/2006 | Voegelé et al. |
| 2005/0137454 | A1 | 6/2005 | Saadat et al. | 2006/0247576 | A1 | 11/2006 | Poncet |
| 2005/0143690 | A1 | 6/2005 | High | 2006/0247663 | A1 | 11/2006 | Schwartz et al. |
| 2005/0143774 | A1 | 6/2005 | Polo | 2006/0253004 | A1 | 11/2006 | Frisch et al. |
| 2005/0143803 | A1 | 6/2005 | Watson et al. | 2006/0259010 | A1 | 11/2006 | Stefanchik et al. |
| 2005/0149087 | A1 | 7/2005 | Ahlberg et al. | 2006/0259073 | A1 | 11/2006 | Miyamoto et al. |
| 2005/0149096 | A1 | 7/2005 | Hilal et al. | 2006/0264752 | A1 | 11/2006 | Rubinsky et al. |
| 2005/0165272 | A1 | 7/2005 | Okada et al. | 2006/0264904 | A1 | 11/2006 | Kerby et al. |
| 2005/0165378 | A1 | 7/2005 | Heinrich et al. | 2006/0270902 | A1 | 11/2006 | Igarashi et al. |
| 2005/0165411 | A1 | 7/2005 | Orban | 2006/0271042 | A1 | 11/2006 | Latterell et al. |
| 2005/0165429 | A1 | 7/2005 | Douglas et al. | 2006/0271102 | A1 | 11/2006 | Bosshard et al. |
| 2005/0182429 | A1 | 8/2005 | Yamanouchi | 2006/0276835 | A1 | 12/2006 | Uchida |
| 2005/0192478 | A1 | 9/2005 | Williams et al. | 2006/0287644 | A1 | 12/2006 | Ingnas et al. |
| 2005/0192602 | A1 | 9/2005 | Manzo | 2006/0287666 | A1 | 12/2006 | Saadat et al. |
| 2005/0209624 | A1 | 9/2005 | Vijay | 2007/0000550 | A1 | 1/2007 | Osinski |
| 2005/0215858 | A1 | 9/2005 | Vail | 2007/0005019 | A1 | 1/2007 | Okishige |
| 2005/0216036 | A1 | 9/2005 | Nakao | 2007/0015965 | A1 | 1/2007 | Cox et al. |
| 2005/0228224 | A1 | 10/2005 | Okada et al. | 2007/0032701 | A1 | 2/2007 | Fowler et al. |
| 2005/0228406 | A1 | 10/2005 | Bose | 2007/0051375 | A1 | 3/2007 | Milliman |
| 2005/0240249 | A1 | 10/2005 | Tu et al. | 2007/0066869 | A1 | 3/2007 | Hoffman |
| 2005/0250987 | A1 | 11/2005 | Ewers et al. | 2007/0067017 | A1 | 3/2007 | Trapp |
| 2005/0251176 | A1 | 11/2005 | Swanstrom et al. | 2007/0073102 | A1 | 3/2007 | Matsumo et al. |
| 2005/0267492 | A1 | 12/2005 | Poncet et al. | 2007/0078439 | A1 | 4/2007 | Grandt et al. |
| 2005/0272977 | A1 | 12/2005 | Saadat et al. | 2007/0083192 | A1 | 4/2007 | Welch et al. |
| 2005/0274935 | A1 | 12/2005 | Nelson | 2007/0100375 | A1 | 5/2007 | Mikkaichi et al. |
| 2005/0277956 | A1 | 12/2005 | Francesce et al. | 2007/0100376 | A1 | 5/2007 | Mikkaichi et al. |
| 2005/0288555 | A1 | 12/2005 | Binmoeller | 2007/0106113 | A1 | 5/2007 | Ravo |
| 2005/0288730 | A1* | 12/2005 | Deem | 2007/0106317 | A1 | 5/2007 | Shelton et al. |
| | | | A61B 18/1492 | 2007/0112251 | A1 | 5/2007 | Nakhuda |
| | | | 607/42 | 2007/0112342 | A1 | 5/2007 | Pearson et al. |
| 2006/0004406 | A1 | 1/2006 | Wehrstein et al. | 2007/0112385 | A1 | 5/2007 | Conlon |
| 2006/0004409 | A1 | 1/2006 | Nobis et al. | 2007/0112417 | A1 | 5/2007 | Shanley et al. |
| 2006/0004410 | A1 | 1/2006 | Nobis et al. | 2007/0118115 | A1 | 5/2007 | Artale et al. |
| 2006/0015009 | A1 | 1/2006 | Jaffe et al. | 2007/0123840 | A1 | 5/2007 | Cox |
| 2006/0015131 | A1 | 1/2006 | Kierce et al. | 2007/0135803 | A1 | 6/2007 | Belson |
| 2006/0020167 | A1 | 1/2006 | Sitzmann | 2007/0142706 | A1 | 6/2007 | Matsui et al. |
| 2006/0025654 | A1 | 2/2006 | Suzuki et al. | 2007/0142710 | A1 | 6/2007 | Yokoi et al. |
| 2006/0025781 | A1 | 2/2006 | Young et al. | 2007/0142779 | A1 | 6/2007 | Duane et al. |
| 2006/0025812 | A1 | 2/2006 | Shelton | 2007/0156028 | A1 | 7/2007 | Van Lue et al. |
| 2006/0036267 | A1 | 2/2006 | Saadat et al. | 2007/0156116 | A1 | 7/2007 | Gonzalez |
| 2006/0041188 | A1 | 2/2006 | Dirusso et al. | 2007/0161855 | A1 | 7/2007 | Mikkaichi et al. |
| 2006/0058582 | A1 | 3/2006 | Maahs et al. | 2007/0167901 | A1 | 7/2007 | Herrig et al. |
| 2006/0064083 | A1 | 3/2006 | Khalaj et al. | 2007/0173686 | A1 | 7/2007 | Lin et al. |
| 2006/0069424 | A1 | 3/2006 | Acosta et al. | 2007/0173691 | A1 | 7/2007 | Yokoi et al. |
| 2006/0069429 | A1 | 3/2006 | Spence et al. | 2007/0173869 | A1 | 7/2007 | Gannoe et al. |
| 2006/0074413 | A1 | 4/2006 | Behzadian | 2007/0173870 | A2 | 7/2007 | Zacharias |
| 2006/0089528 | A1 | 4/2006 | Tartaglia et al. | 2007/0173872 | A1 | 7/2007 | Neuenfeldt |
| 2006/0095031 | A1 | 5/2006 | Ormsby | 2007/0179525 | A1 | 8/2007 | Frecker et al. |
| 2006/0100687 | A1 | 5/2006 | Fahey et al. | 2007/0191904 | A1 | 8/2007 | Libbus et al. |
| 2006/0111209 | A1 | 5/2006 | Hinman et al. | 2007/0198057 | A1 | 8/2007 | Gelbart et al. |
| 2006/0111210 | A1 | 5/2006 | Hinman | 2007/0203398 | A1 | 8/2007 | Bonadio et al. |
| 2006/0111703 | A1 | 5/2006 | Kunis et al. | 2007/0208336 | A1 | 9/2007 | Kim et al. |
| 2006/0111704 | A1 | 5/2006 | Brenneman et al. | 2007/0208407 | A1 | 9/2007 | Gerdts et al. |
| 2006/0129166 | A1 | 6/2006 | Lavelle | 2007/0213754 | A1 | 9/2007 | Mikkaichi et al. |
| 2006/0135962 | A1 | 6/2006 | Kick et al. | 2007/0225552 | A1 | 9/2007 | Segawa et al. |
| 2006/0135971 | A1 | 6/2006 | Swanstrom et al. | 2007/0233040 | A1 | 10/2007 | Macnamara et al. |
| 2006/0142652 | A1 | 6/2006 | Keenan | 2007/0244356 | A1 | 10/2007 | Carrillo et al. |
| 2006/0142790 | A1 | 6/2006 | Gertner | 2007/0244358 | A1 | 10/2007 | Lee |
| 2006/0142798 | A1 | 6/2006 | Holman et al. | 2007/0255303 | A1 | 11/2007 | Bakos et al. |
| 2006/0149129 | A1 | 7/2006 | Watts et al. | 2007/0260121 | A1 | 11/2007 | Bakos et al. |
| 2006/0149131 | A1 | 7/2006 | Or | 2007/0260242 | A1 | 11/2007 | Dycus et al. |
| 2006/0149132 | A1 | 7/2006 | Iddan | 2007/0260273 | A1 | 11/2007 | Cropper et al. |
| 2006/0161190 | A1 | 7/2006 | Gadberry et al. | 2007/0260302 | A1 | 11/2007 | Igaki |
| 2006/0167482 | A1 | 7/2006 | Swain et al. | 2007/0265494 | A1 | 11/2007 | Leanna et al. |
| 2006/0178560 | A1 | 8/2006 | Saadat et al. | 2007/0270629 | A1 | 11/2007 | Charles |
| 2006/0183975 | A1 | 8/2006 | Saadat et al. | 2007/0270907 | A1 | 11/2007 | Stokes et al. |
| 2006/0184161 | A1 | 8/2006 | Maahs et al. | 2007/0282165 | A1 | 12/2007 | Hopkins et al. |
| 2006/0189844 | A1 | 8/2006 | Tien | 2008/0004650 | A1 | 1/2008 | George |
| 2006/0200005 | A1 | 9/2006 | Bjork et al. | 2008/0015413 | A1 | 1/2008 | Barlow et al. |
| | | | | 2008/0021416 | A1 | 1/2008 | Arai et al. |
| | | | | 2008/0022927 | A1 | 1/2008 | Zhang et al. |
| | | | | 2008/0027387 | A1 | 1/2008 | Grabinsky |

(56)

References Cited

U.S. PATENT DOCUMENTS

2008/0033244 A1 2/2008 Matsui et al.
 2008/0058586 A1 3/2008 Karpiel
 2008/0065169 A1 3/2008 Colliou et al.
 2008/0091068 A1 4/2008 Terliuc
 2008/0097159 A1 4/2008 Ishiguro
 2008/0097472 A1 4/2008 Agmon et al.
 2008/0103527 A1 5/2008 Martin et al.
 2008/0114384 A1 5/2008 Chang et al.
 2008/0125765 A1 5/2008 Berenshteyn et al.
 2008/0125774 A1 5/2008 Palanker et al.
 2008/0125796 A1 5/2008 Graham
 2008/0140069 A1 6/2008 Filloux et al.
 2008/0140071 A1 6/2008 Vegesna
 2008/0147056 A1 6/2008 van der Weide et al.
 2008/0150754 A1 6/2008 Quendt
 2008/0171907 A1 7/2008 Long et al.
 2008/0188710 A1 8/2008 Segawa et al.
 2008/0200755 A1 8/2008 Bakos
 2008/0200762 A1 8/2008 Stokes et al.
 2008/0200911 A1 8/2008 Long
 2008/0200933 A1 8/2008 Bakos et al.
 2008/0200934 A1 8/2008 Fox
 2008/0208213 A1 8/2008 Benjamin et al.
 2008/0214890 A1 9/2008 Motai et al.
 2008/0221587 A1 9/2008 Schwartz
 2008/0228213 A1 9/2008 Blakeney et al.
 2008/0230972 A1 9/2008 Ganley
 2008/0243148 A1 10/2008 Mikkaichi et al.
 2008/0262513 A1 10/2008 Stahler et al.
 2008/0262524 A1 10/2008 Bangera et al.
 2008/0262540 A1 10/2008 Bangera et al.
 2008/0287801 A1 11/2008 Magnin et al.
 2008/0300461 A1 12/2008 Shaw et al.
 2008/0300571 A1 12/2008 LePivert
 2008/0306493 A1 12/2008 Shibata et al.
 2008/0309758 A1 12/2008 Karasawa et al.
 2009/0030278 A1 1/2009 Minakuchi
 2009/0054728 A1 2/2009 Trusty
 2009/0062788 A1 3/2009 Long et al.
 2009/0062795 A1 3/2009 Vakharia et al.
 2009/0078736 A1 3/2009 Van Lue
 2009/0082627 A1 3/2009 Karasawa et al.
 2009/0093690 A1 4/2009 Yoshizawa
 2009/0112059 A1 4/2009 Nobis
 2009/0112063 A1 4/2009 Bakos et al.
 2009/0131751 A1 5/2009 Spivey et al.
 2009/0143639 A1 6/2009 Stark
 2009/0143649 A1 6/2009 Rossi
 2009/0143794 A1 6/2009 Conlon et al.
 2009/0163770 A1 6/2009 Torrie et al.
 2009/0177219 A1 7/2009 Conlon
 2009/0182332 A1 7/2009 Long et al.
 2009/0192344 A1 7/2009 Bakos et al.
 2009/0192534 A1 7/2009 Ortiz et al.
 2009/0198212 A1 8/2009 Timberlake et al.
 2009/0198231 A1 8/2009 Esser et al.
 2009/0210000 A1 8/2009 Sullivan et al.
 2009/0221873 A1 9/2009 McGrath
 2009/0228001 A1 9/2009 Pacey
 2009/0259105 A1 10/2009 Miyano et al.
 2009/0281559 A1 11/2009 Swain et al.
 2009/0287206 A1 11/2009 Jun
 2009/0287236 A1 11/2009 Bakos et al.
 2009/0292167 A1 11/2009 Kimoto
 2009/0306470 A1 12/2009 Karasawa et al.
 2009/0322864 A1 12/2009 Karasawa et al.
 2010/0010294 A1 1/2010 Conlon et al.
 2010/0010298 A1 1/2010 Bakos et al.
 2010/0010303 A1 1/2010 Bakos
 2010/0023032 A1 1/2010 Granja Filho
 2010/0036198 A1 2/2010 Tacchino et al.
 2010/0048990 A1 2/2010 Bakos
 2010/0049223 A1 2/2010 Granja Filho
 2010/0056862 A1 3/2010 Bakos
 2010/0076451 A1 3/2010 Zwolinski et al.

2010/0081875 A1 4/2010 Fowler et al.
 2010/0113872 A1 5/2010 Asada et al.
 2010/0121362 A1 5/2010 Clague et al.
 2010/0130817 A1 5/2010 Conlon
 2010/0152539 A1 6/2010 Ghabrial et al.
 2010/0152725 A1 6/2010 Pearson et al.
 2010/0191050 A1 7/2010 Zwolinski
 2010/0191267 A1 7/2010 Fox
 2010/0198248 A1 8/2010 Vakharia
 2010/0210906 A1 8/2010 Wendlandt
 2010/0217367 A1 8/2010 Belson
 2010/0249700 A1 9/2010 Spivey
 2010/0268025 A1 10/2010 Belson
 2010/0286791 A1 11/2010 Goldsmith
 2010/0298642 A1 11/2010 Trusty et al.
 2010/0312056 A1 12/2010 Galperin et al.
 2010/0331622 A2 12/2010 Conlon
 2011/0077476 A1 3/2011 Rofougaran et al.
 2011/0087224 A1 4/2011 Cadeddu et al.
 2011/0093009 A1 4/2011 Fox
 2011/0098694 A1 4/2011 Long
 2011/0098704 A1 4/2011 Long et al.
 2011/0112434 A1 5/2011 Ghabrial et al.
 2011/0112527 A1 5/2011 Hamilton, Jr. et al.
 2011/0115891 A1 5/2011 Trusty
 2011/0152610 A1 6/2011 Trusty et al.
 2011/0152878 A1 6/2011 Trusty et al.
 2011/0152923 A1 6/2011 Fox
 2011/0160514 A1 6/2011 Long et al.
 2011/0190764 A1 8/2011 Long et al.
 2011/0245619 A1 10/2011 Holcomb
 2011/0282149 A1 11/2011 Vargas et al.
 2011/0284014 A1 11/2011 Cadeddu et al.
 2012/0029335 A1 2/2012 Sudam et al.
 2012/0078266 A1 3/2012 Tyson, Jr.
 2012/0088965 A1 4/2012 Stokes et al.
 2012/0089089 A1 4/2012 Swain et al.
 2012/0089093 A1 4/2012 Trusty
 2012/0101331 A1 4/2012 Gilad et al.
 2012/0101413 A1 4/2012 Beetel et al.
 2012/0109122 A1 5/2012 Arena et al.
 2012/0116155 A1 5/2012 Trusty
 2012/0116266 A1 5/2012 Houser et al.
 2012/0149981 A1 6/2012 Khait et al.
 2012/0191075 A1 7/2012 Trusty
 2012/0191076 A1 7/2012 Voegelé et al.
 2012/0289857 A1 11/2012 Toth et al.
 2013/0030430 A1 1/2013 Stewart et al.
 2013/0090666 A1 4/2013 Hess et al.
 2013/0158348 A1 6/2013 Nobis et al.
 2013/0245356 A1 9/2013 Fernandez et al.
 2013/0331646 A1 12/2013 Pell et al.
 2013/0331649 A1 12/2013 Khait et al.
 2014/0039491 A1 2/2014 Bakos et al.
 2014/0052216 A1 2/2014 Long et al.
 2014/0121678 A1 5/2014 Trusty et al.
 2014/0243597 A1 8/2014 Weisenburgh, II et al.
 2015/0032132 A1 1/2015 Harris et al.
 2015/0230858 A1 8/2015 Long et al.
 2015/0265335 A1 9/2015 Bakos et al.
 2015/0374444 A1 12/2015 Conlon et al.
 2016/0074056 A1 3/2016 Conlon
 2016/0100879 A1 4/2016 Long
 2016/0128759 A1 5/2016 Long et al.
 2016/0166311 A1 6/2016 Long et al.
 2016/0296280 A1 10/2016 Long

FOREIGN PATENT DOCUMENTS

DE 4323585 A1 1/1995
 DE 19713797 A1 10/1997
 DE 19757056 B4 8/2008
 DE 102006027873 B4 10/2009
 EP 0086338 A1 8/1983
 EP 0286415 A2 10/1988
 EP 0499491 A2 8/1992
 EP 0589454 A2 3/1994
 EP 0464479 B1 3/1995
 EP 0529675 B1 2/1996

| | | | | | | | |
|------|--------------------------|----|---------|----|------------|----|---------|
| (56) | References Cited | | | JP | 2007020806 | A | 2/2007 |
| | FOREIGN PATENT DOCUMENTS | | | JP | 2007125264 | A | 5/2007 |
| | | | | JP | 2007516792 | A | 6/2007 |
| | | | | JP | 2010503496 | A | 2/2010 |
| EP | 0773003 | A1 | 5/1997 | JP | 5646674 | B2 | 12/2014 |
| EP | 0621009 | B1 | 7/1997 | NL | 1021295 | C2 | 2/2004 |
| EP | 0724863 | B1 | 7/1999 | SU | 194230 | | 5/1967 |
| EP | 0760629 | B1 | 11/1999 | SU | 980703 | A1 | 12/1982 |
| EP | 0818974 | B1 | 7/2001 | WO | 8401707 | A1 | 5/1984 |
| EP | 1281356 | A2 | 2/2003 | WO | 8607543 | A1 | 12/1986 |
| EP | 0947166 | B1 | 5/2003 | WO | 9213494 | A1 | 8/1992 |
| EP | 0836832 | B1 | 12/2003 | WO | 9310850 | A1 | 6/1993 |
| EP | 1402837 | A1 | 3/2004 | WO | 9320760 | A1 | 10/1993 |
| EP | 0744918 | B1 | 4/2004 | WO | 9320765 | A1 | 10/1993 |
| EP | 0931515 | B1 | 8/2004 | WO | 9422383 | A1 | 10/1994 |
| EP | 0941128 | B1 | 10/2004 | WO | 9509666 | A1 | 4/1995 |
| EP | 1411843 | B1 | 10/2004 | WO | 9622056 | A1 | 7/1996 |
| EP | 1150614 | B1 | 11/2004 | WO | 9627331 | A1 | 9/1996 |
| EP | 1481642 | A1 | 12/2004 | WO | 9639946 | A1 | 12/1996 |
| EP | 1493391 | A1 | 1/2005 | WO | 9712557 | A1 | 4/1997 |
| EP | 0848598 | B1 | 2/2005 | WO | 9801080 | A1 | 1/1998 |
| EP | 1281360 | B1 | 3/2005 | WO | 9900060 | A1 | 1/1999 |
| EP | 1568330 | A1 | 8/2005 | WO | 9909919 | A1 | 3/1999 |
| EP | 1452143 | B1 | 9/2005 | WO | 9917661 | A1 | 4/1999 |
| EP | 1616527 | A2 | 1/2006 | WO | 9930622 | A2 | 6/1999 |
| EP | 1006888 | B1 | 3/2006 | WO | 0022996 | A1 | 4/2000 |
| EP | 1629764 | A1 | 3/2006 | WO | 0035358 | A1 | 6/2000 |
| EP | 1013229 | B1 | 6/2006 | WO | 0068665 | A1 | 11/2000 |
| EP | 1721561 | A1 | 11/2006 | WO | 0110319 | A1 | 2/2001 |
| EP | 1153578 | B1 | 3/2007 | WO | 0126708 | A1 | 4/2001 |
| EP | 1334696 | B1 | 3/2007 | WO | 0141627 | A2 | 6/2001 |
| EP | 1836971 | A2 | 9/2007 | WO | 0158360 | A2 | 8/2001 |
| EP | 1836980 | A1 | 9/2007 | WO | 0211621 | A2 | 2/2002 |
| EP | 1854421 | A2 | 11/2007 | WO | 0234122 | A2 | 5/2002 |
| EP | 1857061 | A1 | 11/2007 | WO | 02094082 | A2 | 11/2002 |
| EP | 1875876 | A1 | 1/2008 | WO | 03045260 | A1 | 6/2003 |
| EP | 1891881 | A1 | 2/2008 | WO | 03047684 | A2 | 6/2003 |
| EP | 1902663 | A1 | 3/2008 | WO | 03059412 | A2 | 7/2003 |
| EP | 1477106 | B1 | 6/2008 | WO | 03078721 | A2 | 9/2003 |
| EP | 1949844 | A1 | 7/2008 | WO | 03081761 | A2 | 10/2003 |
| EP | 1518499 | B1 | 8/2008 | WO | 03082129 | A2 | 10/2003 |
| EP | 1582138 | B1 | 9/2008 | WO | 2004006789 | A1 | 1/2004 |
| EP | 1709918 | B1 | 10/2008 | WO | 2004028613 | A2 | 4/2004 |
| EP | 1985226 | A2 | 10/2008 | WO | 2004037123 | A1 | 5/2004 |
| EP | 1994904 | A1 | 11/2008 | WO | 2004037149 | A1 | 5/2004 |
| EP | 1707130 | B1 | 12/2008 | WO | 2004052221 | A1 | 6/2004 |
| EP | 1477104 | B1 | 1/2009 | WO | 2004086984 | A1 | 10/2004 |
| EP | 0723462 | B1 | 3/2009 | WO | 2005009211 | A2 | 2/2005 |
| EP | 1769749 | B1 | 11/2009 | WO | 2005018467 | A2 | 3/2005 |
| EP | 2135545 | A2 | 12/2009 | WO | 2005037088 | A2 | 4/2005 |
| EP | 1769766 | B1 | 2/2010 | WO | 2005048827 | A1 | 6/2005 |
| EP | 1493397 | B1 | 9/2011 | WO | 2005065284 | A2 | 7/2005 |
| EP | 2659847 | A1 | 11/2013 | WO | 2005097019 | A2 | 10/2005 |
| FR | 2731610 | A1 | 9/1996 | WO | 2005097234 | A2 | 10/2005 |
| GB | 330629 | A | 6/1930 | WO | 2005112810 | A2 | 12/2005 |
| GB | 2335860 | A | 10/1999 | WO | 2005120363 | A1 | 12/2005 |
| GB | 2403909 | A | 1/2005 | WO | 2005122866 | A1 | 12/2005 |
| GB | 2421190 | A | 6/2006 | WO | 2006007399 | A1 | 1/2006 |
| GB | 2443261 | A | 4/2008 | WO | 2006012630 | A2 | 2/2006 |
| JP | S63309252 | A | 12/1988 | WO | 2006040109 | A1 | 4/2006 |
| JP | H0438960 | A | 2/1992 | WO | 2006041881 | A2 | 4/2006 |
| JP | H06269460 | A | 9/1994 | WO | 2006060405 | A2 | 6/2006 |
| JP | H0829699 | A | 2/1996 | WO | 2006110733 | A2 | 10/2006 |
| JP | H0975365 | A | 3/1997 | WO | 2006113216 | A2 | 10/2006 |
| JP | H1024049 | A | 1/1998 | WO | 2007013059 | A2 | 2/2007 |
| JP | 3007713 | B2 | 2/2000 | WO | 2007014063 | A2 | 2/2007 |
| JP | 2000107197 | A | 4/2000 | WO | 2007035537 | A2 | 3/2007 |
| JP | 2000245683 | A | 9/2000 | WO | 2007048085 | A2 | 4/2007 |
| JP | 2001526072 | A | 12/2001 | WO | 2007063550 | A2 | 6/2007 |
| JP | 2002369791 | A | 12/2002 | WO | 2007100067 | A1 | 9/2007 |
| JP | 2003088494 | A | 3/2003 | WO | 2007109171 | A2 | 9/2007 |
| JP | 2003235852 | A | 8/2003 | WO | 2007135577 | A2 | 11/2007 |
| JP | 2004033525 | A | 2/2004 | WO | 2007143200 | A2 | 12/2007 |
| JP | 2004065745 | A | 3/2004 | WO | 2007144004 | A1 | 12/2007 |
| JP | 2005121947 | A | 5/2005 | WO | 2008005433 | A1 | 1/2008 |
| JP | 2005261514 | A | 9/2005 | WO | 2008033356 | A2 | 3/2008 |
| JP | 2005296063 | A | 10/2005 | WO | 2008034103 | A2 | 3/2008 |
| JP | 2006297005 | A | 11/2006 | WO | 2008041225 | A2 | 4/2008 |
| JP | 2006343510 | A | 12/2006 | WO | 2008076337 | A1 | 6/2008 |

(56) References Cited

FOREIGN PATENT DOCUMENTS

| | | | |
|----|------------|----|---------|
| WO | 2008076800 | A2 | 6/2008 |
| WO | 2008079440 | A2 | 7/2008 |
| WO | 2008080062 | A2 | 7/2008 |
| WO | 2008101075 | A2 | 8/2008 |
| WO | 2008101086 | A2 | 8/2008 |
| WO | 2008102154 | A2 | 8/2008 |
| WO | 2008108863 | A2 | 9/2008 |
| WO | 2008151237 | A1 | 12/2008 |
| WO | 2009021030 | A1 | 2/2009 |
| WO | 2009027065 | A1 | 3/2009 |
| WO | 2009029065 | A1 | 3/2009 |
| WO | 2009032623 | A2 | 3/2009 |
| WO | 2009036457 | A1 | 3/2009 |
| WO | 2009121017 | A1 | 10/2009 |
| WO | 2009132190 | A2 | 10/2009 |
| WO | 2010027688 | A1 | 3/2010 |
| WO | 2010056716 | A2 | 5/2010 |
| WO | 2010080974 | A1 | 7/2010 |
| WO | 2010088481 | A1 | 8/2010 |
| WO | 2012031204 | A2 | 3/2012 |
| WO | 2012071526 | A2 | 5/2012 |
| WO | 2013044378 | A1 | 4/2013 |

OTHER PUBLICATIONS

"Ethicon Endo-Surgery Studies Presented At DDW Demonstrate Potential Of Pure NOTES Surgery With Company's Toolbox," Jun. 3, 2009 Press Release; URL http://www.jnj.com/connect/news/product/20090603_120000; accessed Aug. 28, 2009 (3 pages).

Castellvi et al., "Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using A Magnetically Anchored Camera and Novel Instrumentation," Abstract submitted along with Poster at SAGES Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).

Castellvi et al., "Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using a Magnetically Anchored Camera and Novel Instrumentation," Poster submitted along with Abstract at Sages Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).

OCTO Port Modular Laparoscopy System for Single Incision Access, Jan. 4, 2010; URL http://www.medgadget.com/archives/2010/01/octo_port_modular_laparo...; accessed Jan. 5, 2010 (4 pages).

Hakko Retractors, obtained Aug. 25, 2009 (5 pages).

Zadno et al., "Linear Superelasticity in Cold-Worked Ni—Ti," Engineering Aspects of Shape Memory Alloys, pp. 414-419 (1990).

How Stuff Works "How Smart Structures Will Work," <http://science.howstuffworks.com/engineering/structural/smart-structure1.htm>; accessed online Nov. 1, 2011 (3 pages).

Instant Armor: Science Videos—Science News—ScienCentral; http://www.sciencentral.com/articles/view.php3?article_id=218392121; accessed online Nov. 1, 2011 (2 pages).

Stanway, Smart Fluids: Current and Future Developments. Material Science and Technology, 20, pp. 931-939, 2004; accessed online Nov. 1, 2011 at <http://www.dynamics.group.shef.ac.uk/smart/smart.html> (7 pages).

Jolly et al., Properties and Applications of Commercial Magnetorheological Fluids. SPIE 5th Annual Int. Symposium on Smart Structures and Materials, 1998 (18 pages).

Rutala et al. "Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008" (available at http://www.cdc.gov/hicpac/Disinfection_Sterilization/13_11sterilizingPractices.html).

Bewlay et al., "Spinning" in ASM Handbook, vol. 14B, Metalworking: Sheet Forming (2006).

Schoenbach et al. "Bacterial Decontamination of Liquids with Pulsed Electric Fields" IEEE Transactions on Dielectrics and Electrical Insulation, vol. 7 No. 5, Oct. 2000, pp. 637-645.

Widera et al., "Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo," The Journal of Immunology, 164, pp. 4635-4640 (2000).

Davalos, et al., "Tissue Ablation with Irreversible Electroporation," Annals of Biomedical Engineering, 33.2 (2005): 223-231.

Maxim Integrated Application Note 3977: Class D Amplifiers: Fundamentals of Operation and Recent Developments, Jan. 31, 2007.

International Search Report for PCT/US2010/020465, dated Jun. 30, 2010 (6 pages).

Written Opinion for PCT/US2010/020465, dated Jun. 30, 2010 (9 pages).

Ethicon, Inc., "Wound Closure Manual: Chapter 3 (The Surgical Needle)," 15 pages, (1994).

Guido M. Sclabas, M.D., et al., "Endoluminal Methods for Gastrotomy Closure in Natural Orifice TransEnteric Surgery (NOTES)," Surgical Innovation, vol. 13, No. 1, pp. 23-30, Mar. 2006.

Fritscher-Ravens, et al., "Transgastric Gastropexy and Hiatal Hernia Repair for GERD Under EUS Control: a Porcine Model," Gastrointestinal Endoscopy, vol. 59, No. 1, pp. 89-95, 2004.

Ogando, "Prototype Tools That Go With the Flow," Design News, 2 pages, Jul. 17, 2006.

Edd, et al., "In Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporation," IEEE Trans Biomed Eng, vol. 53, pp. 1409-1415, 2006.

Kennedy, et al., "High-Burst-Strength, Feedback-Controlled Bipolar Vessel Sealing," Surgical Endoscopy, vol. 12, pp. 376-378 (1998).

Collins et al., "Local Gene Therapy of Solid Tumors with GM-CSF and B7-1 Eradicates Both Treated and Distal Tumors," Cancer Gene Therapy, vol. 13, pp. 1061-1071 (2006).

K. Sumiyama et al., "Transesophageal Mediastinoscopy by Submucosal Endoscopy With Mucosal Flap Safety Value Technique," Gastrointest Endosc., Apr. 2007, vol. 65(4), pp. 679-683 (Abstract).

K. Sumiyama et al., "Submucosal Endoscopy with Mucosal Flap Safety Valve," Gastrointest Endosc. Apr. 2007, vol. 65(4) pp. 694-695 (Abstract).

K. Sumiyama et al., "Transgastric Cholecystectomy: Transgastric Accessibility to the Gallbladder Improved with the SEMF Method and a Novel Multibending Therapeutic Endoscope," Gastrointest Endosc., Jun. 2007, vol. 65(7), pp. 1028-1034 (Abstract).

K. Sumiyama et al., "Endoscopic Caps," Tech. Gastrointest. Endosc., vol. 8, pp. 28-32, 2006.

"Z-Offset Technique Used in the Introduction of Trocar During Laparoscopic Surgery," M.S. Hershey NOTES Presentation to EES NOTES Development Team, Sep. 27, 2007.

F.N. Denans, Nouveau Procédé Pour La Guérison Des Plaies Des Intestines. Extrait Des Seances De La Société Royale De Médecine De Marseille, Pendant Le Mois De Décembre 1825, et le Premier Trimestre De 1826, Séance Du 24 Février 1826. Recueil De La Société Royale De Médecin De Marseille. Marseille: Impr. D'Achard, 1826; 1:127-31. (with English translation).

I. Fraser, "An Historical Perspective on Mechanical Aids in Intestinal Anastomosis," Surg. Gynecol. Obstet. (Oct. 1982), vol. 155, pp. 566-574.

M.E. Ryan et al., "Endoscopic Intervention for Biliary Leaks After Laparoscopic Cholecystectomy: A Multicenter Review," Gastrointest. Endosc., vol. 47(3), 1998, pp. 261-266.

C. Cope, "Creation of Compression Gastroenterostomy by Means of the Oral, Percutaneous, or Surgical Introduction of Magnets: Feasibility Study in Swine," J. Vasc Intery Radio!, (1995), vol. 6(4), pp. 539-545.

J.W. Hazey et al., "Natural Orifice Transgastric Endoscopic Peritoneoscopy in Humans: Initial Clinical Trial," Surg Endosc, (Jan. 2008), vol. 22(1), pp. 16-20.

N. Chopita et al., "Endoscopic Gastroenteric Anastomosis Using Magnets," Endoscopy, (2005), vol. 37(4), pp. 313-317.

C. Cope et al., "Long Term Patency of Experimental Magnetic Compression Gastroenteric Anastomoses Achieved with Covered Stents," Gastrointest Endosc, (2001), vol. 53, pp. 780-784.

H. Okajima et al., "Magnet Compression Anastomosis for Bile Duct Stenosis After Duct to Duct Biliary Reconstruction in Living Donor Liver Transplantation," Liver Transplantation (2005), pp. 473-475.

A. Fritscher-Ravens et al., "Transluminal Endosurgery: Single Lumen Access Anastomotic Device for Flexible Endoscopy," Gastrointestinal Endosc, (2003), vol. 58(4), pp. 585-591.

(56)

References Cited

OTHER PUBLICATIONS

- G.A. Hallenbeck, M.D. et al., "An Instrument for Colorectal Anastomosis Without Sutures," *Dis Col Rectum*, (1963), vol. 5, pp. 98-101.
- T. Hardy, Jr., M.D. et al., "A Biofragmentable Ring for Sutureless Bowel Anastomosis. An Experimental Study," *Dis Col Rectum*, (1985), vol. 28, pp. 484-490.
- P. O'Neill, M.D. et al., "Nonsuture Intestinal Anastomosis," *Am J Surg*, (1962), vol. 104, pp. 761-767.
- C.P. Swain, M.D. et al., "Anastomosis at Flexible Endoscopy: An Experimental Study of Compression Button Gastrojejunostomy," *Gastrointest Endosc*, (1991), vol. 37, pp. 628-632.
- J.B. Murphy, M.D., "Cholecysto-Intestinal, Gastro-Intestinal, Entero-Intestinal Anastomosis, and Approximation Without Sutures (original research)," *Med Rec*, (Dec. 10, 1892), vol. 42(24), pp. 665-676.
- USGI® EndoSurgical Operating System—g-Prox® Tissue Grasper/ Approximation Device; [online] URL: <http://www.usgimedical.com/eos/components-gprox.htm>—accessed May 30, 2008 (2 pages).
- Printout of web page—<http://www.vacumed.com/zcom/product/Product.do?compid=27&prodid=852,#51XX> Low-Cost Permanent Tubes 2MM ID, Smooth Interior Walls, VacuMed, Ventura, California, Accessed Jul. 24, 2007.
- Endoscopic Retrograde Cholangiopancreatogram (ERCP); [online] URL: <http://www.webmd.com/digestive-disorders/endoscopic-retrograde-cholangiopancreatogram-ercp.htm>; last updated: Apr. 30, 2007; accessed: Feb. 21, 2008 (6 pages).
- ERCP; Jackson Siegelbaum Gastroenterology; [online] URL: <http://www.gicare.com/pated/epdgs20.htm>; accessed Feb. 21, 2008 (3 pages).
- D.G. Fong et al., "Transcolonic Ventral Wall Hernia Mesh Fixation in a Porcine Model," *Endoscopy* 2007; 39: 865-869.
- B. Rubinsky, Ph.D., "Irreversible Electroporation in Medicine," *Technology in Cancer Research and Treatment*, vol. 6, No. 4, Aug. (2007), pp. 255-259.
- D.B. Nelson, MD et al., "Endoscopic Hemostatic Devices," *Gastrointestinal Endoscopy*, vol. 54, No. 6, 2001, pp. 533-840.
- CRE™ A Pulmonary Balloon Dilator; [online] URL: http://www.bostonscientific.com/Device.bsci?page=HCP_Overview&navRelId=1000.1003&method=D..., accessed Jul. 18, 2008 (4 pages).
- J.D. Paulson, M.D., et al., "Development of Flexible Culdoscopy," *The Journal of the American Association of Gynecologic Laparoscopists*, Nov. 1999, vol. 6, No. 4, pp. 487-490.
- H. Seifert, et al., "Retroperitoneal Endoscopic Debridement for Infected Peripancreatic Necrosis," *The Lancet, Research Letters*, vol. 356, Aug. 19, 2000, pp. 653-655.
- K.E. Mönkemüller, M.D., et al., "Transmural Drainage of Pancreatic Fluid Collections Without Electrocautery Using the Seldinger Technique," *Gastrointestinal Endoscopy*, vol. 48, No. 2, 1998, pp. 195-200, (Received Oct. 3, 1997; Accepted Mar. 31, 1998).
- D. Wilhelm et al., "An Innovative, Safe and Sterile Sigmoid Access (ISSA) for NOTES," *Endoscopy* 2007, vol. 39, pp. 401-406.
- Nakazawa et al., "Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin," *AJR*, 188, pp. 480-488 (Feb. 2007).
- Miklav?i? et al., "A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy," *Biochimica et Biophysica Acta*, 1523, pp. 73-83 (2000).
- Evans, "Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM)," *EJSO*, 33, pp. S64-S75 (2007).
- Wong et al., "Combined Percutaneous Radiofrequency Ablation and Ethanol Injection for Hepatocellular Carcinoma in High-Risk Locations," *AJR*, 190, pp. W187-W195 (2008).
- Heller et al., "Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo," *Gene Therapy*, 7, pp. 826-829 (2000).
- Weaver et al., "Theory of electroporation: A review," *Bioelectrochemistry and Bioenergetics*, 41, pp. 135-160 (1996).
- Mulier et al., "Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?" *Annals of Surgical Oncology*, 15(1), pp. 144-157 (2008).
- Link et al., "Regional Chemotherapy of Nonresectable Colorectal Liver Metastases with Mitoxanthrone, 5-Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival," *Cancer*, 92, pp. 2746-2753 (2001).
- Guyton et al., "Membrane Potentials and Action Potentials," W.B. Sanders, ed. *Textbook of Medical Physiology*, p. 56 (2000).
- Guyton et al., "Contraction of Skeletal Muscle," *Textbook of Medical Physiology*, pp. 82-84 (2000).

* cited by examiner




FIG. 1




FIG. 2E




FIG. 3




FIG. 4




FIG. 5





FIG. 8




FIG. 9




FIG. 10




FIG. 11






FIG. 12






FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21





FIG. 22



ELECTRICAL ABLATION DEVICES**CROSS REFERENCE TO RELATED APPLICATIONS**

This non-provisional patent application is a continuation patent application claiming priority under 35 U.S.C. § 120 of U.S. patent application Ser. No. 13/602,742, filed Sep. 4, 2012, entitled ELECTRICAL ABLATION DEVICES, now U.S. Patent Application Publication No. 2012/0330306, which is a divisional patent application claiming priority under 35 U.S.C. § 121 of U.S. patent application Ser. No. 12/352,375, filed Jan. 12, 2009, entitled ELECTRICAL ABLATION DEVICES, now U.S. Pat. No. 8,361,066, the entire disclosures of which are hereby incorporated by reference herein.

BACKGROUND

Electrical ablation therapy has been employed in medicine for the treatment of undesirable tissue such as diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths. While conventional apparatuses, systems, and methods for the electrical ablation of undesirable tissue are effective, one drawback with conventional electrical ablation treatment is the resulting permanent damage that may occur to the healthy tissue surrounding the abnormal tissue due primarily to the detrimental thermal effects resulting from exposing the tissue to thermal energy generated by the electrical ablation device. This may be particularly true when exposing the tissue to electric potentials sufficient to cause cell necrosis using high temperature thermal therapies including focused ultrasound ablation, radiofrequency (RF) ablation, or interstitial laser coagulation. Other techniques for tissue ablation include chemical ablation, in which chemical agents are injected into the undesirable tissue to cause ablation as well as surgical excision, cryotherapy, radiation, photodynamic therapy, Moh's micrographic surgery, topical treatments with 5-fluorouracil, laser ablation. Other drawbacks of conventional thermal, chemical, and other ablation therapy are cost, length of recovery, and the extraordinary pain inflicted on the patient.

Conventional thermal, chemical, and other ablation techniques have been employed for the treatment of a variety of undesirable tissue. Thermal and chemical ablation techniques have been used for the treatment of varicose veins resulting from reflux disease of the greater saphenous vein (GSV), in which the varicose vein is stripped and then is exposed to either chemical or thermal ablation. Other techniques for the treatment of undesirable tissue are more radical. Prostate cancer, for example, may be removed using a prostatectomy, in which the entire or part of prostate gland and surrounding lymph nodes are surgically removed. Like most other forms of cancer, radiation therapy may be used in conjunction with or as an alternate method for the treatment of prostate cancer. Another thermal ablation technique for the treatment of prostate cancer is RF interstitial tumor ablation (RITA) via trans-rectal ultrasound guidance. While these conventional methods for the treatment of prostate cancer are effective, they are not preferred by many surgeons and may result in detrimental thermal effects to healthy tissue surrounding the prostate. Similar thermal ablation techniques may be used for the treatment of basal cell carcinoma (BCC) tissue, a slowly growing cutaneous malignancy derived from the rapidly proliferating basal layer of the epidermis. BCC tissue in tumors ranging in size

from about 5 mm to about 40 mm may be thermally ablated with a pulsed carbon dioxide laser. Nevertheless, carbon dioxide laser ablation is a thermal treatment method and may cause permanent damage to healthy tissue surrounding the BCC tissue. Furthermore, this technique requires costly capital investment in carbon dioxide laser equipment. Undesirable tissue growing inside a body lumen such as the esophagus, large bowel, or in cavities formed in solid tissue such as the breast, for example, can be difficult to destroy using conventional ablation techniques. Surgical removal of undesirable tissue, such as a malignant or benign tumor, from the breast is likely to leave a cavity. Surgical resection of residual intraluminal tissue may remove only a portion of the undesirable tissue cells within a certain margin of healthy tissue. Accordingly, some undesirable tissue is likely to remain within the wall of the cavity due to the limitation of conventional ablation instrument configurations, which may be effective for treating line-of-sight regions of tissue, but may be less effective for treating the residual undesirable tissue.

Accordingly, there remains a need for improved electrical ablation apparatuses, systems, and methods for the treatment of undesirable tissue found in diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths. There remains a need for minimally invasive treatment of undesirable tissue through the use of irreversible electroporation (IRE) ablation techniques without causing the detrimental thermal effects of conventional thermal ablation techniques.

FIGURES

The novel features of the various described embodiments are set forth with particularity in the appended claims. The various embodiments, however, both as to organization and methods of operation, together with advantages thereof, may be understood in accordance with the following description taken in conjunction with the accompanying drawings as follows.

FIG. 1 illustrates one embodiment of an electrical ablation system.

FIGS. 2A-D illustrate one embodiment of the electrical ablation device in various phases of deployment.

FIG. 2E illustrates one embodiment of the electrical ablation device comprising multiple needle electrodes.

FIG. 3 illustrates one embodiment of the electrical ablation system shown in FIGS. 1 and 2A-D in use to treat undesirable tissue located on the surface of the liver.

FIG. 4 illustrates a detailed view of one embodiment of the electrical ablation system shown in FIG. 3 in use to treat undesirable tissue located on the surface of the liver.

FIG. 5 is a graphical representation of a series of electrical pulses that may be applied to undesirable tissue to create a first necrotic zone by inducing irreversible electroporation in the tissue and to create a second necrotic zone by inducing thermal effects near the electrode-tissue-interface using the electrical ablation system shown in FIG. 4.

FIGS. 6, 7, and 8 illustrate one embodiment of an electrical ablation device to treat undesirable tissue within body lumen using electrical energy, where FIG. 6 illustrates a sectioned view of one embodiment of an electrical ablation device, FIG. 7 illustrates an end view of one embodiment of the electrical ablation device shown in FIG. 6, and FIG. 8 illustrates a cross-sectional view of one embodiment of the electrical ablation device shown in FIG. 6.

FIG. 9 illustrates one embodiment of an electrical ablation system in use to treat non-metastatic prostate cancer in a patient.

FIG. 10 is a graphical representation of a series of electrical pulses that may be applied to undesirable tissue to induce irreversible electroporation suitable to ablate non-metastatic cancer of the prostate as described in FIG. 9.

FIG. 11 illustrates one embodiment of the electrical ablation system described FIG. 1 in use to treat basal cell carcinoma (BCC) tissue.

FIG. 12 is a graphical representation of a series of electrical pulses for treating basal cell carcinoma (BCC) tissue as shown in FIG. 11 with irreversible electroporation energy.

FIG. 13A illustrates one embodiment of an electrical ablation device, in a collapsed state, the device having a configuration suitable for the treatment of abnormal tissue located in a lumen, abscess, void, or cavity.

FIG. 13B illustrates one embodiment of the electrical ablation device shown in FIG. 13A, in an inflated state, the device having a configuration suitable for the treatment of abnormal tissue located in a lumen, abscess, void, or cavity.

FIG. 14 is a cross-sectional view of the electrical ablation device showing a cross-sectional view of the conductive elastomer electrode and the non-conductive catheter shown in FIGS. 13A and 13B.

FIG. 15 illustrates one embodiment of the electrical ablation device shown in FIG. 13A inserted through the mouth and esophagus to ablate cancerous tissue in the esophagus using electrical pulses.

FIG. 16 illustrates a distal portion of an endoscope used in conjunction with the electrical ablation device shown in FIG. 13A.

FIG. 17 illustrates a cross-sectional view of a breast showing a cavity that may be left after a lumpectomy to remove a tumor from the breast.

FIG. 18 illustrates one embodiment of a catheter inserted into the cavity left in the breast following a lumpectomy procedure as shown in FIG. 17.

FIG. 19 illustrates an expanded sponge filling the cavity left in the breast following a lumpectomy as shown in FIG. 17.

FIG. 20 illustrates the expanded sponge intact to fill the cavity left in the breast as shown in FIG. 17 following irreversible electroporation ablation therapy.

FIG. 21 illustrates a mesh of a finite element model of a sponge inserted in the cavity left in the breast as shown in FIG. 17.

FIG. 22 is a graphical representation of electric potential and electrical field strength sufficient to induce irreversible electroporation when applied to the sponge located within the breast cavity as shown in FIG. 17.

FIG. 23 is a graphical representation of electric field strength contours in volts per meter (V/m) developed when electrodes are energized by an energy source.

DESCRIPTION

Various embodiments are directed to apparatuses, systems, and methods for the electrical ablation treatment of undesirable tissue such as diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths without causing any detrimental thermal effects to surrounding healthy tissue. Numerous specific details are set forth to provide a thorough understanding of the overall structure, function, manufacture, and use of the embodiments as described in the specification and illustrated

in the accompanying drawings. It will be understood by those skilled in the art, however, that the embodiments may be practiced without the specific details. In other instances, well-known operations, components, and elements have not been described in detail so as not to obscure the embodiments described in the specification. Those of ordinary skill in the art will understand that the embodiments described and illustrated herein are non-limiting examples, and thus it can be appreciated that the specific structural and functional details disclosed herein may be representative and do not necessarily limit the scope of the embodiments, the scope of which is defined solely by the appended claims.

Reference throughout the specification to “various embodiments,” “some embodiments,” “one embodiment,” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases “in various embodiments,” “in some embodiments,” “in one embodiment,” or “in an embodiment” in places throughout the specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Thus, the particular features, structures, or characteristics illustrated or described in connection with one embodiment may be combined, in whole or in part, with the features structures, or characteristics of one or more other embodiments without limitation.

It will be appreciated that the terms “proximal” and “distal” may be used throughout the specification with reference to a clinician manipulating one end of an instrument used to treat a patient. The term “proximal” refers to the portion of the instrument closest to the clinician and the term “distal” refers to the portion located furthest from the clinician. It will be further appreciated that for conciseness and clarity, spatial terms such as “vertical,” “horizontal,” “up,” and “down” may be used herein with respect to the illustrated embodiments. However, surgical instruments may be used in many orientations and positions, and these terms are not intended to be limiting and absolute.

Various embodiments of apparatuses, systems, and methods for the electrical ablation treatment of undesirable tissue such as diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths, are described throughout the specification and illustrated in the accompanying drawings. The electrical ablation devices in accordance with the described embodiments may comprise one or more electrodes configured to be positioned into or proximal to undesirable tissue in a tissue treatment region (e.g., target site, worksite) where there is evidence of abnormal tissue growth, for example. In general, the electrodes comprise an electrically conductive portion (e.g., medical grade stainless steel) and are configured to electrically couple to an energy source. Once the electrodes are positioned into or proximal to the undesirable tissue, an energizing potential is applied to the electrodes to create an electric field to which the undesirable tissue is exposed. The energizing potential (and the resulting electric field) may be characterized by multiple parameters such as frequency, amplitude, pulse width (duration of a pulse or pulse length), and/or polarity. Depending on the diagnostic or therapeutic treatment to be rendered, a particular electrode may be configured either as an anode (+) or a cathode (−) or may comprise a plurality of electrodes with at least one configured as an anode and at least one other configured as a cathode. Regardless of the initial polar configuration, the

polarity of the electrodes may be reversed by reversing the polarity of the output of the energy source.

In various embodiments, a suitable energy source may comprise an electrical waveform generator, which may be configured to create an electric field that is suitable to create irreversible electroporation in undesirable tissue at various electric field amplitudes and durations. The energy source may be configured to deliver irreversible electroporation pulses in the form of direct-current (DC) and/or alternating-current (AC) voltage potentials (e.g., time-varying voltage potentials) to the electrodes. The irreversible electroporation pulses may be characterized by various parameters such as frequency, amplitude, pulse length, and/or polarity. The undesirable tissue may be ablated by exposure to the electric potential difference across the electrodes.

In one embodiment, the energy source may comprise a wireless transmitter to deliver energy to the electrodes using wireless energy transfer techniques via one or more remotely positioned antennas. Those skilled in the art will appreciate that wireless energy transfer or wireless power transmission is the process of transmitting electrical energy from an energy source to an electrical load without interconnecting wires. An electrical transformer is the simplest instance of wireless energy transfer. The primary and secondary circuits of a transformer are not directly connected and the transfer of energy takes place by electromagnetic coupling through a process known as mutual induction. Power also may be transferred wirelessly using RF energy. Wireless power transfer technology using RF energy is produced by Powercast, Inc. and can achieve an output of 6 volts for a little over one meter. Other low-power wireless power technology has been proposed such as described in U.S. Pat. No. 6,967,462.

The apparatuses, systems, and methods in accordance with the described embodiments may be configured for minimally invasive ablation treatment of undesirable tissue through the use of irreversible electroporation to be able to ablate undesirable tissue in a controlled and focused manner without inducing thermally damaging effects to the surrounding healthy tissue. The apparatuses, systems, and methods in accordance with the described embodiments may be configured to ablate undesirable tissue through the use of electroporation or electroporabilization. More specifically, the apparatuses, systems, and methods in accordance with the described embodiments may be configured to ablate undesirable tissue through the use of irreversible electroporation. Electroporation increases the permeabilization of a cell membrane by exposing the cell to electric pulses. The external electric field (electric potential/per unit length) to which the cell membrane is exposed to significantly increases the electrical conductivity and permeability of the plasma in the cell membrane. The primary parameter affecting the transmembrane potential is the potential difference across the cell membrane. Irreversible electroporation is the application of an electric field of a specific magnitude and duration to a cell membrane such that the permeabilization of the cell membrane cannot be reversed, leading to cell death without inducing a significant amount of heat in the cell membrane. The destabilizing potential forms pores in the cell membrane when the potential across the cell membrane exceeds its dielectric strength causing the cell to die under a process known as apoptosis and/or necrosis. The application of irreversible electroporation pulses to cells is an effective way for ablating large volumes of undesirable tissue without deleterious thermal effects to the surrounding healthy tissue associated with thermal-inducing ablation treatments. This is because irreversible electroporation

destroys cells without heat and thus does not destroy the cellular support structure or regional vasculature. A destabilizing irreversible electroporation pulse, suitable to cause cell death without inducing a significant amount of thermal damage to the surrounding healthy tissue, may have amplitude in the range of about several hundred to about several thousand volts and is generally applied across biological membranes over a distance of about several millimeters, for example, for a relatively long duration. Thus, the undesirable tissue may be ablated in-vivo through the delivery of destabilizing electric fields by quickly creating cell necrosis.

The apparatuses, systems, and methods for electrical ablation therapy in accordance with the described embodiments may be adapted for use in minimally invasive surgical procedures to access the tissue treatment region in various anatomic locations such as the brain, lungs, breast, liver, gall bladder, pancreas, prostate gland, and various internal body lumen defined by the esophagus, stomach, intestine, colon, arteries, veins, anus, vagina, cervix, fallopian tubes, and the peritoneal cavity, for example, without limitation. Minimally invasive electrical ablation devices may be introduced to the tissue treatment region using a trocar inserted through a small opening formed in the patient's body or through a natural body orifice such as the mouth, anus, or vagina using transluminal access techniques known as Natural Orifice Transluminal Endoscopic Surgery (NOTES)TM. Once the electrical ablation devices (e.g., electrodes) are located into or proximal to the undesirable tissue in the treatment region, electric field potentials can be applied to the undesirable tissue by the energy source. The electrical ablation devices comprise portions that may be inserted into the tissue treatment region percutaneously (e.g., where access to inner organs or other tissue is done via needle-puncture of the skin). Other portions of the electrical ablation devices may be introduced into the tissue treatment region endoscopically (e.g., laparoscopically and/or thoracoscopically) through trocars or working channels of the endoscope, through small incisions, or transcutaneously (e.g., where electric pulses are delivered to the tissue treatment region through the skin).

FIG. 1 illustrates one embodiment of an electrical ablation system 10. The electrical ablation system 10 may be employed to ablate undesirable tissue such as diseased tissues, cancers, tumors, masses, lesions, abnormal tissue growths inside a patient using electrical energy. The electrical ablation system 10 may be used in conjunction with endoscopic, laparoscopic, thoracoscopic, open surgical procedures via small incisions or keyholes, percutaneous techniques, transcutaneous techniques, and/or external non-invasive techniques, or any combinations thereof without limitation. The electrical ablation system 10 may be configured to be positioned within a natural body orifice of the patient such as the mouth, anus, or vagina and advanced through internal body lumen or cavities such as the esophagus, colon, cervix, urethra, for example, to reach the tissue treatment region. The electrical ablation system 10 also may be configured to be positioned and passed through a small incision or keyhole formed through the skin or abdominal wall of the patient to reach the tissue treatment region using a trocar. The tissue treatment region may be located in the brain, lungs, breast, liver, gall bladder, pancreas, prostate gland, various internal body lumen defined by the esophagus, stomach, intestine, colon, arteries, veins, anus, vagina, cervix, fallopian tubes, and the peritoneal cavity, for example, without limitation. The electrical ablation system 10 can be configured to treat a number of lesions and osteopathologies comprising metastatic lesions, tumors, fractures, infected sites, inflamed sites. Once positioned into or

proximate the tissue treatment region, the electrical ablation system **10** can be actuated (e.g., energized) to ablate the undesirable tissue. In one embodiment, the electrical ablation system **10** may be configured to treat diseased tissue in the gastrointestinal (GI) tract, esophagus, lung, or stomach that may be accessed orally. In another embodiment, the electrical ablation system **10** may be adapted to treat undesirable tissue in the liver or other organs that may be accessible using transluminal access techniques such as, without limitation, NOTES™ techniques, where the electrical ablation devices may be initially introduced through a natural orifice such as the mouth, anus, or vagina and then advanced to the tissue treatment site by puncturing the walls of internal body lumen such as the stomach, intestines, colon, cervix. In various embodiments, the electrical ablation system **10** may be adapted to treat undesirable tissue in the brain, liver, breast, gall bladder, pancreas, or prostate gland, using one or more electrodes positioned percutaneously, transcutaneously, translumenally, minimally invasively, and/or through open surgical techniques, or any combination thereof.

In one embodiment, the electrical ablation system **10** may be employed in conjunction with a flexible endoscope **12**, as well as a rigid endoscope, laparoscope, or thoracoscope, such as the GIF-100 model available from Olympus Corporation. In one embodiment, the endoscope **12** may be introduced to the tissue treatment region trans-anally through the colon, trans-orally through the esophagus and stomach, trans-vaginally through the cervix, transcutaneously, or via an external incision or keyhole formed in the abdomen in conjunction with a trocar. The electrical ablation system **10** may be inserted and guided into or proximate the tissue treatment region using the endoscope **12**.

In the embodiment illustrated in FIG. 1, the endoscope **12** comprises an endoscope handle **34** and an elongate relatively flexible shaft **32**. The distal end of the flexible shaft **32** may comprise a light source and a viewing port. Optionally, the flexible shaft **32** may define one or more working channels for receiving various instruments, such as electrical ablation devices, for example, therethrough. Images within the field of view of the viewing port are received by an optical device, such as a camera comprising a charge coupled device (CCD) usually located within the endoscope **12**, and are transmitted to a display monitor (not shown) outside the patient.

In one embodiment, the electrical ablation system **10** may comprise an electrical ablation device **20**, a plurality of electrical conductors **18**, a handpiece **16** comprising an activation switch **62**, and an energy source **14**, such as an electrical waveform generator, electrically coupled to the activation switch **62** and the electrical ablation device **20**. The electrical ablation device **20** comprises a relatively flexible member or shaft **22** that may be introduced to the tissue treatment region using a variety of known techniques such as an open incision and a trocar, through one of more of the working channels of the endoscope **12**, percutaneously, or transcutaneously.

In one embodiment, one or more electrodes (e.g., needle electrodes, balloon electrodes), such as first and second electrodes **24a,b**, extend out from the distal end of the electrical ablation device **20**. In one embodiment, the first electrode **24a** may be configured as the positive electrode and the second electrode **24b** may be configured as the negative electrode. The first electrode **24a** is electrically connected to a first electrical conductor **18a**, or similar electrically conductive lead or wire, which is coupled to the positive terminal of the energy source **14** through the acti-

vation switch **62**. The second electrode **24b** is electrically connected to a second electrical conductor **18b**, or similar electrically conductive lead or wire, which is coupled to the negative terminal of the energy source **14** through the activation switch **62**. The electrical conductors **18a,b** are electrically insulated from each other and surrounding structures, except for the electrical connections to the respective electrodes **24a,b**. In various embodiments, the electrical ablation device **20** may be configured to be introduced into or proximate the tissue treatment region using the endoscope **12** (laparoscope or thoracoscope), open surgical procedures, or external and non-invasive medical procedures. The electrodes **24a,b** may be referred to herein as endoscopic or laparoscopic electrodes, although variations thereof may be inserted transcutaneously or percutaneously. As previously discussed, either one or both electrodes **24a,b** may be adapted and configured to slideably move in and out of a cannula, lumen, or channel defined within the flexible shaft **22**.

Once the electrodes **24a,b** are positioned at the desired location into or proximate the tissue treatment region, the electrodes **24a,b** may be connected to or disconnected from the energy source **14** by actuating or de-actuating the switch **62** on the handpiece **16**. The switch **62** may be operated manually or may be mounted on a foot switch (not shown), for example. The electrodes **24a,b** deliver electric field pulses to the undesirable tissue. The electric field pulses may be characterized based on various parameters such as pulse shape, amplitude, frequency, and duration. The electric field pulses may be sufficient to induce irreversible electroporation in the undesirable tissue. The induced potential depends on a variety of conditions such as tissue type, cell size, and electrical pulse parameters. The primary electrical pulse parameter affecting the transmembrane potential for a specific tissue type is the amplitude of the electric field and pulse length that the tissue is exposed to.

In one embodiment, a protective sleeve or sheath **26** may be slidably disposed over the flexible shaft **22** and within a handle **28**. In another embodiment, the sheath **26** may be slidably disposed within the flexible shaft **22** and the handle **28**, without limitation. The sheath **26** is slideable and may be located over the electrodes **24a,b** to protect the trocar and prevent accidental piercing when the electrical ablation device **20** is advanced therethrough. Either one or both of the electrodes **24a,b** of the electrical ablation device **20** may be adapted and configured to slideably move in and out of a cannula, lumen, or channel formed within the flexible shaft **22**. The second electrode **24b** may be fixed in place. The second electrode **24b** may provide a pivot about which the first electrode **24a** can be moved in an arc to other points in the tissue treatment region to treat larger portions of the diseased tissue that cannot be treated by fixing the electrodes **24a,b** in one location. In one embodiment, either one or both of the electrodes **24a,b** may be adapted and configured to slideably move in and out of a working channel formed within a flexible shaft **32** of the flexible endoscope **12** or may be located independently of the flexible endoscope **12**. Various features of the first and second electrodes **24a,b** are described in more detail in FIGS. 2A-D.

In one embodiment, the first and second electrical conductors **18a,b** may be provided through the handle **28**. In the illustrated embodiment, the first electrode **24a** can be slideably moved in and out of the distal end of the flexible shaft **22** using a slide member **30** to retract and/or advance the first electrode **24a**. In various embodiments either or both electrodes **24a,b** may be coupled to the slide member **30**, or additional slide members, to advance and retract the elec-

trodes **24a,b**, e.g., position the electrodes **24a,b**. In the illustrated embodiment, the first electrical conductor **18a** coupled to the first electrode **24a** is coupled to the slide member **30**. In this manner, the first electrode **24a**, which is slidably movable within the cannula, lumen, or channel defined by the flexible shaft **22**, can advanced and retracted with the slide member **30**.

In various other embodiments, transducers or sensors **29** may be located in the handle **28** of the electrical ablation device **20** to sense the force with which the electrodes **24a,b** penetrate the tissue in the tissue treatment zone. This feedback information may be useful to determine whether either one or both of the electrodes **24a,b** have been properly inserted in the tissue treatment region. As is particularly well known, cancerous tumor tissue tends to be denser than healthy tissue and thus greater force is required to insert the electrodes **24a,b** therein. The transducers or sensors **29** can provide feedback to the operator, surgeon, or clinician to physically sense when the electrodes **24a,b** are placed within the cancerous tumor. The feedback information provided by the transducers or sensors **29** may be processed and displayed by circuits located either internally or externally to the energy source **14**. The sensor **29** readings may be employed to determine whether the electrodes **24a,b** have been properly located within the cancerous tumor thereby assuring that a suitable margin of error has been achieved in locating the electrodes **24a,b**.

In one embodiment, the input to the energy source **14** may be connected to a commercial power supply by way of a plug (not shown). The output of the energy source **14** is coupled to the electrodes **24a,b**, which may be energized using the activation switch **62** on the handpiece **16**, or in one embodiment, an activation switch mounted on a foot activated pedal (not shown). The energy source **14** may be configured to produce electrical energy suitable for electrical ablation, as described in more detail below.

In one embodiment, the electrodes **24a,b** are adapted and configured to electrically couple to the energy source **14** (e.g., generator, waveform generator). Once electrical energy is coupled to the electrodes **24a,b**, an electric field is formed at a distal end of the electrodes **24a,b**. The energy source **14** may be configured to generate electric pulses at a predetermined frequency, amplitude, pulse length, and/or polarity that are suitable to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region. For example, the energy source **14** may be configured to deliver DC electric pulses having a predetermined frequency, amplitude, pulse length, and/or polarity suitable to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region. The DC pulses may be positive or negative relative to a particular reference polarity. The polarity of the DC pulses may be reversed or inverted from positive-to-negative or negative-to-positive a predetermined number of times to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region.

In one embodiment, a timing circuit may be coupled to the output of the energy source **14** to generate electric pulses. The timing circuit may comprise one or more suitable switching elements to produce the electric pulses. For example, the energy source **14** may produce a series of *n* electric pulses (where *n* is any positive integer) of sufficient amplitude and duration to induce irreversible electroporation suitable for tissue ablation when the *n* electric pulses are applied to the electrodes **24a,b**. In one embodiment, the electric pulses may have a fixed or variable pulse length, amplitude, and/or frequency.

The electrical ablation device **20** may be operated either in bipolar or monopolar mode. In bipolar mode, the first electrode **24a** is electrically connected to a first polarity and the second electrode **24b** is electrically connected to the opposite polarity. For example, in monopolar mode, the first electrode **24a** is coupled to a prescribed voltage and the second electrode **24b** is set to ground. In the illustrated embodiment, the energy source **14** may be configured to operate in either the bipolar or monopolar modes with the electrical ablation system **10**. In bipolar mode, the first electrode **24a** is electrically connected to a prescribed voltage of one polarity and the second electrode **24b** is electrically connected to a prescribed voltage of the opposite polarity. When more than two electrodes are used, the polarity of the electrodes may be alternated so that any two adjacent electrodes may have either the same or opposite polarities, for example.

In monopolar mode, it is not necessary that the patient be grounded with a grounding pad. Since a monopolar energy source **14** is typically constructed to operate upon sensing a ground pad connection to the patient, the negative electrode of the energy source **14** may be coupled to an impedance simulation circuit. In this manner, the impedance circuit simulates a connection to the ground pad and thus is able to activate the energy source **14**. It will be appreciated that in monopolar mode, the impedance circuit can be electrically connected in series with either one of the electrodes **24a,b** that would otherwise be attached to a grounding pad.

In one embodiment, the energy source **14** may be configured to produce RF waveforms at predetermined frequencies, amplitudes, pulse widths or durations, and/or polarities suitable for electrical ablation of cells in the tissue treatment region. One example of a suitable RF energy source is a commercially available conventional, bipolar/monopolar electrosurgical RF generator such as Model Number ICC 350, available from Erbe, GmbH.

In one embodiment, the energy source **14** may be configured to produce destabilizing electrical potentials (e.g., fields) suitable to induce irreversible electroporation. The destabilizing electrical potentials may be in the form of bipolar/monopolar DC electric pulses suitable for inducing irreversible electroporation to ablate tissue undesirable tissue with the electrical ablation device **20**. A commercially available energy source suitable for generating irreversible electroporation electric filed pulses in bipolar or monopolar mode is a pulsed DC generator such as Model Number ECM 830, available from BTX Molecular Delivery Systems Boston, Mass. In bipolar mode, the first electrode **24a** may be electrically coupled to a first polarity and the second electrode **24b** may be electrically coupled to a second (e.g., opposite) polarity of the energy source **14**. Bipolar/monopolar DC electric pulses may be produced at a variety of frequencies, amplitudes, pulse lengths, and/or polarities. Unlike RF ablation systems, however, which require high power and energy levels delivered into the tissue to heat and thermally destroy the tissue, irreversible electroporation requires very little energy input into the tissue to kill the undesirable tissue without the detrimental thermal effects because with irreversible electroporation the cells are destroyed by electric field potentials rather than heat.

In one embodiment, the energy source **14** may be coupled to the first and second electrodes **24a,b** by either a wired or a wireless connection. In a wired connection, the energy source **14** is coupled to the electrodes **24a,b** by way of the electrical conductors **18a,b**, as shown. In a wireless connection, the electrical conductors **18a,b** may be replaced with a first antenna (not shown) coupled the energy source **14** and

a second antenna (not shown) coupled to the electrodes **24a,b**, wherein the second antenna is remotely located from the first antenna. In one embodiment, the energy source may comprise a wireless transmitter to deliver energy to the electrodes using wireless energy transfer techniques via one or more remotely positioned antennas. As previously discussed, wireless energy transfer or wireless power transmission is the process of transmitting electrical energy from the energy source **14** to an electrical load, e.g., the abnormal cells in the tissue treatment region, without using the inter-connecting electrical conductors **18a,b**. An electrical transformer is the simplest instance of wireless energy transfer. The primary and secondary circuits of a transformer are not directly connected. The transfer of energy takes place by electromagnetic coupling through a process known as mutual induction. Wireless power transfer technology using RF energy is produced by Powercast, Inc. The Powercast system can achieve a maximum output of 6 volts for a little over one meter. Other low-power wireless power technology has been proposed such as described in U.S. Pat. No. 6,967,462.

In one embodiment, the energy source **14** may be configured to produce DC electric pulses at frequencies in the range of about 1 Hz to about 10000 Hz, amplitudes in the range of about ± 100 to about ± 3000 VDC, and pulse lengths (e.g., pulse width, pulse duration) in the range of about 1 μ s to about 100 ms. The polarity of the electric potentials coupled to the electrodes **24a,b** may be reversed during the electrical ablation therapy. For example, initially, the DC electric pulses may have a positive polarity and an amplitude in the range of about +100 to about +3000 VDC. Subsequently, the polarity of the DC electric pulses may be reversed such that the amplitude is in the range of about -100 to about -3000 VDC. In one embodiment, the undesirable cells in the tissue treatment region may be electrically ablated with DC pulses suitable to induce irreversible electroporation at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse lengths of about 10 μ s to about 50 μ s. In another embodiment, the abnormal cells in the tissue treatment region may be electrically ablated with an electrical waveform having an amplitude of about +500 VDC and pulse duration of about 20 ms delivered at a pulse period T or repetition rate, frequency $f=1/T$, of about 10 Hz. It has been determined that an electric field strength of 1,000V/cm is suitable for destroying living tissue by inducing irreversible electroporation.

FIGS. 2A-D illustrate one embodiment of the electrical ablation device **20** in various phases of deployment. In the embodiment illustrated in FIGS. 2A-D, the sheath **26** is disposed over the flexible shaft **22**, however, those skilled in the art will appreciate that the sheath **26** may be disposed within the flexible shaft **22**. The electrical ablation device **20** may be used in conjunction with the electrical ablation system **10** shown in FIG. 1. It will be appreciated that other devices and electrode configurations may be employed without limitation. FIG. 2A illustrates an initial phase of deployment wherein the sheath **26** is extended in the direction indicated by arrow **40** to cover the electrodes **24a,b**. The electrodes **24a,b** may have dimensions of about 0.5 mm, about 1 mm, or about 1.5 mm in diameter. It will be appreciated that the dimensions of the electrodes **24a,b** may be anywhere from about 0.5 mm to about 1.5 mm in diameter. The electrical ablation device **20** may be introduced into the tissue treatment region through a trocar, as illustrated in FIG. 3, for example. FIG. 2B illustrates another phase of deployment wherein the sheath **26** is retracted

within the handle **28** in the direction indicated by arrow **42**. In this phase of deployment, the first and second electrodes **24a,b** extend through the distal end of the flexible shaft **22** and are ready to be inserted into or proximate the tissue treatment region. The first electrode **24a** may be retracted in direction **42** through a lumen **44** formed in the flexible shaft **22** by holding the handle **28** and pulling on the slide member **30**. FIG. 2C illustrates a transition phase wherein the first electrode **24a** is the process of being retracted in direction **42** by pulling on the slide member **30** handle, for example, in the same direction. FIG. 2D illustrates another phase of deployment wherein the first electrode **24a** is in a fully retracted position. In this phase of deployment the electrical ablation device **20** can be pivotally rotated about an axis **46** defined by the second electrode **24b**. The electrodes **24a,b** are spaced apart by a distance "r." The distance "r" between the electrodes **24a,b** may be 5.0 mm, about 7.5 mm, or about 10 mm. It will be appreciated that the distance "r" between the electrodes **24a,b** may be anywhere from about 5.0 mm to about 10.0 mm. Thus, the electrical ablation device **20** may be rotated in an arc about the pivot formed by the second electrode **24b**, the first electrode **24a** may be placed in a new location in the tissue treatment region within the radius "r." Retracting the first electrode **24a** and pivoting about the second electrode **24b** enables the surgeon or clinician to target and treat a larger tissue treatment region essentially comprising a circular region having a radius "r," which is the distance between the electrodes **24a,b**. Thus, the electrodes **24a,b** may be located in a plurality of positions in and around the tissue treatment region in order to treat much larger regions of tissue. Increasing the electrode **24a,b** diameter and spacing the electrodes **24a,b** further apart enables the generation of an electric field over a much larger tissue regions and thus the ablation of larger volumes of undesirable tissue. In this manner, the operator can treat a larger tissue treatment region comprising cancerous lesions, polyps, or tumors, for example.

Although the electrical ablation electrodes according to the described embodiments have been described in terms of the particular needle type electrodes **24a,b** as shown and described in FIGS. 1 and 2A-D, those skilled in the art will appreciate that other configurations of electrical ablation electrodes may be employed for the ablation of undesirable tissue, without limitation. In one embodiment, the electrical ablation device **20** may comprise two or more fixed electrodes that are non-retractable. In another embodiment, the electrical ablation device **20** may comprise two or more retractable electrodes, one embodiment of which is described below with reference to FIG. 2E. In another embodiment, the electrical ablation device **20** may comprise at least one slidable electrode disposed within at least one working channel of the flexible shaft **32** of the endoscope **12**. In another embodiment, the electrical ablation device **20** may comprise at least one electrode may be configured to be inserted into the tissue treatment region transcutaneously or percutaneously. Still in various other embodiments, the electrical ablation device **20** may comprise at least one electrode configured to be introduced to the tissue treatment region transcutaneously or percutaneously and at least one other electrode may be configured to be introduced to the tissue treatment region through at least one working channel of the flexible shaft **32** of the endoscope **12**. The embodiments, however, are not limited in this context.

FIG. 2E illustrates one embodiment of an electrical ablation device **800** comprising multiple needle electrodes **824m**, where m is any positive integer. In the illustrated embodiment, the electrical ablation device **800** comprises

four electrodes **824a**, **824b**, **824c**, **824d**. It will be appreciated that in one embodiment, the electrical ablation device **800** also may comprise three needle electrodes **824a**, **824b**, **824c**, without limitation. The electrical ablation device **800** may be used in conjunction with the electrical ablation system **10** shown in FIG. 1. It will be appreciated that other devices and electrode configurations may be employed without limitation. The electrodes **824a-m** each may have dimensions of about 0.5 mm, about 1 mm, or about 1.5 mm in diameter. It will be appreciated that the dimensions of each of the electrodes **824a-m** may be anywhere from about 0.5 mm to about 1.5 mm in diameter. The electrical ablation device **800** may be introduced into the tissue treatment region through a trocar, as subsequently described and illustrated with reference to FIG. 3, for example.

The electrical ablation device **800** comprises essentially the same components as the electrical ablation device **20** described with reference to FIGS. 2A-D. The electrical ablation device **800** comprises the relatively flexible member or shaft **22**, the protective sheath **26**, and one or more handles **28** to operate either the sheath **26**, the electrodes **824a,b,c,d**, or both. The electrodes **824a,b,c,d** may be individually or simultaneously deployable and/or retractable in the direction indicated by arrow **842**. The electrodes **824a,b,c,d** extend out from the distal end of the electrical ablation device **800**. In one embodiment, the first and second electrodes **824a**, **824b** may be configured as the positive electrode coupled to the anode of the energy source **14** via corresponding first and second electrical conductors **818a**, **818b**, and the third and fourth **824c**, **824d** may be configured as the negative electrode coupled to the cathode of the energy source **14** via corresponding third and fourth electrical conductors **818c**, **818d**, or similar electrically conductive leads or wires, through the activation switch **62**. Once the electrodes **824a,b,c,d** are positioned at the desired location into or proximate the tissue treatment region, the electrodes **824a,b,c,d** may be connected/disconnected from the energy source **14** by actuating/de-actuating the switch **62**.

As previously discussed with reference to FIGS. 2A-D, as shown in FIG. 2E in one embodiment, the protective sleeve or sheath **26** may be slidably disposed over the flexible shaft **22** and within the handle **28**. In an initial phase of deployment, the sheath **26** is extended in direction **40** to cover the electrodes **824a,b,c,d** to protect the trocar and prevent accidental piercing when the electrical ablation device **800** is advanced therethrough. Once the electrodes **824a,b,c,d** are located into or proximate the tissue treatment region, the sheath **26** is refracted in direction **42** to expose the electrodes **824a,b,c,d**. One or more of the electrodes **824a,b,c,d** of the electrical ablation device **800** may be adapted and configured to slideably move in and out of a cannula, lumen, or channel formed within the flexible shaft **22**. In one embodiment all of the electrodes **824a,b,c,d** are configured to slideably move in and out channels formed within lumens formed within the flexible shaft **22**, referred to for example as the lumen **44** in FIGS. 2A-D, to advance and retract the electrodes **824a,b,c,d** as may be desired by the operator. Nevertheless, in other embodiments, it may be desired to fix all or certain ones of the one or more electrodes **824a,b,c,d** in place.

The various embodiments of electrodes described in the present specification, e.g., the electrodes **24a,b**, or **824a-m**, may be configured for use with an electrical ablation device (not shown) comprising an elongated flexible shaft to house the needle electrodes **24a,b**, or **824a-m**, for example. The needle electrodes **24a,b**, or **824a-m**, are free to extend past

a distal end of the electrical ablation device. The flexible shaft comprises multiple lumen formed therein to slidably receive the needle electrodes **24a,b**, or **824a-m**. A flexible sheath extends longitudinally from a handle portion to the distal end. The handle portion comprises multiple slide members received in respective slots defining respective walls. The slide members are coupled to the respective needle electrodes **24a,b**, or **824a-m**. The slide members are movable to advance and retract the electrode **24a,b**, or **824a-m**. The needle electrodes **24a,b**, or **824a-m**, may be independently movable by way of the respective slide members. The needle electrodes **24a,b**, or **824a-m**, may be deployed independently or simultaneously. An electrical ablation device (not shown) comprising an elongated flexible shaft to house multiple needle electrodes and a suitable handle is described with reference to FIGS. 4-10 in commonly owned U.S. patent application Ser. No. 11/897,676 titled ELECTRICAL ABLATION SURGICAL INSTRUMENTS, filed Aug. 31, 2007, now U.S. Patent Application Publication No. 2009/0062788, the entire disclosure of which is incorporated herein by reference in its entirety.

It will be appreciated that the electrical ablation devices **20**, **800** described with referenced to FIGS. 2A-E, may be introduced inside a patient endoscopically (as shown in FIG. 15, transcutaneously, percutaneously, through an open incision, through a trocar (as shown in FIG. 3), through a natural orifice (as shown in FIG. 15), or any combination thereof. In one embodiment, the outside diameter of the electrical ablation devices **20**, **800** may be sized to fit within a working channel of an endoscope and in other embodiments the outside diameter of the electrical ablation devices **20**, **800** may be sized to fit within a hollow outer sleeve **620**, or trocar, as shown in FIG. 15, for example. The hollow outer sleeve **620** or trocar is inserted into the upper gastrointestinal tract of a patient and may be sized to also receive a flexible endoscopic portion of an endoscope **622** (e.g., gastrocope), similar to the endoscope **12** described in FIG. 1.

FIG. 3 illustrates one embodiment of the electrical ablation system **10** shown in FIGS. 1 and 2A-D in use to treat undesirable tissue **48** located on the surface of the liver **50**. The undesirable tissue **48** may be representative of a variety of diseased tissues, cancers, tumors, masses, lesions, abnormal tissue growths, for example. In use, the electrical ablation device **20** may be introduced into or proximate the tissue treatment region through a port **52** of a trocar **54**. The trocar **54** is introduced into the patient via a small incision **59** formed in the skin **56**. The endoscope **12** may be introduced into the patient trans-anally through the colon, trans-orally down the esophagus and through the stomach using transluminal techniques, or through a small incision or keyhole formed through the patient's abdominal wall (e.g., the peritoneal wall). The endoscope **12** may be employed to guide and locate the distal end of the electrical ablation device **20** into or proximate the undesirable tissue **48**. Prior to introducing the flexible shaft **22** through the trocar **54**, the sheath **26** is slid over the flexible shaft **22** in a direction toward the distal end thereof to cover the electrodes **24a,b** (as shown in FIG. 2A) until the distal end of the electrical ablation device **20** reaches the undesirable tissue **48**.

Once the electrical ablation device **20** has been suitably introduced into or proximate the undesirable tissue **48**, the sheath **26** is retracted to expose the electrodes **24a,b** (as shown in FIG. 2B) to treat the undesirable tissue **48**. To ablate the undesirable tissue **48**, the operator initially may locate the first electrode **24a** at a first position **58a** and the second electrode **24b** at a second position **60** using endo-

scopic visualization and maintaining the undesirable tissue 48 within the field of view of the flexible endoscope 12. The first position 58a may be near a perimeter edge of the undesirable tissue 48. Once the electrodes 24a,b are located into or proximate the undesirable tissue 48, the electrodes 24a,b are energized with irreversible electroporation pulses to create a first necrotic zone 65a. For example, once the first and second electrodes 24a,b are located in the desired positions 60 and 58a, the undesirable tissue 48 may be exposed to an electric field generated by energizing the first and second electrodes 24a,b with the energy source 14. The electric field may have a magnitude, frequency, and pulse length suitable to induce irreversible electroporation in the undesirable tissue 48 within the first necrotic zone 65a. The size of the necrotic zone is substantially dependent on the size and separation of the electrodes 24a,b, as previously discussed. The treatment time is defined as the time that the electrodes 24a,b are activated or energized to generate the electric pulses suitable for inducing irreversible electroporation in the undesirable tissue 48.

This procedure may be repeated to destroy relatively larger portions of the undesirable tissue 48. The position 60 may be taken as a pivot point about which the first electrode 24a may be rotated in an arc of radius "r," the distance between the first and second electrodes 24a,b. Prior to rotating about the second electrode 24b, the first electrode 24a is refracted by pulling on the slide member 30 (FIGS. 1 and 2A-D) in a direction toward the proximal end and rotating the electrical ablation device 20 about the pivot point formed at position 60 by the second electrode 24b. Once the first electrode 24a is rotated to a second position 58b, it is advanced to engage the undesirable tissue 48 at point 58b by pushing on the slide member 30 in a direction towards the distal end. A second necrotic zone 65b is formed upon energizing the first and second electrodes 24a,b. A third necrotic zone 65c is formed by retracting the first electrode 24a, pivoting about pivot point 60 and rotating the first electrode 24a to a new location, advancing the first electrode 24a into the undesirable tissue 48 and energizing the first and second electrodes 24a,b. This process may be repeated as often as necessary to create any number of necrotic zones 65p, where p is any positive integer, within multiple circular areas of radius "r," for example, that is suitable to ablate the entire undesirable tissue 48 region. At anytime, the surgeon or clinician can reposition the first and second electrodes 24a,b and begin the process anew. In other embodiments, the electrical ablation device 800 comprising multiple needle electrodes 824a-m described with reference to FIG. 2E may be employed to treat the undesirable tissue 48. Those skilled in the art will appreciate that similar techniques may be employed to ablate any other undesirable tissues that may be accessible trans-anally through the colon, and/or orally through the esophagus and the stomach using transluminal access techniques. Therefore, the embodiments are not limited in this context.

FIG. 4 illustrates a detailed view of one embodiment of the electrical ablation system 10 shown in FIG. 3 in use to treat undesirable tissue 48 located on the surface of the liver 50. The first and second electrodes 24a,b are embedded into or proximate the undesirable tissue 48 on the liver 50. The first and second electrodes 24a,b are energized to deliver one or more electrical pulses of amplitude and length sufficient to induce irreversible electroporation in the undesirable tissue 48 and create the first necrotic zone 65a. Additional electric pulses may be applied to the tissue immediately surrounding the respective electrodes 24a,b to form second, thermal, necrotic zones 63a,b near the electrode-tissue-

interface. The duration of an irreversible electroporation energy pulse determines whether the temperature of the tissue 63a,b immediately surrounding the respective electrodes 24a,b raises to a level sufficient to create thermal necrosis. As previously discussed, varying the electrode 24a,b size and spacing can control the size and shape of irreversible electroporation induced necrotic zone 65a. Electric pulse amplitude and length can be varied to control the size and shape of the thermally induced necrotic zones near the tissue-electrode-interface. In other embodiments, the electrical ablation device 800 comprising multiple needle electrodes 824a-m may be used to treat the undesirable tissue 48 located on the surface of the liver 50, for example.

FIG. 5 is a graphical representation of a series of electrical pulses that may be applied to undesirable tissue to create a first necrotic zone by inducing irreversible electroporation in the tissue and to create a second necrotic zone by inducing thermal effects near the electrode-tissue-interface using the electrical ablation system 10 shown in FIG. 4. Time (t) is shown along the horizontal axis and voltage (VDC) is shown along the vertical axis. Initially the undesirable tissue 48 is exposed to a first series of electrical pulses 70 of a first predetermined amplitude, length, and frequency sufficient to induce the irreversible electroporation necrotic zone 65a. Subsequently, the undesirable tissue near the electrode-tissue-interface is exposed to a second series of electrical pulses 72 of a second predetermined amplitude, length, and frequency sufficient to induce thermal necrotic effects on the tissue and create thermal necrotic zones 63a,b. As shown in FIG. 5, the first series of pulses 70 comprises about 20 to 40 electric pulses having an amplitude of about 1000 VDC, pulse length t_1 of about 10 μ s to about 15 μ s, and a period T_1 (e.g., pulse repetition rate $f_1=1/T_1$) of about 100 μ s ($f_1=10000$ Hz). The first series of pulses is sufficient to induce irreversible electroporation in the necrotic zone 65a. The period T_1 is defined as the pulse length t_1 plus the pulse spacing 74, e.g., the time between a falling edge of a pulse and a rising edge of a subsequent pulse. The second series of pulses 72 may comprises a single pulse or multiple pulses having an amplitude of about 500 VDC, pulse length t_2 of about 10 ms to about 15 ms, and a period T_2 of about 100 ms ($f_2=10$ Hz). The second series of pulses is sufficient to create thermal necrotic zones 63a,b in the tissue near the electrode-tissue-interface immediately surrounding the respective electrodes 24a,b. In one embodiment, $f_1=f_2=10$ Hz (i.e., $T_1=T_2=100$ MS).

In one embodiment, the thermal necrotic zones 63a,b formed in the tissue immediately surrounding the electrodes 24a,b at the tissue-electrode-interface are beneficial to stop bleeding in the undesirable tissue 48 as a result of the mechanical trauma resulting from inserting or embedding the electrodes 24a,b into the undesirable tissue 48 of the liver 50. Although in general irreversible electroporation induced by electric pulses do not cause thermal necrosis or other detrimental thermal effects, the longer electrical pulses 72 may be applied to the undesirable tissue 48 in succession to thermally seal the tissue immediately surrounding the electrodes 24a,b at the tissue-electrode-interface. Thus, the technique of applying a combination of a first series of substantially shorter electrical pulses 70 (in the microseconds range) and a second series of substantially longer energy pulses 72 (in the milliseconds range) may be employed for sealing vessels prior to transecting a vessel. Accordingly, the first series of pulses 70 may be applied to a vessel to induce cell necrosis by irreversible electropora-

tion. Then, the second series of pulses **72** may be applied to vessel to create thermal necrotic zones to seal the vessel prior to dissecting the vessel.

In various embodiments, a series of electrical pulses may be characterized according to the following parameters as may be provided by the energy source **14**, for example. In one embodiment, the energy source **14** may be configured to produce DC electric pulses at frequencies in the range of about 1 Hz to about 10000 Hz, amplitudes in the range of about ± 100 to about ± 3000 VDC, and pulse lengths (e.g., pulse width, pulse duration) in the range of about 1 μ s to about 100 ms. The polarity of the electric potentials coupled to the electrodes **24a,b** may be reversed during the electrical ablation therapy. For example, initially, the DC electric pulses may have a positive polarity and an amplitude in the range of about +100 to about +3000 VDC. Subsequently, the polarity of the DC electric pulses may be reversed such that the amplitude is in the range of about -100 to about -3000 VDC. In one embodiment, the undesirable cells in the tissue treatment region may be electrically ablated with DC pulses suitable to induce irreversible electroporation at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse lengths of about 10 μ s to about 50 μ s. In another embodiment, the abnormal cells in the tissue treatment region may be electrically ablated with an electrical waveform having an amplitude of about +500 VDC and pulse duration of about 20 ms delivered at a pulse period T or repetition rate, frequency $f=1/T$, of about 10 Hz.

FIGS. **6**, **7**, and **8** illustrate one embodiment of an electrical ablation device **290** to treat undesirable tissue located within body lumen using electrical energy. FIG. **6** illustrates a sectioned view of one embodiment of the electrical ablation device **290**. FIG. **7** illustrates an end view of the embodiment of the electrical ablation device **290** shown in FIG. **6**. FIG. **8** illustrates a cross-sectional view of the embodiment of the electrical ablation device **290** shown in FIG. **6**. As previously discussed, reflux disease of the greater saphenous vein (GSV) can result in a varicose vessel **292**, which is illustrated in FIG. **8**. Conventionally, varicose veins have been treated by stripping and then applying either chemical or thermal ablation to internal portions of a lumen defined by the varicose vessel **292**. In the embodiment illustrated in FIGS. **6-8**, the electrical ablation device **290** is configured to couple to the energy source **14** and to be inserted within a lumen defined by the varicose vessel **292**. Once inserted into the varicose vessel **292**, the electrical ablation device **290** may be energized by the energy source **14** to apply high-voltage DC electrical pulses to an inner wall **294** portion of the varicose vessel **292**. High-voltage DC pulses may be used to ablate the undesirable tissue and to subsequently seal the varicose vessel **292**. The embodiment illustrated in FIGS. **6-8**, however, is not limited in this context, and the electrical ablation device **290** may be employed to treat and seal tissue within any inner body lumen using energy in the form of electrical pulses supplied by the energy source **14**.

Referring to FIGS. **6-8**, the electrical ablation device **290** comprises a probe **296** comprising a cannula, channel, or lumen **300** extending longitudinally therethrough. The distal end **298** of the probe **296** comprises first and second ring electrodes **302a,b** to which a potential difference may be applied by the energy source **14**. The first and second ring electrodes **302a,b** may be coupled to respective positive and negative terminals of the energy source **14** through corresponding first and second electrical conductors **304a,b**. The first and second electrical conductors **304a,b** extend through

respective conduits **306a,b** formed within the probe **296** and extend longitudinally therethrough. The first and second electrical conductors **304a,b** may be electrically coupled to the first and second ring electrodes **302a,b** in any suitable manner. The first and second ring electrodes **302a,b** are adapted to receive energy in the form of electrical pulses from the energy source **14**. The electrical pulses generate an electric field suitable for treating, e.g., ablating, the undesirable tissue within a lumen such as the lumen defined by the varicose vessel **292** as shown in FIG. **8**. In one embodiment, once energized by the energy source **14**, the first and second ring electrodes **302a,b** generate an electric field suitable to induce irreversible electroporation in the undesirable tissue. It will be appreciated that a potential difference may be created across the first and second ring electrodes **302a,b** to generate an electric field strength suitable to induce irreversible electroporation in the undesirable tissue. In other embodiments, the probe **296** may comprise one or more electrodes in addition to the first and second ring electrodes **302a,b**.

The electrical ablation probe **296** has a form factor that is suitable to be inserted within a lumen defined by the varicose vessel **292** and to ablate tissue in the tapered lumen **298** portion of the varicose vessel **292**. The probe **296** engages the inner wall **294** of the varicose vessel **292** in the tapered lumen **298** portion of the varicose vessel **292**. Suction **306** applied at a proximal end of the probe **296** draws a vacuum within the lumen **300** of the probe **296** to collapse the varicose vessel **292** at the distal end **298** of the probe **296**. Once the vessel **292** is collapsed or pulled down by the suction **306**, a first pulse train **302** of high-voltage DC electrical pulses at a first amplitude A_1 (e.g., ~1000V amplitude) and a first pulse length T_1 (e.g., ~50 microseconds) is applied to the first and second ring electrodes **302a,b** by the energy source **14**. The high-voltage DC pulse train **302** eventually kills the cells within the tapered lumen **298** portion of the varicose vessel **292** by irreversible electroporation. A second pulse train **304** having a lower voltage amplitude A_2 (e.g., ~500 VDC) and a second longer pulse length T_2 (e.g., ~15 milliseconds) is applied to the first and second ring electrodes **302a,b** of the probe **296** to thermally seal the varicose vessel **292**. As previously discussed, in one embodiment, the polarity of the electrical pulses may be inverted or reversed by the energy source **14** during the ablation or sealing treatment process. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source **14** as discussed with respect to FIGS. **1** and **5**, for example.

FIG. **9** illustrates one embodiment of an electrical ablation system **400** in use to treat non-metastatic prostate cancer in a patient. As previously discussed, a radical prostatectomy in which the entire prostate **404** and surrounding lymph nodes are removed is one of the conventional treatments for prostate cancer. Like most other forms of cancer, radiation therapy may be used in conjunction with or as an alternate method for the treatment of prostate cancer. Another thermal ablation technique for the treatment of prostate cancer is RF interstitial tumor ablation (RITA) via trans-rectal ultrasound guidance. While these conventional methods for the treatment of prostate cancer are effective, they are not preferred by many surgeons and may result in detrimental thermal effects to healthy tissue surrounding the prostate. The electrical ablation system **400** in accordance with the described embodiments provides improved electrical ablation of prostate cancer using irreversible electroporation pulses through

supplied by an energy source to electrodes positioned into and/or proximate the prostate cancer tissue.

With reference to FIG. 9, the electrical ablation system 400 comprises an electrical ablation device 402 comprising at least two electrodes 402a,b, and the energy source 14. The electrical ablation system 400 may be adapted for use in conjunction with the electrical ablation system 10 described in FIG. 1. The electrodes 402a,b are configured to be positioned within internal body lumens or cavities and, in one embodiment, may be configured for use in conjunction with the flexible endoscope 12 also described in FIG. 1. The electrodes 402a,b are configured to couple to the corresponding electrical conductors 18a,b, the handpiece 16, the activation switch 62, and the energy source 14, as previously discussed in FIG. 1. The first electrode 402a comprises a wire or flexible conductive tube that may be introduced through the urethra 406 into the prostate 404 proximally to the bladder 410. The first electrode 402a may be located into the prostate 404 using well known fluoroscopy or ultrasonic guidance, for example. The second electrode 402b comprises a pad and may be introduced into the anus 408 and advanced to a location proximate to the prostate 404. The first electrode 402a has a much smaller surface area relative to the trans-anally placed second electrode 402b pad. The first electrode 402a may be connected to the positive (+) terminal of the energy source 14 and the second electrode 402b may be connected to the negative (-) terminal of the energy source 14. In one embodiment, the energy source 14 may be configured as a high-voltage DC electric pulse generator. The activation switch 62 portion of the handpiece 16, as shown in FIG. 1, can be used to energize the electrical ablation system 400 to ablate the non-metastatic cancer in the prostate 404 by irreversible electroporation pulses supplied by the energy source 14 and delivered through the electrodes 402a,b as described in FIG. 10 below. In other embodiments, the probe 296 may comprise one or more electrodes in addition to the first and second electrodes 402a,b.

FIG. 10 is a graphical representation of a series of electrical pulses 412 that may be applied to undesirable tissue to induce irreversible electroporation suitable to ablate non-metastatic cancer of the prostate 404 as described in FIG. 9. Time (t) is shown along the horizontal axis and voltage (V) is shown along the vertical axis. A series of electrical pulses 412 having a predetermined amplitude V_o and pulse length t_o sufficient to induce irreversible electroporation may be applied to the prostate 404 through the electrodes 402a,b to ablate the undesirable cancerous tissue. Multiple electrical pulses 412, for example, 20 to 40 pulses, of amplitude of about 1500 to about 3000 volts DC (V_o) each having a pulse length t_o of about 10 μ s to about 50 μ s, and a period (T) of about 10 ms. The electrical pulses 412 having such parameters are sufficient to induce irreversible electroporation to ablate the cancerous tissue in the prostate 404. The period T (e.g., pulse repetition rate $f=1/T$) may be defined as the pulse length t_o plus 10 μ s the length of time between pulses, or the pulse spacing 414. A conductive fluid may be introduced into the urethra 406 to extend the range of the positive electrode 402a. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source 14 as discussed with respect to FIGS. 1 and 5, for example.

FIG. 11 illustrates one embodiment of the electrical ablation system 10 described in FIG. 1 in use to treat basal cell carcinoma (BCC) tissue. In FIG. 11, the electrical ablation system 10, described in FIG. 1, is shown in use to treat BCC tissue 502. BCC tissue 502 is a slowly growing cutaneous

malignancy derived from a rapidly proliferating basal layer of the epidermis 504. As previously discussed, conventional treatments for BCC include surgical excision, cryotherapy, radiation, photodynamic therapy, Moh's micrographic surgery, and topical treatments with 5-fluorouracil. Minimally-invasive methods of treating BCC include laser ablation with a pulsed carbon dioxide laser. Although, the treatment of BCC with a carbon dioxide laser has been shown to be effective on tumors ranging in size from about 5 mm to about 40 mm, carbon dioxide treatment is a thermal method of treating tissue that may cause permanent thermal damage to healthy tissue surrounding the BCC tissue and requires costly capital investment in carbon dioxide laser equipment.

The electrical ablation device 20 of the electrical ablation system 10 may be used to induce irreversible electroporation suitable to treat undesirable BCC tissue using electrical pulses supplied by the energy source 14. The first and second electrodes 24a,b are transcutaneously inserted through the epidermis 504 and embedded into the BCC tissue 502. The first and second electrodes 24a,b are separated by a distance "D." The first electrode 24a is electrically connected to the positive (+) output of the energy source 14 and the second electrode 24b is electrically connected to the negative (-) output of the energy source 14. In one embodiment, the energy source 14 may be a high-voltage DC generator. The energized electrodes 24a,b generate an electric field inducing irreversible electroporation suitable for ablating the undesirable BCC tissue 502 located between the electrodes 24a,b. A larger portion of the BCC tissue 502 may be ablated by relocating and re-energizing the first and second electrodes 24a,b using the technique previously described with reference to FIG. 3, for example. As previously discussed, varying the electrode 24a,b size and spacing can control the size and shape of irreversible electroporation induced necrotic zone. Accordingly, as previously discussed, increasing the electrode 24a,b diameter and spacing between the electrodes 24a,b enables the generation of an electric field over a much larger tissue regions and thus the ablation of larger volumes of undesirable tissue. In other embodiments, the electrical ablation device 800 comprising multiple needle electrodes 824a-m may be used to treat the BCC tissue 502, for example.

FIG. 12 is a graphical representation of a series of electrical pulses 512 that may be applied to undesirable tissue to induce irreversible electroporation suitable to ablate BCC tissue as described in FIG. 11. Time (t) is shown along the horizontal axis and voltage (V) is shown along the vertical axis. As shown in FIG. 12, a series of electrical pulses 512 having a predetermined amplitude V_o and pulse length t_o sufficient to induce irreversible electroporation may be applied to the BCC tissue 502 to ablate the undesirable cancerous tissue. About 20 to about 40 pulses 512 of with an amplitude of about 1500 to about 3000 VDC (V_o), a pulse length t_o of about 10 μ s to about 50 μ s, a period T (the pulse length t_o plus the pulse spacing 54) of about 10 ms may be suitable for inducing irreversible electroporation to ablate the undesirable BCC tissue 502 in the region D between the electrodes 24a,b. Multiple placements of the electrode 24a,b in rapid succession and the application of additional pulses 512 can be used to ablate larger portions of the BCC tissue 502, as previously discussed in FIG. 3. As previously discussed, varying the electrode 24a,b size and spacing can control the size and shape of irreversible electroporation induced necrotic zone. Accordingly, increasing the electrode 24a,b diameter and spacing the electrodes 24a,b further apart (e.g., greater than "D") enables the generation of an electric field over a much larger tissue regions and thus the

ablation of larger volumes of undesirable tissue. Injecting a conductive fluid into the BCC tissue **502** is another technique to increase the size and shape of the irreversible electroporation induced necrotic zone and extend the range of the positive electrode **24a**, for example. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source **14** as discussed with respect to FIGS. **1** and **5**, for example.

FIG. **13A** illustrates one embodiment of an electrical ablation device **600** in a collapsed state. The electrical ablation device **600** has a configuration suitable for the treatment of undesirable tissue located in a lumen, abscess, void, or cavity. Although other electrode configurations may be effective for treating line-of-sight regions of tissue, such electrodes may not be as effective at treating tissue within a cavity. To overcome these limitations, the electrical ablation device **600** comprises an electrode configured to inflate and expand into the cavity to make contact with tissue along the inner wall of the cavity. The electrical ablation device **600** comprises an elongate tubular body extending from a proximal end to a distal end. In one embodiment, the electrical ablation device **600** may comprise a conductive elastomer electrode **602** portion (e.g., balloon, tip) and a non-conductive catheter **604** portion, which may be formed of a non-electrically conductive (e.g., electrically insulative) elastomeric material. The electrical ablation device **600** may be referred to as a balloon catheter, balloon probe, or balloon-tipped catheter, for example, without limitation. In one embodiment, the inflatable portion of the conductive elastomer electrode **602** may be formed of an electrically conductive elastomer suitable for coupling to the energy source **14** via an electrically conductive terminal **610** and a first electrically conductive wire **608a**. Once inflated, the elastomeric properties of the conductive elastomer electrode **602** conform to the internal walls of the cavity. Upon energizing, the conductive elastomer electrode **602** delivers electrical pulses to the tissue within the internal walls of the cavity to induce irreversible electroporation.

In one embodiment, the electrical ablation device **600** may be fabricated using a concurrent injection process such that the conductive elastomer electrode **602** portion and the non-conductive catheter **604** portion are formally integrally. In another embodiment, the electrical ablation device **600** may be fabricated by manufacturing the conductive elastomer electrode **602** and the non-conductive catheter **604** separately and then joining the two components using any suitable joining method such as, for example, bolting, screwing, welding, crimping, gluing, bonding, brazing, soldering, press fitting, riveting, heat shrinking, heat welding, ultrasonic welding, or any other suitable method.

FIG. **13B** illustrates one embodiment of the electrical ablation device **600** shown in FIG. **13A** in an inflated state. As previously discussed, in an inflated state the conductive elastomer electrode **602** may be employed for ablating cancerous tumors growing within internal body lumens such as the esophagus or the large bowel, or in cavities remaining when cancerous tumors are removed from solid tissue, such as the breast. Although surgical resection of tumors in solid tissue can include a margin of healthy tissue, cancer cells may remain in the tissue within the cavity. The conductive elastomer electrode **602** may be inserted in the cavity, inflated, and energized by the energy source **14** to expose the tissue within the cavity to electrical pulses suitable to induce irreversible electroporation to ablate any cancer cells remaining within the cavity.

FIG. **14** is a cross-sectional view of the electrical ablation device **600** showing a cross-sectional view of the conductive elastomer electrode **602** and the non-conductive catheter **604** shown in FIGS. **13A** and **13B**. The conductive elastomer electrode **602** may be coupled to a first end **606** of the electrically conductive wire **608a**. The wire **608a** may be located through the non-conductive catheter **604** and the first end **606** electrically connected (e.g., bonded, soldered, brazed) to the conductive elastomer electrode **602** through the electrically conductive terminal **610**. In one embodiment, the non-conductive catheter **604** may be extruded with an embedded strip of conductive material serving as the electrically conductive terminal **610**. The wire **608a** may be electrically connected to one end of the electrically conductive terminal **610**. In one embodiment, the electrical ablation device **600** may be configured to couple to one terminal of the energy source **14** via a second end of the electrically conductive wire **608a**. A return electrode **612** (e.g., in the form of a pad or needle electrode) is coupled to a second electrically conductive wire **608b**, which is coupled to another terminal of the energy source **14**. The return electrode **612** may be orientated proximal to the conductive elastomer electrode **602** of the electrical ablation device **600** (e.g., the balloon catheter). When irreversible electroporation energy pulses are applied to the conductive elastomer electrode **602** of the electrical ablation device **600**, the tissue between the conductive elastomer portion **602** and the return electrode **608b** is ablated, e.g., destroyed by the pulsed irreversible electroporation energy. In other embodiments, the return electrode **612** may comprise multiple electrodes, for example.

In one embodiment, the conductive elastomer electrode **602** may be fabricated from or may comprise an electrically conductive material suitable for conducting electrical energy from the energy source **14** to the internal cavity sufficient to induce irreversible electroporation to the tissue within the cavity. The electrically conductive elastomer material is similar to conductive elastomers used as gasket material for electronic enclosures used for shielding electronic devices from electromagnetic interference (EMI). Conductive elastomers may be formed by infiltrating an elastomeric matrix with electrically conductive filler materials such as silver, gold, copper, or aluminum, to produce a hybrid material having the elastic properties of the elastomeric matrix and the electrically conductive properties of the metallic filler materials (some materials may have volume resistivity values as low as 0.004 Ω -cm, for example). The conductive elastomer may be formed as thin sheets, catheters, and balloons suitable for medical applications. In one embodiment, the conductive elastomer electrode **602** may be fabricated from medical grade polyurethane material comprising at least one electrically conductive coating on an outer surface thereof. In another embodiment, the conductive elastomer electrode **602** may be made from an electrically conductive material. In yet another embodiment, the conductive elastomer electrode **602** may be made from an electrically insulative material, such as the medical grade polyurethane, and inflated with a conductive fluid (e.g., saline) to form the electrically conductive portion of the conductive elastomer electrode **602**.

In one embodiment the conductive elastomer electrode **602** may be coupled to the anode (+) electrode of the energy source **14** and in another embodiment the conductive elastomer electrode **602** may be coupled to the cathode (-) electrode of the energy source **14**. It will be appreciated that the polarity of the conductive elastomer electrode **602** may be reversed by reversing the output polarity of the energy

source **14**. In one embodiment, the conductive elastomer electrode **602** may be coupled to either the anode (+) or the cathode (−) of the energy source **14**. For example, the conductive elastomer electrode **602** may be coupled to the cathode (+) of the energy source **14** relative to a ground plane cathode (−) in contact with the patient and coupled to the negative terminal of the energy source **14**.

FIG. **15** illustrates one embodiment of the electrical ablation device shown in FIG. **13A** inserted through the mouth and esophagus to ablate cancerous tissue in the esophagus using electrical pulses. As shown in FIG. **15**, a hollow outer sleeve **620** or trocar is inserted into the upper gastrointestinal tract of a patient and receives a flexible endoscopic portion of an endoscope **622** (e.g., gastroscope), similar to the endoscope **12** described in FIG. **1**. A variety of different types of endoscopes are known and, therefore, their specific construction and operation will not be discussed in great detail herein. In various embodiments, the flexible endoscopic portion **620** may be fabricated from nylon or high-density polyethylene plastic, for example. FIG. **15** illustrates, in general form, one embodiment of the electrical ablation device **600** that can be inserted through a natural orifice such as the mouth **626** and advanced through a cavity or lumen such as the esophagus **628**, e.g., esophageal cavity, to apply electrical pulses sufficient to induce irreversible electroporation to ablate the undesirable cancerous tissue **630** located in the esophagus **628**.

FIG. **16** illustrates the distal portion **624** of the endoscope **622** shown in FIG. **15**. As shown in FIG. **16**, the electrical ablation device **600** is advanced through the distal end **624** of the endoscope **622**. In various embodiments, the endoscope **622** can serve to define various tool-receiving passages **628**, or “working channels,” that extend from the natural orifice **626** to the surgical site. In addition, the endoscope **622** comprises a viewing port **630**. The endoscope **622** may be used for viewing the surgical site within the patient’s body. Various cameras and/or lighting apparatuses may be inserted into the viewing port **630** of the endoscope **622** to provide the surgeon with a view of the surgical site.

With reference now to FIGS. **15** and **16**, the electrical ablation device **600** is one of the tools or surgical instruments that can be accommodated in the tool-receiving passage **628** of the endoscope **622**. The conductive elastomer electrode **602** (e.g., balloon, tip) and the non-conductive catheter **604** are configured to communicate with at least one pressurized air source **634** and a vacuum source **632** to respectively inflate and deflate the conductive elastomer electrode **602**. In one embodiment, a vacuum/air tube **636** can be sized to receive other surgical instruments therein. In various embodiments, the endoscope **622** may comprise a video camera that communicates with a video display unit **638** that can be viewed by the surgeon during the operation. In addition, the endoscope **622** may further comprise a fluid-supply lumen therethrough that is coupled to an inflation fluid such as a water source **640**, saline solution, and/or any other suitable inflation fluid and/or an air supply lumen that is coupled to the air source **642**. In various embodiments, the fluid-supply lumen, e.g., the inflation fluid line, may be coupled to conventional inline valves (not shown) to control the flow of inflation fluid. For example, a proximal end of the inline valve may be removably coupled to a conventional inflation syringe. The fluid-supply lumen defines an inflation lumen that fluidically communicates with the interior of the conductive elastomer electrode **602** (e.g., the balloon electrode) via an aperture (not shown). The fluid-supply lumen provides a fluid communication path for

inflating the conductive elastomer electrode **602** with a conductive fluid. The fluid may be either saline or air or other suitable electrically conductive inflation fluid. As previously discussed, the conductive elastomer electrode **602** is coupled to the energy source **14** to deliver electrical pulses to the esophageal cavity. The transcutaneous electrode **612** is also coupled to the energy source **14** through electrically conductive wire **608b**.

In use, the electrical ablation device **600** may be introduced into a natural orifice such as the mouth **626** and advanced into a lumen, abscess, void, or cavity such as the esophagus **628**, as shown in FIG. **15**. In the illustrated embodiment, the conductive elastomer electrode **602** is inserted through the working channel **628** of the endoscope **622** and into the lumen or cavity defined by the esophagus **628** and the return electrode **612** is inserted transcutaneously and is located proximate to the cancerous tissue **630**. Once located within the esophagus **628**, the conductive elastomer electrode **602** may be inflated using either the water source **640** or the air source **642**. The water source **640** may supply a conductive solution (e.g., saline solution) to enhance the conductivity of the conductive elastomer electrode **602** and to enhance the contact area between the conductive elastomer electrode **602** and the inner wall of the esophageal cavity **628** including the cancerous tissue **630**. Once inflated, the conductive elastomer electrode **602** is energized by the energy source **14** with a number of high-voltage DC electrical pulses to cause necrosis of the undesirable cancerous tissue **630** between the conductive elastomer electrode **602** and the return electrode **612**. In this example, the high-voltage DC electrical pulses generate an electric field in a concentric zone around the esophageal cavity **628**. The electric field has a sufficient magnitude and pulse length to induce irreversible electroporation in the undesirable cancerous tissue **630**. The depth of the necrotic zone depends on the amplitude of the applied electric field, the pulse length, the number of pulses, and the repetition rate or frequency of the pulses. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source **14** as discussed with respect to FIGS. **1** and **5**, for example.

FIGS. **17-20** illustrate a method of treating residual undesirable tissue within cavities formed in the solid tissue after removal of a mass of undesirable tissue. FIG. **17** illustrates a cross-sectional view of a breast **702** showing a cavity **700** that may be left after a lumpectomy to remove a tumor from the breast **702**. In tumors that grow in solid tissue, the rate of recurrence of undesirable tissue depends on the margin of healthy tissue relative to the undesirable tissue that is removed. Accordingly, to minimize the recurrence of the tumor once the undesirable tissue is removed from the breast **702**, the residual tissue in the cavity **700** should be ablated. The residual tissue may be ablated using the techniques previously described in FIGS. **13-16** above or the techniques described in FIGS. **18-20** below.

FIG. **18** illustrates one embodiment of a catheter **704** inserted into the cavity **700** left in the breast **702** after a lumpectomy procedure. A distal end **706** of the catheter **704** comprises a compressed sponge **708** or any suitable type of expandable foam material. A sleeve **710** slidably disposed over the catheter **704** and the sponge **708** contains the sponge **708** until it is ready to expand into the cavity **700**. When the sleeve **710** is retracted in the direction indicated by arrow **712**, the sponge **708** may be expanded into the cavity **700** by pumping saline into the sponge **708** through the catheter **704**. An electrode **714** is inserted through the catheter **704** and into the sponge **708** such that the electrode

714 is in electrical communication with the sponge **708**. The electrode **714** may be coupled to the positive terminal of the energy source **14**, for example.

FIG. **19** illustrates an expanded sponge filling the cavity **700** left in the breast **702** following a lumpectomy as shown in FIG. **17**. As shown in FIG. **19**, the sponge **708** has been soaked with saline solution and has expanded to fill the cavity **700** upon removal of the sleeve **710**. Multiple wire electrodes **714** may be embedded in the saline soaked sponge **708**. Each of these wire electrodes **714** may be coupled to the positive terminal of the energy source **14**. The body or outer portion of the breast **702** may be electrically grounded through one or more large surface area electrodes **716a,b**. It will be appreciated that in other embodiments that either a single surface area electrode or more than two surface area electrodes may be employed, without limitation. The negative electrodes **716a,b** are connected to the negative terminal of the energy source **14**. The sponge **708** and the residual tissue within the cavity **700** are exposed to a series of electric pulses (e.g., high-voltage DC electric pulses) suitable for inducing irreversible electroporation. The high-voltage DC electric pulses in the form graphically illustrated in FIG. **5**, **10**, or **12** generate an electric field sufficient to cause apoptosis/necrosis in a zone extending beyond the edge of the cavity **700**, for example. In various embodiments, the electrical pulses may be characterized by the parameters in accordance with the output of the energy source **14** as discussed with respect to FIGS. **1** and **5**, for example.

FIG. **20** illustrates the expanded sponge **708** intact to fill the cavity **700** left in the breast **702** as shown in FIG. **17** following irreversible electroporation ablation therapy. After the irreversible electroporation ablation treatment is completed, the positive electrode **714** is removed from the cavity **700** and the negative electrodes **716a,b** are removed from the breast **702**. The sponge **708**, however, may be left inside to fill the cavity **700**.

FIG. **21** illustrates a mesh of a finite element model **709** of a sponge inserted in the cavity **700** left in the breast **702** as shown in FIG. **17**. The horizontal and the vertical axes represent distance in meters (m) with the center defined at (0,0). As shown in FIG. **21**, the mesh of the finite element model **709** is a two-dimensional representation of the sponge similar to the sponge **708** inserted in the cavity **700** of the breast **702** previously described in FIGS. **17-20**, for example.

FIG. **22** is a graphical representation of electric potential and electrical field strength sufficient to induce irreversible electroporation when applied to the sponge **708** located within the breast cavity **700** as shown in FIG. **17**. The horizontal and the vertical axes represent distance in meters (m) with the center defined at (0,0). As shown in FIG. **22**, electric field strength in Volts/meter (V/m) is represented by electric field lines **718** shown as concentric contours or circles extending from an outer perimeter of the sponge **708** to a point in space **726** where the electric field strength is at a minimum. A scale **722** to the right of the graph represents electric field strength in V/m. Electric potential **720** in Volts (V) applied to the sponge **708** within the cavity **700** is represented by the shaded zones **720**. A vertical scale **724** shown to the right of the electric field strength scale **722** represents electric potential in V with the minimum potential at the bottom and the maximum potential at the top. The electrical field lines **718a,b** just outside the outer perimeter of the sponge **708** are representative of an electric field potential **720a** of about 1400 to about 2000 V sufficient to cause cell necrosis by irreversible electroporation.

FIG. **23** is a graphical representation of electric field strength contours in volts per meter (V/m) developed when electrodes are energized by an energy source. The horizontal and the vertical axes represent distance in meters (m) with the center defined at (0,0). FIG. **23** illustrates a graph **730** of electric field strength contours developed when the electrodes **24a,b** are inserted into the sponge **708** and energized by the energy source **14**, as described in FIGS. **17-22**. A vertical scale **732** shown to the right of the graph **730** represents the electric field strength in a range from a minimum of about 50,000V/m (bottom) to a maximum of about 100,000V/m (top). Irreversible electroporation energy in this range of electric field strength (e.g., about 50,000V/m to about 100,000V/m) are suitable for efficient and effective treatment of medical conditions that require the ablation of undesirable tissue from a localized region (i.e., in the case of the treatment of cancer). With reference to the embodiment described in FIGS. **17-22**, needle-probes or electrodes **24a,b** are inserted into the sponge **708**. As shown in the graph **730**, electric field strength contours **734**, **736** represent the maximum electric field strength (e.g., about 80,000 to about 100,000V/m) in a region proximate to the location where the needle electrodes **24a,b** are inserted into the sponge **708**. Electric field strength contour **738** represents electric field strength of about 50,000V/m. In regions outside the sponge **708**, the electric field strength peaks at contour **742** to about 100,000V/m and then tapers off with distance to about 80,000V/m at contour **744** to about 50,000V/m at contour **746**. It will be appreciated that other electric field strength contours may be developed to render effective irreversible electroporation ablation therapy. Accordingly, the embodiments described herein should not be limited in this context.

The embodiments of the electrical ablation devices described herein may be introduced inside a patient using minimally invasive or open surgical techniques. In some instances it may be advantageous to introduce the electrical ablation devices inside the patient using a combination of minimally invasive and open surgical techniques. Minimally invasive techniques provide more accurate and effective access to the treatment region for diagnostic and treatment procedures. To reach internal treatment regions within the patient, the electrical ablation devices described herein may be inserted through natural openings of the body such as the mouth, anus, and/or vagina, for example. Minimally invasive procedures performed by the introduction of various medical devices into the patient through a natural opening of the patient are known in the art as NOTESTM procedures. Surgical devices, such as an electrical ablation devices, may be introduced to the treatment region through the working channels of the endoscope to perform key surgical activities (KSA), including, for example, electrical ablation of tissues using irreversible electroporation energy. Some portions of the electrical ablation devices may be introduced to the tissue treatment region percutaneously or through small-keyhole-incisions.

Endoscopic minimally invasive surgical and diagnostic medical procedures are used to evaluate and treat internal organs by inserting a small tube into the body. The endoscope may have a rigid or a flexible tube. A flexible endoscope may be introduced either through a natural body opening (e.g., mouth, anus, and/or vagina). A rigid endoscope may be introduced via trocar through a relatively small-keyhole-incision (usually 0.5-1.5 cm). The endoscope can be used to observe surface conditions of internal organs, including abnormal or diseased tissue such as lesions and other surface conditions and capture images for visual inspection and photography. The endoscope may be adapted

and configured with working channels for introducing medical instruments to the treatment region for taking biopsies, retrieving foreign objects, and/or performing surgical procedures.

Once an electrical ablation device is inserted in the human body internal organs may be reached using trans-organ or transluminal surgical procedures. The electrical ablation device may be advanced to the treatment site using endoscopic transluminal access techniques to perforate a lumen, and then, advance the electrical ablation device and the endoscope into the peritoneal cavity. Transluminal access procedures for perforating a lumen wall, inserting, and advancing an endoscope therethrough, and pneumoperitoneum devices for insufflating the peritoneal cavity and closing or suturing the perforated lumen wall are well known. During a transluminal access procedure, a puncture must be formed in the stomach wall or in the gastrointestinal tract to access the peritoneal cavity. One device often used to form such a puncture is a needle knife which is inserted through the working channel of the endoscope, and which utilizes energy to penetrate through the tissue. A guidewire is then fed through the endoscope and is passed through the puncture in the stomach wall and into the peritoneal cavity. The needle knife is removed, leaving the guidewire as a placeholder. A balloon catheter is then passed over the guidewire and through the working channel of the endoscope to position the balloon within the opening in the stomach wall. The balloon can then be inflated to increase the size of the opening, thereby enabling the endoscope to push against the rear of the balloon and to be feed through the opening and into the peritoneal cavity. Once the endoscope is positioned within the peritoneal cavity, numerous procedures can be performed through the working channel of the endoscope.

The endoscope may be connected to a video camera (single chip or multiple chips) and may be attached to a fiber-optic cable system connected to a "cold" light source (halogen or xenon), to illuminate the operative field. The video camera provides a direct line-of-sight view of the treatment region. The abdomen is usually insufflated with carbon dioxide (CO₂) gas to create a working and viewing space. The abdomen is essentially blown up like a balloon (insufflated), elevating the abdominal wall above the internal organs like a dome. CO₂ gas is used because it is common to the human body and can be removed by the respiratory system if it is absorbed through tissue.

Once the electrical ablation devices are located at the target site, the diseased tissue may be electrically ablated or destroyed using the various embodiments of electrodes discussed herein. The placement and location of the electrodes can be important for effective and efficient electrical ablation therapy. For example, the electrodes may be positioned proximal to a treatment region (e.g., target site or worksite) either endoscopically or transcutaneously (percutaneously). In some implementations, it may be necessary to introduce the electrodes inside the patient using a combination of endoscopic, transcutaneous, and/or open techniques. The electrodes may be introduced to the tissue treatment region through a working channel of the endoscope, an overtube, or a trocar and, in some implementations, may be introduced through percutaneously or through small-key-hole-incisions.

Preferably, the various embodiments of the devices described herein will be processed before surgery. First, a new or used instrument is obtained and if necessary cleaned. The instrument can then be sterilized. In one sterilization technique, the instrument is placed in a closed and sealed

container, such as a plastic or TYVEK® bag. The container and instrument are then placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, or high-energy electrons. The radiation kills bacteria on the instrument and in the container. The sterilized instrument can then be stored in the sterile container. The sealed container keeps the instrument sterile until it is opened in the medical facility.

It is preferred that the device is sterilized. This can be done by any number of ways known to those skilled in the art including beta or gamma radiation, ethylene oxide, steam.

Although the various embodiments of the devices have been described herein in connection with certain disclosed embodiments, many modifications and variations to those embodiments may be implemented. For example, different types of end effectors may be employed. Also, where materials are disclosed for certain components, other materials may be used. The foregoing description and following claims are intended to cover all such modification and variations.

Any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated materials does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.

The invention claimed is:

1. A method for using an electrical ablation apparatus, comprising:

inserting an elongated tubular body made of an electrically conductive material comprising an arcuate closed distal end and a first electrode received in an open proximal end of the elongated tubular body into a first natural orifice of a body, wherein the first electrode is electrically coupled to the elongated tubular body;

inserting a second electrode, located external to the elongated tubular body, into the body;

electrically contacting a first conductive terminal of an energy source with the first electrode, and electrically contacting a second conductive terminal of the energy source with the second electrode; and

delivering, by the energy source, a first series of electrical pulses sufficient to induce cell necrosis by irreversible electroporation across the first electrode and the second electrode,

wherein the first series of electrical pulses are characterized by a first amplitude, a first pulse length, and a first frequency.

2. The method of claim 1, wherein inserting an elongated tubular body into a first natural orifice of a body comprises inserting the elongated tubular body through the first natural orifice of the body into a lung of the body.

3. The method of claim 1, wherein inserting the second electrode into the body comprises inserting the second electrode into a second natural orifice of the body.

4. The method of claim 1, wherein inserting the second electrode into the body comprises inserting the second electrode transcutaneously into the body.

29

5. The method of claim 1, further comprising placing a distal end of the second electrode proximate to a distal end of the first electrode independent of a placement of the distal end of the first electrode.

6. An electrical ablation system, comprising:

an elongated tubular body made of an electrically conductive material, the elongated tubular body comprising:

an arcuate closed distal end configured for entry into a first natural orifice of a body;

an open proximal end; and

a first electrode received in the open proximal end of the elongated tubular body, the first electrode electrically coupled to the elongated tubular body;

a visualization device configured to visualize an internal compartment of the body and configured to receive the elongated tubular body;

a second electrode, located external to the elongated tubular body, the second electrode configured for entry into the body; and

an energy source having a first conductive terminal in electrical communication with the first electrode and a second conductive terminal in electrical communication with the second electrode, the energy source con-

30

figured to deliver a first series of electrical pulses sufficient to induce cell necrosis by irreversible electroporation across the first electrode and the second electrode;

5 wherein the first series of electrical pulses are characterized by a first amplitude, a first pulse length, and a first frequency.

7. The system of claim 6, wherein visualization device comprises an endoscope, a thoracoscope, or a laparoscope.

10 8. The system of claim 6, wherein visualization device comprises a plurality of working channels.

9. The system of claim 6, wherein the visualization device further comprises a viewing port.

15 10. The system of claim 6, wherein the second electrode further comprises a conductive portion in electrical communication with a distal end of the second electrode.

11. The system of claim 10, wherein the conductive portion is a sharpened portion.

20 12. The system of claim 10, wherein the conductive portion is a pad.

13. The system of claim 10, further comprising a hand-piece comprising an activation switch in electrical communication with the energy source.

* * * * *

| | | | |
|----------------|---|---------|------------|
| 专利名称(译) | 电消融装置 | | |
| 公开(公告)号 | US10004558 | 公开(公告)日 | 2018-06-26 |
| 申请号 | US14/673111 | 申请日 | 2015-03-30 |
| [标]申请(专利权)人(译) | 伊西康内外科公司 | | |
| 申请(专利权)人(译) | 爱惜康内镜手术，INC. | | |
| 当前申请(专利权)人(译) | 爱惜康内镜手术，INC. | | |
| [标]发明人 | LONG GARY L GHABRIAL RAGAE M PLESCIA DAVID N VAKHARIA OMAR J | | |
| 发明人 | LONG, GARY L. GHABRIAL, RAGAE M. PLESCIA, DAVID N. VAKHARIA, OMAR J. | | |
| IPC分类号 | A61B18/14 A61B18/12 A61B18/00 | | |
| CPC分类号 | A61B18/1492 A61B18/1206 A61B18/1477 A61B2018/00214 A61B2018/00482 A61B2018/1425 A61B2018/00577 A61B2018/00613 A61B2018/00898 A61B2018/124 A61B2018/00547 | | |
| 其他公开文献 | US20150265342A1 | | |
| 外部链接 | Espacenet | | |

摘要(译)

电消融装置包括第一和第二电极。每个电极包括被配置成耦合能量源的第一端和被配置成耦合到组织治疗区域的第二端。能量源连接到第一和第二电极。能量源被配置为通过第一和第二电极中的至少一个传递足以通过不可逆电穿孔诱发细胞坏死的第一系列电脉冲和足以通过热加热诱发细胞坏死的第二系列电脉冲。第一系列电脉冲的特征在于第一振幅，第一脉冲长度和第一频率。第二系列电脉冲的特征在于第二振幅，第二脉冲长度和第二频率。

